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Summary 
 
The uptake, transport and presentation of antigens by lung dendritic cells (DCs) is 
central to the initiation of CD8 T-cell responses against respiratory viruses. Although 
several studies have demonstrated a critical role of CD11blo/negCD103+ DCs for the 
initiation of cytotoxic T-cell responses against the influenza virus, the underlying 
mechanisms for its potent ability to prime CD8 T-cells remain poorly understood. 
Using a novel approach of fluorescent lipophilic dye-labelled influenza virus, we 
demonstrate that CD11blo/negCD103+ DCs are the dominant lung DC population 
transporting influenza virus to the posterior mediastinal lymph node as early as 20 
hours after infection. By contrast, CD11bhiCD103neg DCs although more efficient for 
taking up the virus within the lung, migrate poorly to the lymph node and remain in 
the lung to produce pro-inflammatory cytokines instead. CD11blo/negCD103+ DCs 
efficiently load viral peptide onto MHC-I complexes and therefore uniquely possess 
the capacity to potently induce proliferation of naïve CD8 T-cells. In addition, the 
peptide transporter TAP1 and TAP2 is constitutively expressed at higher levels in 
CD11blo/negCD103+ DCs, providing first evidence of a distinct regulation of the 
antigen-processing pathway in these cells. Collectively, these results show that 
CD11blo/negCD103+ DCs are functionally specialised for the transport of antigen from 
the lung to the lymph node and also for efficient processing and presentation of viral 
antigens to CD8 T-cells.  
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Chapter 1: Introduction 
1.1    Influenza virus 
 
The influenza virus is a negative strand, single-stranded RNA virus of the family 
orthomyxoviridae. The name “influenza” originated in Italy due to a pandemic in 
Europe in the 1500s attributed to the “influence of the stars”, although the first 
description of the virus was not made until 1933 when it was first isolated. The 
influenza virus can be further classified into three distinct classes, A, B and C, based 
on differences in the genetic structure of the virus. Influenza A viruses are classified 
by their surface hemagglutinin (HA) and neuraminidase (NA) proteins, of which 
there are currently 16 known HA subtypes and 9 NA subtypes.  
 
1.1.1 The Health Threat of Influenza 
 
The success of the influenza A virus is attributed to its ability to reassort viral RNAs 
in a host cell infected with more than one strain of influenza A virus – a process 
termed as antigenic shift. This gives the virus the ability to rapidly change its surface 
antigens and avoid neutralization by host antibodies against HA and NA molecules 
from an earlier strain. Reassortment of the virus occurs mainly in wild waterfowl as 
these avian host harbour all the known HA and NA subtypes and are a natural 
reservoir for the virus (Webster et al. 1992). The segmented nature of the influenza 
genome (elaborated in section 1.1.3) greatly facilitates the process of viral 
reassortment by allowing exchange of large proportions of the influenza genome and 
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thus the creation of novel progeny viruses. The influenza A virus can also mutate by 
antigenic drift – mutation in amino acid sequences due to the low fidelity of the 
influenza RNA dependent RNA polymerase which has an transcriptional error rate of 
1 in every 105 bases per infectious cycle (Parvin et al. 1986). This results in a high 
rate of mutation and allows the virus to rapidly evolve and develop enhanced tropism 
towards its host. In contrast, Influenza B and C viruses mutate principally by antigen 
drift and hence pose less of a pandemic threat. 
 
Influenza A is by far the most successful virus and in the past century alone has 
caused 3 global pandemics, namely the devastating 1918 H1N1 ‘Spanish flu’ which 
killed an estimated 20-50 million people worldwide, the 1957 H2N2 Asian flu and 
the 1968 H3N2 Hong Kong flu, both of which caused a mortality of approximately 1 
million (Nguyen-Van-Tam and Hampson 2003; Gani et al. 2005). In the recent 
decade, influenza A has also been responsible for the deaths of several hundred from 
the highly pathogenic H5N1 virus, commonly known as the ‘avian flu’. The H5N1 
virus has an alarmingly high cumulative mortality rate of approximately 60% in 
zoonotic infections (Komar and Olsen 2008) and thus continues to pose a significant 
pandemic threat. Most recently, influenza A was also responsible for the H1N1 2009 
pandemic which showcased the rapid speed at which the influenza infections could 
spread around the globe. Since the outbreak was first announced in Mexico, the virus 
had spread to 43 countries within the space of one month.  
 
Aside from pandemic outbreaks, influenza A is also destructive on an annual basis, 
spreading around the world in seasonal epidemics. According to the World Health 
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Organisation, annual seasonal outbreaks cause an estimated 3 to 5 million cases of 
severe illness, and approximately 250,000 to 500,000 deaths around the world.  In the 
United States alone, influenza results in approximately 200,000 hospitalisation and 
40,000 deaths in a typical endemic season (Thompson et al. 2003) and in Singapore, a 
recent study estimates that influenza accounts for 588 deaths annually (Chow et al. 
2006).   
 
1.1.2 Clinical Symptoms of Infection and Pathology 
 
Under non-pandemic situations, clinical manifestations of influenza infection include 
any or all of these symptoms: sudden onset of fever, sore throat, non-productive 
cough, myalgia, malaise, headache and rhinitis. Diagnosis of influenza infection 
based on these clinical symptoms alone is difficult as the disease manifestation can be 
similar to those caused by other respiratory viruses such as the parainfluenza virus, 
respiratory syncytial virus and rhinovirus. The incubation period of the virus is brief, 
lasting approximately 2 days, and upon manifestation of symptoms, viral shedding 
continues for approximately another 5 days. In an experimental infection setting, the 
severity of the symptoms was reported to peak 2-3 days after infection and gradually 
decline thereafter, which was in close tandem with the kinetics of nasal viral titres 
(Hayden et al. 1998). Although influenza infection is usually self-limiting, the risk of 
complications and death are associated with the very young (less than 5 years old) 
and the elderly (more than 65 years old) due to reduced immune function in these 
groups. Influenza infection also poses a high risk for exacerbating chronic pulmonary 
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diseases such as chronic obstructive lung dieasese and accounts for a significant 
number of hospitalizations arising from respiratory complications (Tan et al. 2003). 
Influenza-induced pulmonary complications for this risk group can be life threatening 
as the development of hemorrhagic bronchitis and pneumonia can occur within hours 
(Taubenberger and Morens 2008).  Secondary bacterial infection of the lung 
following is also another cause of pulmonary complications and has been attributed to 
be significant contributing factor to the high mortality of the 1918 pandemic (Morens 
et al. 2008).  
 
In non-fatal infections in humans, the influenza virus predominantly infects the upper 
respiratory tract and trachea. Analysis of bronchoscopic biopsies by light and electron 
microscopes indicate that influenza infection results in diffuse inflammation of the 
larynx, trachea and bronchi accompanied by lymphocyte and histiocyte cellular 
infiltrate (Walsh et al. 1961). Infection of the ciliated epithelium results in initial 
shrinkage and vacuolaization of the cells, culminating in necrosis and eventual 
desquamation of these cells into the luminal space. The lung interstitium may show 
congestion and edema and the air spaces lled with edema, brin, and neutrophils 
infiltrate (Taubenberger and Morens 2008). 
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1.1.3 Genetics and Replication of the Influenza A Virus 
 
The influenza A virion has a diameter of 80-120nm and exists as both filamentous 
and spherical form. Clinical isolates that have undergone a limited number of 
passages in tissue culture or embryonated eggs tend to exhibit a filamentous 
morphology whereas those that have been repeatedly passaged are more likely to be 
spherical. Influenza viruses have a lipid bilyaer envelope derived from the host cell’s 
plasma membrane that encapsulates 8 negative-sense viral RNA segments (McGeoch 
et al. 1976). Protruding out from the lipid envelope into the surface are HA and NA 
glycoproteins which are spike-like proteoglycans responsible for viral binding and 
release from the host cell respectively (Figure 1.1). Proteolytic cleavage of the HA 
molecule HA0 into HA1 and HA2 subunits by trypsin-like enzymes found within the 
respiratory tract is a prerequisite for viral infectivity (Klenk et al. 1975). This exposes 
the hydrophobic N-terminus of the HA2 subunit which contains a highly conserved 
fusion peptide that inserts into the endosomal membrane (Stegmann et al. 1991). 
Proteolytic cleavage of HA also allows it to conformationally change in response to 
endosome acidification in order to bring the HA2 fusion peptide closer to the host 
membrane to facilitate fusion with the virus membrane (Bullough et al. 1994).  
 
The NA spikes on the virus surface exist as mushroom-shaped tetramers with a stalk 
and a head. The NA protein is a glycoside hydrolase enzyme and catalyses the 
hydrolysis of terminal sialic acid residues from host cell receptors to release newly 
formed virus particles from the infected cell’s surface. It is also able to cleave sialic 
acids residues bound to surface viral proteins, preventing aggregation of virions 
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which may hamper infectivity. The cleavage of sialic acid by the NA enzyme to 
release progeny virus budding from the cell surface is a major requirement for spread 
of the virus. Interference of this key function of NA formed the basis for the 
successful development of influenza neuraminidase inhibitors zanamivir and 
oseltamivir, also known as Relenza and Tamiflu respectively, which bind to the 
active site of the NA and renders the virus unable to escape from the host cell 
(Hayden et al. 1997; Hayden et al. 1999). 
 
Also embedded within the lipid envelope but at a much lower frequency compared to 
HA and NA is the M2 matrix protein, a small protein generated by alternative 
splicing of the RNA segment encoding the matrix protein. Unlike the HA and NA 
molecules, most part of the M2 protein is localised within the internal portion of the 
virus and only a small part, the ectodomain M2e, is exposed to the surface (Lamb et 
al. 1985). The M2 protein is a proton channel and is also involved in mediating viral 
entry. Within the endosome, the M2 proton pump is responsible for lowering the 
internal pH of the virus to permit the dissociation of viral RNA-nuceloprotein 
complexes from the structural M1 protein during fusion with the host membrane 
(Kemler et al. 1994). This allows the viral RNPs tethered to the M1 proteins to be 
released into the cytoplasm where they can be imported into the nucleus by nuclear 
localisation signals found on the NP molecule (O'Neill et al. 1995). Inhibitors of the 
M2 protein, rimantidine and amantidine, prevent the import of protons into the virus 
core by blocking opening of the M2 channel (Schnell and Chou 2008), thus 
preventing the release of viral RNPs from the M1 protein, and ultimately into the host 
cell’s cytoplasm.  
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Beneath the host-derived lipid envelope lies a layer of M1 matrix protein, which is 
the most abundant protein of the virion. The M1 protein functions as an internal 
scaffold for the viral ribonucleoproteins to be anchored to, mediated by protein-
protein interactions between the non-structural NS2 protein bound to the viral RNA 
and the M1 protein (Yasuda et al. 1993). Apart from mediating structural support of 
the virion, the M1 protein is also important molecule for driving virus assembly and 
release – the expression of the M1 protein itself results in the spontaneous formation 
of virus-like budding vesicles at the cell surface (Gomez-Puertas et al. 2000).  
 
Within the core of the virus, each of the viral RNA segment is associated with several 
viral proteins, namely, the nucleoprotein NP and components of the viral RNA 
dependent RNA polymerase, PA, PB1 and PB2. The 8 viral RNA segments encode a 
total of 11 proteins and the details of each protein and their function are summarised 
in the table below (Table 1).  
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Figure 1.1 Schematic diagram of the influenza A virus  
 
The two major surface glycoproteins of the influenza virus are hemagglutinin (HA), 
neuraminidase (NA), which form spike-like projections from the viral envelope. The 
ribonucleoprotein complex comprises a viral RNA segment associated with the 
nucleoprotein (NP) and three polymerase proteins (PA, PB1, and PB2). The matrix 
(M1) protein is associated with both ribonucleoprotein and the viral envelope. 
Adapted from (Horimoto and Kawaoka 2005). 
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Viral 
RNA 
Segment 
Protein(s) Approximate 
Molecular 
Weight (KDa) 
 
Function 
1 
PB2  
Basic Polymerase 
86 Viral polymerase subunit 
2 
PB1  
Basic Polymerase 
87 Viral polymerase subunit 
PB1-F2  
Alternate open reading 
frame 
11 Unknown – inhibits host 
mitochondrial function and 
induces apoptosis 
3 
PA  
Acid Polymerase 
83 Viral polymerase subunit 
4 
HA  
Haemagglutinin 
64 Binding to sialic acid 
containing cell surface 
receptors and membrane fusion 
5 
NP  
Nucleoprotein 
56 Encapsidation of RNA 
6 
NA  
Neuraminidase 
50 Sialidase – Cleavage of sialic 
acids  to release mature virion 
from host cell 
7 
M1  
Matrix Protein 
28 Viral assembly.  
Structural support of virion 
M2 
Matrix Protein 
11 Proton channel. Dissociation of 
viral components during 
uncoating. 
8 
NS1  
Non-structural Protein 
26 RNA splicing and translation. 
Antagonism of host immune 
responses. 
NS2 
Non-structural Protein 
14 Nuclear export of RNP 
 
Table 1: List of the 8 influenza viral segments and function of the 11 proteins 
coded for  
Adapted from (Steinhauer and Skehel 2002) and (Hale et al. 2010).  
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1.1.4  Influenza Tropism  
 
The influenza virus binds to cell surface glycoproteins or glycolipids containing 
terminal sialyl-galactosyl residues through the HA molecule. The cell tropism of the 
influenza virus depends on the type of sialic acid glycosylated on the proteins or 
lipids on the cell surface. In human strains (H1 to H3), the virus via the HA molecule 
preferentially binds to residues terminating with 2,6-linked sialic acid. In contrast, 
avian strains of the virus (H4 to H16) bind preferentially to 2,3-linked sialic acid 
residues. Accordingly, 2,6-linked sialic acid linkages are mainly expressed on the 
apical surface of ciliated cells in the tracheal epithelium, whereas in birds, the 2,3-
linked sialic acid linkages predominate in the upper airways. Of note, 2,3-linked 
sialic acid residues are also expressed in non-ciliated cells in the human tracheal 
epithelium, but these cells constitute a minority and the density of sialic-acid 
expression on the cell surface is also lower, which may explain the relatively poor 
transmissibility of avian influenza strains to a human host (Matrosovich et al. 2004). 
In pigs however, the tracheal epithelium expresses both 2,6 and 2,3-linked sialic 
acid residues. This has led to the hypothesis that pigs serve as a ‘mixing bowl’ for 
both avian and human influenza strains, facilitating viral reassortment and the 
generation of novel human viral strains with the potential of carrying genetic material 
from highly pathogenic avian H5 strains. 
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1.2    Host Innate Immune Sensors of Influenza Virus A 
 
The innate immune system is the first line of defence for the host and has an essential 
role in detecting invading pathogens by recognising distinct pathogen associated 
molecular patterns (PAMPs) through a variety of receptors. There are currently 3 
known families of these pattern recognition receptors, namely, the Toll-like receptors 
(TLRs), Nucleotide Oligomerization Domain (NOD)-like receptors (NLRs) and the 
Retinoic acid Induced Gene I (RIG-I)-like receptors (RLRs). The influenza virus can 
be detected by a variety of components from all three families of pattern recognition 
receptors and the activation of individual component results in the induction of 
distinct signalling cascades and immune responses (Pang and Iwasaki 2011). This 
initiation of multiple signalling pathways ultimately culminates in the release of pro-
inflammatory cytokines as well as mobilisation of immune cells through chemokine 
gradients to combat the infection. 
 
1.2.1 TLR-mediated detection of the Influenza Virus 
 
The TLR family is the largest as well as the best characterised family of pattern 
recognition receptors in mammals with currently 10 and 12 TLRs identified in 
humans and mice respectively (Kawai and Akira 2010). TLRs can be found either on 
the cell surface (TLRs 1, 2, 4, 5, 6, 10 and 11) or within intracellular endosomal 
compartments (TLRs 3, 7, 8, and 9). The diversity of the TLRs is further enhanced by 
the fact that the repertoire of TLRs expressed by various cell types differs broadly, 
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even within subsets of the same cell type. The influenza virus is detected by TLR3 
which recognises double stranded RNA generated during viral replication (Le Goffic 
et al. 2006) as well as by TLR7 and TLR8 which both recognise endosomal single-
stranded RNA (Diebold et al. 2004; Wang et al. 2008). It should be noted however 
that TLR8 in mice is non-functional (Jurk et al. 2002) and any direct evidence that 
TLR8 mediates recognition of the influenza virus comes from work with human cells 
where TLR8 was transfected into non-TLR expressing cell-lines.  
 
Although both TLRs 3 and 7 share a common intracellular compartment, engagement 
by their respective ligands results in the triggering of distinct signalling pathways. 
TLR3 primarily signals through the adaptor molecule TRIF (Yamamoto et al. 2003), 
resulting in the nuclear localisation of IRF-3 and IRF-7 which cooperate to mediate 
the transcription of interferon-. In contrast, TLR7 engagement signals mainly 
through its associated adaptor molecule MyD88 which utilises MAP kinase and NFB 
signalling pathways and results in the trasnscription of pro-inflammatory cytokines 
such as IL-6 and TNF- (Hemmi et al. 2002). The importance of TLRs 3 and 7 in 
mediating influenza immune responses has been clearly demonstrated in mice 
deficient for these molecules. In response to infection, TLR3-/- mice exhibit delayed 
viral clearance, secrete lower levels of pro-inflammatory cytokines and have 
attenuated cellular infiltrate into the alveolar spaces (Le Goffic et al. 2006). In 
addition to immune cells, TLR3 is also expressed on human bronchial and alveolar 
epithelial cells and the infection of these cells results in the the upregulation of TLR3 
expression as well as the release of soluble mediators such as IL-8, IL-6, RANTES 
and IFN- (Guillot et al. 2005). In a clinical setting, a missense mutation of the TLR3 
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gene resulting in a loss-of-function was associated with influenza-associated 
encephalopathy in one patient, proving additional evidence that TLR3 plays an 
important role to control influenza viral replication (Hidaka et al. 2006). Interestingly 
although TLR3 is essential for driving the host anti-viral immune response, TLR3 
deficiency also resulted in a paradoxical increase in survival rates at high infectious 
doses, which indicates that excessive TLR3 activation can have a detrimental 
contribution to immunopathology (Le Goffic et al. 2006).  
 
TLR7 has a critical role for the induction of type I interferons by plasmacytoid DCs 
(Diebold et al. 2004). TLR7 also regulates the quality of the antibody response to 
influenza and its absence results in the lower antibody titres and defective isotype 
switching (Heer et al. 2007). Detection of the influenza virus by TLR7 is also a 
critical step for the activation of the inflammasome response, the details of which will 
be elaborated in the next section (Ichinohe et al. 2010). Although both TLR3 and 
TLR7 are involved in the early innate immune response, these are dispensable for T-
cell responses as mice deficient for either molecule mount an equivalent CD8 and 
CD4 responses to wild-type mice (Lopez et al. 2004; Heer et al. 2007).   
 
1.2.2 NLR-mediated detection of the Influenza Virus 
 
The inflammasome is a multiprotein complex that is responsible for the triggering of 
an inflammation cascade by activating caspase-1, which in turn mediates the cleavage 
of pro-IL-1 and pro-IL-18 into their active form. The inflammasome plays an 
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essential role in host defense against the influenza virus and mice lacking components 
of the inflammasome such as ASC1, caspase-1 and NLRP3 have compromised 
survival following infection (Allen et al. 2009; Ichinohe et al. 2009; Thomas et al. 
2009). The ability of the influenza virus to activate the inflammasome was discovered 
slightly more than a decade ago when Pirhonen et. al. observed that the influenza 
virus could activate IL-1 and IL-18 production in macrophages in a caspase-1-
dependment manner (Pirhonen et al. 1999), several years before the inflammasome 
complex was first identified and characterised (Martinon et al. 2002).  
 
It is currently thought that the activation of the NLRP3 inflammasome and production 
of IL-1 requires two signals – the first signal being triggered by a TLR and second 
signal involving various cellular stress signals such as ionic perturbation 
(Mariathasan and Monack 2007). Infection with the influenza virus but not other 
respiratory viruses is uniquely able to trigger both signals 1 and 2 required for 
inflammasome activation (Ichinohe et al. 2010). The first signal is triggered by 
TLR7-dependent recognition of the influenza ssRNA genome, which is a feature 
common to many viruses. The uniqueness of the influenza virus in activating the 
inflammasome lies in the triggering of the second signal. This is mediated by the 
unique properties of the M2 ion channel which transports proton ions out of the trans-
Golgi network lumen resulting in intracellular ionic imbalance and activation of the 
inflammasome (Ichinohe et al. 2010). Although influenza infection results in 
activation of the inflammasome in both lung stromal and hematopoietic cells, only 
inflammasome activation in hematopoietic cells was necessary for the induction of 
adaptive T-cell responses. 
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1.2.3 RLR-mediated detection of the Influenza Virus 
 
RIG-I-like receptors, also known as RIG-I-like helicases, are a family of cytoplasmic 
RNA helicases that mediates the detection of viruses by binding double stranded 
RNA formed during viral replication. There are currently 3 known RLRs, melanoma-
differentiation-association gene 5 (MDA-5), retinoic-acid-inducible protein 1 (RIG-I) 
and laboratory of genetics and physiology 2 (LGP2). Interestingly, the recognition of 
the influenza virus is mediated only by RIG-I even though both MDA-5 and RIG-I 
are structurally highly similar. Both consist of a DExD/H box RNA helicase domain 
to bind dsRNA, two CARD-like signalling domains, and are able to bind and respond 
to Poly (I:C) (Kato et al. 2006). LGP2 does not have a CARD domain and functions 
as a regulator of MDA-5 and RIG-I responses (Satoh et al. 2010). RIG-I recognises 
influenza by binding the 5’-triphosphate (5’-ppp) group that is present at the terminal 
end of viral RNA (Pichlmair et al. 2006). Such 5’-ppp groups are usually removed or 
modified from host RNA species are the principle means of RIG-I discrimination 
between self and non-self RNA (Rehwinkel and Reis e Sousa 2011). Given that RLRs 
are cytosolic sensors by nature, this discrimination mechanism is particularly 
important given that host RNA are abundant within the cytosol. Upon RIG-I binding 
to influenza vRNA, the CARD domains initiate a signalling cascade by associating 
with the adaptor protein, IFN- promoter stimulator 1 (IPS-1) (Kawai et al. 2005), 
which in turn binds to TNF-receptor-associated factor 3 (TRAF3) (Saha et al. 2006) 
and initiates multiple downstream signalling pathways that ultimately results in the 
transcription of type I IFNs and pro-inflammatory cytokines.  
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1.3    Viral evasion of immune dectection 
 
Although the immune system possesses multiple mechanisms for detection of the 
influenza virus, the virus itself has also developed several means to evade and even 
counteract host immune responses. The non-structural protein 1 (NS1) of the 
influenza virus has a major role in antagonising the host immune response due to its 
ability to interact with as well as modulate multiple host factors. The NS1 protein has 
been demonstrated to attenuate the early type I interferon response by interfering with 
both the pre-transcriptional and post-transcriptional events associated with the 
production of IFN-. NS1 prevents the activation of transcription factors essential for 
the transcription of IFN-, such as IRF-3, NF-B and c-Jun/ATF-2 (Talon et al. 2000; 
Wang et al. 2000; Ludwig et al. 2002). NS1 also interferes with post-transcription 
export of the host mRNA from the nucleus to the cytosol (Fortes et al. 1994). The 
inhibition of host mRNA nuclear export is not limited to IFN- as NS1 mediates a 
general inhibition of host mRNA processing so as to facilitate the transcription of 
viral RNA. NS1 therefore has the potential to inhibit a much wider spectrum of early 
response elements of innate immunity by blocking nuclear export of newly 
synthesised host mRNA. The NS1 also antagonises host viral sensors through 
blockade of RIG-I function (Pichlmair et al. 2006) by binding to TRIM25 and 
inhibiting its ubiquitination of the CARD domain on RIG-I (Gack et al. 2009) which 
is a crucial requirement for RIG-I to induce antiviral signal transduction (Gack et al. 
2007). 
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Apart from NS1, the NA protein also potentially contributes to immune evasion. The 
NA molecule from various influenza strains have been demonstrated to enzymatically 
cleave latent TGF-, converting it into its bioactive form in vitro as well as in vivo 
(Schultz-Cherry and Hinshaw 1996; Carlson et al. 2010). As TGF- is a potent 
immunosuppressive cytokine, the influenza virus can potentially modulate TGF- 
levels in order to dampen host immune responses in its favour.  
 
1.4    Innate Immune Responses to the influenza virus 
 
The innate immune system forms the first layer of defence against the influenza virus.  
As elaborated in the previous section, the virus is recognised in a non-specific manner 
by multiple PAMP receptors which are present in various innate immune cell 
populations. The innate immune response against the influenza virus comprises 
multiple lines of defence involving a diverse set of functionally distinct cell types and 
soluble factors which act in a concerted manner to prevent or limit the spread of 
infection. As viral replication occurs exponentially within hours whereas the adaptive 
immune response requires several days to be initiated, the innate immune response in 
the lung is a crucial component to control viral titres during the early phase of 
infection so as to allow sufficient time for development of the adaptive anti-viral 
response.  
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1.4.1       Mucus Secretions and Epithelial Layer 
 
The first line of protection against the influenza virus is provided by the mucus lining 
of the respiratory tract which contains sialic acid-glycoproteins with anti-
hemagglutinating properties. These glycans serve as decoy receptors for the virus and 
prevent binding to the epithelial cells beneath (Boat et al. 1976). One such protein 
that has been characterised is the lung scavenger receptor glycoprotein-340 
(Hartshorn et al. 2003). The mucus also contains collectins, such as mannose binding 
lectin, and surfactant protein D which can bind to glycosylated residues on the HA 
protein, resulting in either direct blockade of viral binding or opsonisation of the virus 
for clearance by phagocytes (Reading et al. 1997). The lung epithelium is also 
equipped with cilia which push viruses trapped within the mucus to the larynx to be 
swallowed and destroyed by the high acidity within the stomach. Upon infection, the 
alveolar epithelial cell layer is also able to actively recruit immune cells such as 
monocytes to the site of infection by upregulating adhesion molecules and secreting 
chemokines to facilitate leukocyte transepithelial migration (Herold et al. 2006).  
 
1.4.2       Type I Interferons 
 
Type I interferons (IFNs) IFN/ play a crucial role in limiting the replication of the 
virus and are secreted by epithelial cells as well as by innate immune cells such as 
monocytes, macrophages and plasmacytoid dendritic cells. Stimulation of cells by 
IFNs results in the activation of a diverse range of IFN-stimulated genes (ISGs) 
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which act in concert to induce an anti-viral state. Two prominent antiviral 
mechanisms triggered by IFN signalling are the activation of Protein Kinase R, which 
inhibits global protein translation by phosphorylating the elongation initiation factor 
eIF2, and the activation of RNase L which nonspecifically degrades both viral and 
host RNA in order to suppress viral replication (Garcia-Sastre and Biron 2006). The  
myxovirus virus resistance gene Mx is another critical ISG involved in host defence, 
the name ‘myxovirus’ referring to the influenza virus against which the protein was 
first discovered to have a protective role. The Mx protein suppresses transcription of 
influenza RNA by sequestering both the NP as well as PB2 viral polymerase (Turan 
et al. 2004) and mice deficient in either the type I interferon receptor (IFN-/R) or 
the Mx1 gene demonstrate enhanced susceptibility to infection (Salomon et al. 2007; 
Szretter et al. 2009). 
 
Apart from directly mediating antiviral effects, IFNs also stimulate cells to upregulate 
expression of MHC I expression to enhance presentation of viral peptides on the cell 
surface. IFN-mediated upregulation of MHC I is especially important in dendritic 
cells which have a key role in the initiation of the cytotoxic CD8 T-cell response. 
This is discussed in greater detail in section 1.5.3.  
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1.4.3       Phagocytes 
 
Macrophages and neutrophils have a critical role in controlling viral titres early in 
infection and antibody-mediated depletion of either macrophages or neutrophils prior 
to sublethal infection with the 1918HA/NA:Tx91 recombinant virus results in 
uncontrolled virus growth and mortality. By contrast, depletion of macrophages and 
neutrophils initiated 3 or 5 days after infection did not alter the disease outcome, 
demonstrating that macrophages and neutrophils act primarily to control viral 
replication at the early stages of infection (Tumpey et al. 2005). As the introduction 
of phagocytosis inhibitors into the airways of mice results in increased lethality 
(Watanabe et al. 2005), it is likely that the principle contribution of macrophages of 
neutrophils during the early phase of infection is to phagocytose the virus or infected 
cells. It should also be noted that macrophages are highly susceptible to infection, 
however synthesis of viral proteins is abruptly halted midway and the macrophage 
undergoes apoptosis before progeny virus can be released from the cell (Hofmann et 
al. 1997). The generation of reactive oxygen species (ROS) by oxidative/respiratory 
burst in phagocytes does not appear to be a major factor for conferring host protection 
against influenza infection. In fact, mice deficient in NADPH oxidase (which is 
necessary to generate ROS in phagocytes) exhibit improved phagocyte recruitment to 
the airways, enhanced rate of viral clearance and improved lung function upon 
influenza infection, suggesting that phagocyte ROS not only contributes significantly 
to lung injury, but also attenuates the immune response possibly by acting as a second 
messenger in cell signalling pathways (Snelgrove et al. 2006).  
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1.5    Adaptive Immune Responses to the influenza virus 
 
In the event that the innate immune system is unable to eliminate the virus, the 
adaptive immune response is mobilised to neutralise the invading pathogenic 
challenge. The main arms of the adaptive immune system involved in clearing the 
virus are the B-cells and cytotoxic CD8 T-cells. CD4 T-cells, although not directly 
involved in mediating viral clearance, are nonetheless essential in providing T helper 
function for optimal generation of antibody and cytotoxic responses.  
 
1.5.1       Humoral Immunity 
 
Humoral immunity against the influenza virus mediates long-term protection through 
neutralizing antibodies against HA and NA epitopes which prevent reinfection by an 
antigenically similar or identical strain. This forms the basis for current seasonal 
influenza vaccination regimes and continues to be a subject of major interest as 
current vaccination strategies are unable to provide a large degree of cross-protection. 
Apart from providing long-term immunity against homologous reinfection, B-cells 
also have a significant contribution to host immunity against the influenza virus 
during primary challenge. This is demonstrated by observations that mice deficient in 
B-cells, either by chronic anti-IgM administration or by transgenic disruption of the 
immunoglobulin μ heavy chain locus (μMT mice) have compromised clearance of 
the virus from the respiratory tract (Kris et al. 1985; Topham and Doherty 1998). 
Antibody responses are rapidly engendered in response to infection and begin as early 
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as 48 hours p.i. in the lymph node (Coro et al. 2006), with detectable antiviral IgM 
titres in the serum within 4 to 5 days p.i. (Baumgarth et al. 1999). IgG and secretory 
IgA (sIgA) are also involved in protective immunity and cooperate to provide 
protection at different anatomical sites. In the upper respiratory tract, sIgA in the 
muscociliary blanket is the predominant immunoglobulin and serves to prevent 
attachment of the influenza virus to epithelial cells in the nasal passages (Renegar et 
al. 2004) whereas in the lower respiratory tract, serum IgG transudate forms the main 
protective barrier for the larger surface area of alveolar epithelia (Ito et al. 2003).  
 
1.5.2       CD4 T-cell response to Influenza 
 
Unlike their CD8 T-cell counterparts, the role of CD4 T-cells in influenza has not 
been as widely and intensively studied due to two limiting factors; the paucity of CD4 
T-cells during infection and difficulty of detecting virus-specific CD4 T-cells using 
MHC II ultimers owing to their low binding avidity (La Gruta et al. 2007). Also, 
unlike the CD8 T-cell response which has several immunodominant epitopes such as 
the PB1701-713 PA224-233 and NP366-374 which alone account for three-quarters of the 
virus-specific CD8 T-cells (Doherty et al. 2006), CD4 T-cell epitopes are widely 
distributed (Crowe et al. 2006) and thus present a challenge when trying to obtaining 
a sufficiently large quantum for estimating the virus-specific response. To overcome 
these limitations, novel approaches such as the development of transgenic mice 
strains with CD4 T-cells specific for influenza virus (Scott et al. 1994) or the use of 
recombinant influenza expressing the OVA CD4 T-cell epitope (OT-II flu) have been 
employed to dissect the role of CD4 T-cells (Thomas et al. 2010). 
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The principle role of virus-specific CD4 T-cells during infection is to provide T-cell 
help to augment B-cell antibody production and CD8 T-cell cytolysis of infected cells 
to clear the virus from the respiratory tract. Th1 CD4 T-cell responses are important 
for promoting viral clearance as the adoptive transfer of Th1 virus-specific CD4 T-
cell clones are able to confer protection against a lethal dose of influenza whereas 
mice that received Th2 clones fail to survive (Graham et al. 1994). CD4 T-cell are 
also vital for proper development of CD8 T-cell memory responses (Sun and Bevan 
2003) and the absence of CD4 T-cell help during primary infection results in a 
diminished secondary memory CD8 response in response to heterologous virus 
challenge (Belz et al. 2002). Memory CD4 T-cell responses have recently been 
identified to be important for the early induction of innate pro-inflammatory 
cytokines in heterosubtypic infection. Cognate interaction of memory but not naïve 
CD4 T-cells could mediate early control of viral titres in an IFN- dependent manner 
(Teijaro et al. 2010), and only Th1 and Th17 but not Th2 and unpolarized Th0 CD4 
memory subsets could perform this function (Strutt et al. 2010).  
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1.5.3       CD8 T-cell response to Influenza 
 
CD8 T-cells are important for mediating viral clearance through lysis of infected cells 
and the establishment of a robust CD8 T-cell response is a key factor in determining 
the outcome of an influenza infection. Mice deficient in CD8 T-cells exhibit delayed 
clearance of the influenza virus, elevated pulmonary viral titres and increased 
mortality (Bender et al. 1992). Conversely, enhancement of CD8 T-cell responses by 
adoptive transfer of virus-specific effector CD8 T-cells is able to confer protection 
against lethal doses of influenza (Cerwenka et al. 1999; Hamada et al. 2009), even in 
mice lacking B-cells (Graham and Braciale 1997). CD8 T-cells recognise infected 
cells by cognate interaction of the TCR with viral antigens presented in the context of 
MHC I on the cell surface, and cytolysis of the infected cell is mediated through FAS, 
Perforin, Granzyme B and TRAIL. The abrogation of any of these effector molecules 
results in the reduction of cytotoxic activity and delayed viral clearance (Topham et 
al. 1997; Brincks et al. 2008). Effector CD8 T-cells also secrete large amounts of 
proinflammatory cytokines such as IFN-, TNF- and GM-CSF. IL-17 secreting CD8 
T-cells, Tc17, were also recently identified during influenza infection, and adoptive 
transfer of in vitro generated Tc17 cells can confer protection against lethal challenge 
(Hamada et al. 2009).  
 
Although the quality of CD8 T-cell response in terms of effector function is crucial to 
viral clearance, the quantity of virus-specific cells generated is equally important in 
determining the outcome of infection. Tetramer staining of CD8 T-cells reveals that 
there is a strong correlation between the number of virus-specific effector CD8 T-
cells in the lung and viral titre reduction (Flynn et al. 1999; Lawrence et al. 2005). 
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Studies employing the adoptive transfer of effector CD8 T-cells to demonstrate 
protection against lethal challenge typically inject 106 to 107 cells and survival is 
correlated with the number of cells transferred in a dose dependent manner 
(Cerwenka et al. 1999; Hamada et al. 2009). This highlights the importance of 
generating sufficiently large numbers of effector CD8 T-cells populations during 
influenza infection.  
 
Interestingly, although effector CD8 T-cells significantly contribute to pro-
inflammatory responses, they were recently described to have a crucial 
immunomodulatory role during actue influenza infection. TNF- and IFN- secreting 
effector virus-specific CD8 T-cells were observed to simultaneously produce large 
quantities of IL-10 to counterbalance proinflammatory responses and the blockade of 
T-cell derived IL-10 resulted in enhanced pulmonary inflammation and lethality (Sun 
et al. 2009).  
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1.6    Dendritic Cells 
 
Dendritic cells (DCs) are specialised antigen presenting cells (APCs) of the innate 
immune system that have a critical role in initiating adaptive immune responses 
through their ability to mediate the capture, processing and presentation of antigens to 
T cells (Steinman 1991). The Langerhans cell, the archetypal DC, was first identified 
in the skin within the basal layer of the epidermis by Paul Langerhans in the mid-
nineteenth century, but it was then thought to be a neuron owing to its dendrite 
structure. In the 1970s, Ralph Steinmann coined the term ‘dendritic cells’ to describe 
adherent cells isolated from the peripheral lymphoid organs that had long dendrite 
extensions and were morphologically distinct from other mononuclear phagocytes 
(Steinman and Cohn 1973). Several years later, DCs were shown to be critical 
accessory cells for the induction of primary mixed lymphocytes responses, providing 
the first evidence that DCs are the principal simulators of T-cell responses (Steinman 
et al. 1983).  
 
1.6.1       Origin and Function of DCs 
 
DCs are derived from hematopoietic bone marrow progenitor cells which seed 
various tissue sites through the circulation and develop into dendritic cells (Fogg et 
al. 2006; Onai et al. 2007). Within the tissue, the differentiation of the precursors into 
DCs is critically dependent on the receptor tyrokinase kinase Flt3 (Waskow et al. 
2008) and depending on the subtype it terminally differentiates to, further requires the 
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expression of key transcription factors unique to the development of that subset 
(Merad and Manz 2009). The function of DCs changes as they differentiate from 
immature to mature form; Immature DCs are functionally specialised for immune 
surveillance and actively acquire antigen from the surrounding environment to 
monitor for the presence of pathogens. Upon encounter with pathogens, DCs rapidly 
acquire a ‘mature’ phenotype where they down-regulate antigen acquisition and 
correspondingly increase surface expression of MHC Class I and II and also co-
stimulatory molecules CD40, CD80 and CD86 required for effective priming of T-
cells (Banchereau et al. 2000). At this stage, DCs also upregulate the chemokine 
receptor CCR7 for homing to lymphoid tissues and migrate from peripheral tissues 
sites to the draining lymph node to present the antigens acquired to circulating T-cells 
(Gunn et al. 1999).  
 
DCs can be distinguished from other APCs such as B-cells and macrophages by their 
unique ability to efficiently prime naive T-cells and play a crucial role in bridging the 
innate and adaptive immune systems. This ability of DCs to mediate T-cell priming 
can been attributed to several unique characteristics: DCs when matured express high 
levels of costimulatory molecules, possess long dendritic process that enable cell 
contact with multiple T-cells simultaneously, and secrete cytokines that have a 
modulatory effect on the threshold of T-cell priming (Raue et al. 2004). Another 
important attribute in particular for priming of CD4 T-cells, is the possession of 
specialised intracellular MHC Class II-rich compartments which are recruited to 
phagosomes containing internalised antigens to facilitate peptide loading onto MHC-
Class II (Nijman et al. 1995).  
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1.6.2       Heterogeneity of DCs 
 
DCs exist as a heterogeneous population and can be broadly categorised by the type 
of tissues they populate – lymphoid and non-lymphoid organs. Within lymphoid 
organs such as the spleen and lymph nodes, three distinct DCs populations can be 
identified, namely CD4+CD8neg, CD4negCD8+ and CD4negCD8neg DCs (Vremec et 
al. 2000). Within non-lymphoid organs, the complexity of DC subsets increases as the 
surface markers of the DC subsets varies with the tissue. In the gut for example, three 
DC subsets can be identified based, namely CD103+CD11b+, CD103negCD11b+, 
CD103+CD11bneg DCs whereas in the lung however, only two subsets exist, which 
are the CD103negCD11bhi, CD103+CD11blo/neg DCs (Edelson et al. 2010). 
Plasmacytoid DCs, which are non-classical DCs expressing the B-cell marker B220 
are also present in many tissue sites, however, they are mainly found in lymphoid 
organs and exist at low frequencies at peripheral tissue sites. Different subsets of DCs 
have specialized functions, for example, although all DCs can present antigen via 
MHC II, splenic CD4+ DC are more efficient at antigen presentation via the MHC II 
route to CD4 T-cells compared to CD8+ DC. On the other hand, CD8+ DC possess 
a unique capability to efficiently cross-present antigen to CD8 T-cells whereas other 
DCs perform this less efficiently. These differences in antigen presentation capacities 
are due to intrinsic differences in the expression of molecules involved in the antigen 
processing machinery (Dudziak et al. 2007) as well as the manner in which antigen is 
processed within intracellular compartments (Lin et al. 2008). 
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1.7    Lung Dendritic Cells 
 
Lung DCs were first described in 1986 as MHC Class II positive cells in the visceral 
pleura which shared structural similarities to Langerhans cells and possessed a 
distinct phenotype from alveolar macrophages and B-cells (Sertl et al. 1986). DCs 
isolated from enzyme-digested lungs displayed a low buoyant density, were loosely 
adherent and also potent stimulators of resting T-cells in a primary allogenic mixed 
leucocyte reaction (Pollard and Lipscomb 1990). Lung DCs are widely disseminated 
at steady state and can be found in the tracheal epithelium, alveolar septal walls and 
conducting airways (Holt and Schon-Hegrad 1987). The lung DC network in the 
conducting airways is extensive and staining of the trachea for MHC Class II reveals 
that the airways are populated by numerous DCs with multiple long delicate 
processes. The density of DCs in the airways varies with anatomical location, ranging 
from 600-800 per mm2 epithelial surface in the large upper airways to 75 per mm2 
epithelial surface in the smaller airways (Schon-Hegrad et al. 1991).  
 
1.7.1       Lung Dendritic Cell Subsets and Origin 
 
The current consensus of the literature is that DCs in the lung comprise two main 
subsets, namely the CD11blo/negCD103+ and CD11bhiCD103neg DCs, both of which 
are positive for CD11c as well (Sung et al. 2006). A small number of plasmacytoid 
DC are also present in the lung which can be identified as 
CD11clowCD11bnegSiglecH+ cells, however these constitute a minority population at 
steady-state (GeurtsvanKessel and Lambrecht 2008). Imaging of the lung 
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parenchyma reveals that both CD11blo/negCD103+ DCs and CD11bhiCD103neg DCs are 
present in the periarteriolar region, however, CD11blo/negCD103+ DCs form the 
majority in the subepithelial region in the airway mucosa and are tightly apposed to 
the basal surface of bronchial epithelial cells. Whilst there is clear evidence that both 
lung conventional DC subsets are derived from hematopoietic bone marrow 
progenitor cells, there is ambiguity to the precursors of these populations. Fate-
mapping experiments using fluorescent latex beads injected into the blood of mice by 
Jakubzick and colleagues suggest that the Ly6ClowCCR2low monocytes differentiated 
into CD11b+ lung DCs, whereas Ly6ChiCCR2hi monocytes differentiated into 
CD103+ DCs (Jakubzick et al. 2008). However, experiments by others show that 
blood monocytes do not give rise to lung DCs, but instead originate from a rare DC 
progenitor cell found in the blood and bone marrow called the pre-DC, which 
requires Flt3 for homeostatic differentiation into both CD11b+ and CD103+ DCs 
(Ginhoux et al. 2009). 
 
1.7.2       Lung Dendritic Cells and Tolerance 
 
Due to the constant exposure of the lung to the environment, lung DCs have a critical 
role as sentinels to detect invading airborne pathogens. To perform this function, lung 
DCs constitutively sample antigens from the airways, even under baseline conditions, 
and migrate to the draining lymph node to present antigens to circulating 
lymphocytes. Further evidence supporting the lung DC sentinel paradigm was 
provided by Holt and colleagues who demonstrated the lung DCs in the rat had a 
rapid turn-over rate of 2-days in contrast to epidermal Langerhans cells which had a 
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half-life of 15-days (Holt et al. 1994). This reflects a continual and rapid 
replenishment of DCs in the lung to take the place of those that have migrated to the 
lymph node. Upon encounter with pathogens or TLR-stimuli, lung DCs can be 
rapidly mobilised and display an accelerated rate of migration to the lymph node 
within the first 24 hours after challenge (Legge and Braciale 2003). 
 
Lung DCs play a critical role in discriminating between airborne pathogens and 
innocuous environmental antigens that challenge the lung. In response to non-
pathogenic proteins, lung DCs induce tolerance in an IL-10 and ICOS-dependent 
manner by stimulating the development of IL-10 secreting CD4 T-regulatory 1 cells 
(Akbari et al. 2001; Akbari et al. 2002). The induction of tolerance is also critically 
dependent on the ability of lung DCs to migrate to the lymph node and is CCR7-
dependent (Hintzen et al. 2006). The activation status of lung DCs is critical for 
establishing tolerance to inhaled antigens as maturation of lung DCs induced by TLR 
stimulation (Eisenbarth et al. 2002) or infection with influenza (Brimnes et al. 2003) 
results in the induction of inflammatory responses against inhaled non-immunogenic 
proteins. In vivo imaging of CD4 T-cell and lung DC interactions in the lung draining 
lymph node by two-photon laser microscopy reveals that DC-CD4 T-cell contacts are 
more stable and long-lasting when DCs had been stimulated with LPS compared to 
contacts of shorter duration under tolerising conditions in the absence of TLR signals 
(Bakocevic et al. 2011).  
 
DCs in the lung play a key role in the induction of Th2 responses under non-
tolerizing conditions. The adoptive transfer of OVA-pulsed DCs into the lungs can 
induce Th2 responses against OVA (Lambrecht et al. 2000). Similarly, depletion of 
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lung DCs prior to intranasal challenge of allergen using the CD11c-DTR mice model 
was accompanied by the loss of the characteristic features of asthma (van Rijt et al. 
2005). It was recently suggested that basophils and not lung DCs are necessary and 
sufficient for the induction of Th2 immunity to inhaled antigen and serve as an early 
source of IL-4 for skewing of type II responses (Sokol et al. 2009). However this 
conclusion was later shown to be incorrect as the use of anti-FcRI to deplete 
basophils also resulted in concomitant depletion of a subset of inflammatory DCs 
which also expressed FcRI. Furthermore, when more stringent protocols were 
applied for cell purification and analysis, basophils poorly acquired fluorescent 
antigen in the lung, did not express high levels of MHC II, poorly stimulated CD4 T-
cell proliferation and did not induce sensitisation to allergen when adoptively 
transferred intratracheally (Hammad et al. 2010).  
 
There is increasing evidence that lung DCs do not act in isolation but instead rely on 
instructions from bronchial epithelial cells which first attract DCs via release of 
chemokines and skew DC function towards a Th2 activating mode by secreting pro-
Th2 cytokines such as GM-CSF, TSLP, IL-25 and IL-33 (Lambrecht and Hammad 
2010). Further support for this hypothesis comes from the observation that 
overexpression of these cytokines (which are non-DC derived), results in spontaneous 
Th2 sensitisation to harmless proteins (Zhou et al. 2005).   
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1.7.3       Lung Dendritic Cells and Influenza  
 
Although a large part of research on lung DCs has focussed on the characterisation of 
on their role in mediating respiratory tolerance and the pathogenesis of asthma, lung 
DCs also have been demonstrated to play an important role in mediating clearance of 
respiratory viral infection. Lung DC are pivotal to the initiation of the adaptive 
immune response against respiratory viral infection and depletion of lung DCs prior 
to influenza infection results in a dramatic attenuation of virus-specific lung CD8 T-
cell responses and higher viral loads (GeurtsvanKessel et al. 2008). Apart from being 
involved in the initial process of priming CD8 T-cells during early infection, DCs 
also play an essential role in the late phase of infection by orchestrating the efficient 
recruitment of virus-specific CD8 T-cells in the lung parenchyma (Aldridge et al. 
2009), promoting their survival by stimulating IL-2 secretion through CD70-CD27 
interactions (Ballesteros-Tato et al. 2010), and restimulating virus-specific effector 
CD8 T-cells infiltrating the lung for optimal cytotoxicity through cognate TCR-MHC 
interactions (McGill et al. 2008). The efficient release of CD8 T-cell effector 
cytokines in the lung is also highly dependent of lung DC expression of co-
stimulatory molecules as virus-specific CD8 T-cells require interaction with lung 
DCs presenting antigen and expressing CD80 and CD86 in order secrete 
proinflammatory cytokines (Hufford et al. 2011). 
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A seminal study by van Heijst and colleagues using a DNA bar-coding technology to 
track T-cells derived from individual clones demonstrate that the recruitment of naive 
antigen-specific cells to the lymph node is near complete during influenza infection, 
and thus the CD8 T-cell clonal burst size is not limited by the recruitment of CD8 T-
cells, but instead by the recruitment rate of DCs to the lymph node (van Heijst et al. 
2009). This further underscores the importance of lung DCs in controlling the 
magnitude of CD8 T-cell response to influenza infection. 
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1.8    Aims Of This Study 
 
While the importance of dendritic cells in the initiation of CD8 T-cell expansion 
during influenza infection is well established, the relative contribution of different 
DC populations to initiate this process through viral uptake, migration to the draining 
lymph node remain poorly addressed owing to difficulties in the visualization of viral 
uptake in vivo. The present study sought to investigate these aspects of influenza 
immunity, providing a base for rational vaccine designs able to provide optimal CD8 
T-cell mediated immunity. We also investigated the relative contributions of DC 
populations to mediate priming of CD8 T-cells and identified key differences in the 
antigen processing pathways. 
 
Specific Aims 
1. Establish a mouse model of influenza infection and broadly characterise the 
inflammatory response 
2. Characterise DCs isolated from the lung both at resting state and during 
influenza infection 
3. Characterise the uptake and migration of influenza virus by lung DCs subsets 
using lipophilic-dye-labelled virus 
4. Characterise the antigen presenting capacities of lung DC subsets and identify 
differences in the underlying mechanisms of antigen processing 
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Chapter 2: Materials and Methods 
 
2.1    Media and buffers 
 
PBS Buffer 
PBS buffer was commercially obtained from 1st base (Singapore) as a 10  stock, 
ultrapure grade. The 10 stock consists of 137mM NaCl, 2.7mM KCl and 10mM 
phosphate buffer. The stock was diluted with 9 parts with sterile water to give 1  
PBS.  pH of the buffer was 7.4. 
 
MACS buffer 
MACS buffer consists of 1  sterile PBS supplemented with 2% FCS and 5mM 
EDTA. The pH of the buffer was adjusted to 7.4. 
 
FACS buffer 
FACS buffer consists of 1  PBS supplemented with 1% FCS and 5mM EDTA. 
0.05% sodium azide was added as a preservative to permit use and storage under non-
sterile conditions. The pH of the buffer was adjusted to 7.4.  
Important note: Although the components are similar, FACS buffer cannot be 
substituted for MACS buffer to isolate cells as the presence of sodium azide, although 
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not toxic to the cells at the concentration used, may potentially inhibit certain 
metabolic functions of the cells. 
 
Permeabilization buffer 
Cell permeablisation buffer was prepared for intracellular staining using 1  PBS 
containing 0.1% BSA, 0.1% Saponin and 0.1% sodium azide. The pH of the buffer 
was adjusted to 7.4. 
 
Red Blood Cell Lysis 
The following components were added to make a 10  RBC lysis stock solution 
a) Ammonium Chloride  8.3g 
b) Sodium Bicarbonate  0.84g 
c) EDTA    0.03g 
The components were dissolved in water and the pH adjusted to 7.4, filter sterilised 
and made up to 100ml. For use as a 1  solution, the 10  stock solution was diluted 
with water. 
 
Optiprep density centrifugation media for APC isolation 
Optiprep (Axis-shield, Sigma, Singapore) was provided as a 60% w/v Iodixanol in 
water with a density of 1.32g/ml that has been tested for endotoxin and is certified to 
have less than 0.13EU/ml.  Optiprep was diluted using optiprep diluent (see below for 
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formulation) to achieve a density of 1.064g/ml. This density corresponds to a 
11.173% w/v Iodixanol solution.  
 
Optiprep diluent 
Optiprep diluent consists of 0.8% (w/v) NaCl, 5mM EDTA and 10mM Tricine NaOH 
at pH 7.4 at 4oC made under sterile conditions. 
 
Optiprep Formulation for a density of 1.064g/ml 
For 
1.064g/ml
Vol. of OPTIPREP 
/ml 
Vol. of diluent 
/ml 
Total Volume 
/ml 
18.62 81.38 100 
37.24 162.76 200 
55.87 244.13 300 
74.49 325.51 400 
93.11 406.89 500 
 
 
Liberase Enzyme Blend 
Liberase TL Research Grade (low thermolysin concentration) was obtained from 
Roche (Roche Applied Science, USA) and dissolved in plain RPMI-1640 to obtain a 
concentration of 2mg/ml which corresponds to a colleganse activity of 0.52 Wünsch 
units/ml. This forms a 10  Liberase stock solution which is aliquoted and stored at -
30oC. For digestion of tissues, the 10  Liberase stock solution is diluted 10-fold with 
plain RPMI-1640 and supplemented with 1% v/v FCS, which is added to preserve the 
viability of DCs. 
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Buffers for ELISA 
Wash buffer for ELISA was 1  PBS with 0.5% v/v Tween-20, pH adjusted to 7.2 to 
7.4.  
Blocking buffer was 1  PBS with 1% w/v BSA. 
 
Alsever’s Solution for storage of Guinea Pig RBCs 
The following components were added to make Alsever’s Solution 
a) Citric Acid  55mg 
b) Sodium Citrate  800mg 
c) Sodium Chloride 420mg 
d) D-glucose  2050mg 
The components were dissolved in distilled water, and the pH adjusted to 6.1 and 
made up to 100ml.  
 
Complete RPMI for cell culture 
Complete RPMI was prepared using RPMI-1640 with L-Glutamine (Gibco, 
Invitrogen, Singapore) supplemented with the following,  
a) 10% v/v FCS (Gibco, Invitrogen, Singapore), heat inactivated for 30 mins at 
55oC. 
b) 1% v/v Non-essential amino acid (Sigma, Singapore) from 100  stock 
c) 1mM Sodium Pyruvate (Sigma, Singapore) 
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d) 50μM -Mercaptotethanol (Sigma, Singapore) 
e) 100 IU/ml Penicillin and 0.1mg/ml Streptomycin (Sigma, Singapore) 
 
Complete DMEM for cell culture 
Complete DMEM was prepared using Dulbecco’s Modified Eagle Medium with L-
Glutamine and 4.5g/L D-glucose (Gibco, Invitrogen, Singapore) supplemented with 
the same components as complete RPMI. 
 
Plain DMEM at 2 Concentration 
DMEM with L-Glutamine and 4.5g/L D-glucose in powdered form was purchased 
from Gibco and dissolved in half the recommended volume of sterile water. The pH 
of the solution was adjusted to 7.4 and supplemented with 2% v/v Non-essential 
amino acid (Sigma, Singapore) as well as 200 IU/ml Penicillin and 0.2mg/ml 
Streptomycin (Sigma, Singapore) before sterile filtration through a 0.22m filter 
(Nalgene, USA). 
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2.2    List of Antibodies Used 
 
  
Primary Antibodies
Target Host Clone Conjugation Source
B220 Rat RA3-6B2 FITC BD Pharmingen
CCR7 Rat 4B12 Biotin eBioscience
Hamster 500A2 eFluor450 eBioscience
Rat 17A2 APC eBioscience
Rat RM4-5 PB BD Pharmingen
Rat RM4-5 PE BD Pharmingen
Rat RM4-5 APC eBioscience
Rat 53-6.7 PB BD Pharmingen
Rat 53-6.7 PE BD Pharmingen
Rat 53-6.7 PE-Cy7 BD Pharmingen
Rat M1/70 PE BD Pharmingen
Rat M1/70 PE-Cy7 eBioscience
Rat M1/70 APC BD Pharmingen
Hamster N418 FITC BD Pharmingen
Hamster HL3 PE BD Pharmingen
Hamster N418 PerCP Cy5.5 eBioscience
Hamster N418 AF647 Biolegend
CD16/32 Rat 2.4G2 None Biolegend
CD19 Rat 1D3 PE BD Pharmingen
CD25 Rat PC61 PE BD Pharmingen
CD40 Rat 3/23 FITC BD Pharmingen
CD44 Rat IM7 APC BD Pharmingen
CD62L Rat MEL-14 FITC BD Pharmingen
CD80 Rat 16-10A1  FITC BD Pharmingen
CD86 Rat GL1  FITC BD Pharmingen
Rat 2E7 PE eBioscience
Rat 2E7 APC eBioscience
Granzyme B Rat 16G6 AF647 eBioscience
H-2Kb Mouse 28-8-6  FITC eBioscience
Ly6C Rat HK1.4 PB Biolegend
Ly6G Rat 1A8 PE BD Pharmingen
Rat M5/ 114.15.2 eFluor450 eBioscience
Rat M5/ 114.15.2 PE BD Pharmingen
Rat M5/ 114.15.2 PerCP Cy5.5 eBioscience
SIINFEKL-Kb Mouse 25-D1.16 Biotin eBioscience
TAP1 Goat sc11465 - Santa Cruz
TAP2 Goat sc11474 - Santa Cruz
TNF- Rat MP6-XT22 AF488 Biolegend
V8.1/8.2 Rat KJ16  PE eBioscience
Seconday Antibodies/Detection Reagents
Target Host Conjugation
Anti-Goat Chicken AF488
Anti-Human Goat AF488
Strepavidin Dylight 546
Strepavidin PE
Jackson Laboratories
Invitrogen
CD103
IA/IE
Source
Invitrogen
Invitrogen
CD3e
CD4
CD8
CD11b
CD11c
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2.3    Cell Isolation 
 
Isolation of CD8 T-cells 
1. Spleens and lymph nodes were harvested from mice and physically disrupted 
by pushing through a 70m cell strainer to obtain a single cell suspension.  
2. Cells were washed once in MACS buffer and layered onto Ficoll-Paque (GE 
Healthcare, USA) and centrifuged at 600  g for 20 mins at room temperature.  
3. Cells accumulating at the interface were collected, washed, and counted. The 
cells were pelleted and the supernatant was decanted as much as possible to 
reduce the amount of liquid remaining.  
4. The cell pellet was then raked to resuspend the cells and anti-CD8 
conjugated MACS beads was added to the cell pellet at 4l per million cells 
(Miltenyi Biotec, Germany).  
5. The cells were incubated in the dark at 4oC for 30mins with occasional 
flicking of the tube every 5 mins to prevent cells from settling at the bottom.  
6. After incubation, cells were washed once with 3ml of MACS buffer, pelleted 
and resuspended in 1ml of MACS buffer and loaded onto an LS column 
(Miltenyi Biotec, Germany).  
7. The column was washed with 3ml of MACS buffer for 4 times before eluting 
with 4ml of complete RPMI.  
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CFSE Labelling of CD8 T-cells and adoptive transfer 
CD8 T-cells that have been isolated by magnetic separation were labelled with 5μM 
of either carboxyfluorescein succinimidyl ester, CFSE or the violet equivalent, violet 
CFSE (Molecular Probes, Invitrogen, USA) according to manufacturer’s instructions. 
Labelled cells were washed twice and resuspended in PBS before intravenous 
injection into tail vein of BALBc mice for Clone 4 cells and C57BL6 mice for OT-I 
cells.  Approximately 2  106 cells were injected into each mice. 
 
Isolation of Splenic Dendritic cells 
1. Spleens were digested in 1  Liberase (which contains collagenase) 
supplemented with 1% v/v FCS to preserve the viability of DCs. The spleens 
were finely cut using scissors in the Liberase buffer and incubated at 37oC for 
15 minutes. The partially digested spleen tissue was then resuspended with a 
pastuer pipette to break it up further and incubated for another 15 minutes.  
2. The resulting digested cells were then pushed through a 70m cell strainer 
(BD pharmingen, USA) to obtain a single cell suspension. The cells were 
washed twice in MACS buffer to remove any trace of Liberase.  
3. After the second wash, the cell pellet was raked vigorously and resuspended 
in 3ml of OPTIPREP (g=1.064g/ml) following which 2ml of FCS was gently 
overlaid on top of the OPTIPREP cell solution. The cells were centrifuged at 
1700  g for 10 minutes at 4oC with brakes and acceleration set to zero.  
4. The low density cells which accumulated at the interface between OPTIPREP 
and FCS were harvested and transferred into a fresh tube.  
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5. The cells were washed with MACS buffer to remove any OPTIPREP present 
in the solution. The cell pellet was raked to resuspend cells and anti-CD11c 
MACS beads were added to at a volume of 10μl per 10 million cells with a 
minimum of 10μl of beads being used if cell numbers were below 10 million. 
The mixture was incubated at 4oC for 10 minutes.  
6. The cells were washed by addition of 3ml of MACS buffer and centrifuged at 
350  g to pellet the cells. As much of the supernatant was decanted as 
possible and the cell pellet resuspended in 1ml of MACS buffer before being 
placed in a LS MACS column that has been pre-equilibrated with MACS 
buffer.  
7. Once all the cells have entered, the column was washed with 3ml of MACS 
buffer for 4 times before eluting with 4ml of complete RPMI. 
 
Isolation of Lung Dendritic cells 
The protocol for isolating DCs from the lung is identical to that of isolating DCs from 
the spleen with the exception that prior to the addition of anti-CD11c MACS beads, 
Fc block (2.4G2) is added at 0.2μg/million cells to the cells and incubated for 10 
minutes at 4oC. This is to increase the purity of the cells isolated and remove 
contaminating B-cells which otherwise non-specifically bind to the MACS beads via 
the Fc receptor. It is also important to note that CD11c is also expressed by lung 
macrophages, thus when isolating CD11c+ cells by positive selection, approximately 
50% of the cells will be macrophages. Nonetheless, this technique is useful for the 
enrichment of lung DCs for in vitro experiments and facilitates analysis by removing 
a large number of irrelevant cells from the preparation.   
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2.4    Preparation of Influenza Virus 
 
Influenza Virus Culture in Chicken Eggs 
9 to 10 day old embryonated chicken eggs were purchased from Bestar (Singapore). 
After candling to locate the air cell and mark out the large blood vessels, a 21G 
needle was used to puncture the egg shell. Using a fine needle, the influenza virus 
A/PR8/34 (H1N1) stock (ATCC VR-95, ATCC, USA) diluted 100  in PBS buffer 
was carefully injected into the allantoic cavity through the hole. The hole was then 
sealed with melted wax to preserve sterility. The eggs were then kept in a 37oC 
incubator without CO2. The eggs were candled daily to check for viability of the 
embryo. After 2 to 3 days, the embryos were culled by placing the eggs at 4oC for 4 
hours afterwhich the egg was broken through the air cell and the allatoic fluid was 
harvested. The allantoic fluid was clarified by spinning at 3000  g before it was 
aliquoted and stored at -80oC.  
 
Influenza Virus Culture in MDCK cells 
Manine Darby Canine Kidney (MDCK) cells (ATCC CCL-34, ATCC, USA) were 
grown in T75 tissue culture flasks (NUNC, USA) using complete DMEM until 
completely confluent. Before addition of virus, the cells were washed with sterile 
PBS to remove traces of serum which may inhibit viral growth. 10ml of plain DMEM 
supplemented with 4μg/ml of TPCK treated trypsin (Pierce, USA) was added to the 
flask followed by the virus stock. The cells were incubated at 37oC with 5% CO2 and 
were visually checked daily for signs of cytopathological effects. When more than 
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90% the MDCK cells exhibited cytopathological effects, the media was harvested and 
centrifuged at 3000  g at 4oC for 5 minutes to pellet floating cells and other large 
debris. The supernatant was decanted and frozen at -80oC until sufficient quantity had 
been obtained for concentration of the virus. 
 
RBC Hemagglutination Assay 
Fresh guinea pig RBCs were washed twice in Alsever’s solution and stored for up to 
2 weeks at 4oC. For hemagglutination assay, RBCs in Alsever’s solution were washed 
twice in PBS and pelleted. To obtain a 1% RBC solution for the assay, the required 
volume of RBCs was directly pipetted from the pellet and added to 1  PBS. 
The influenza virus was serially diluted two-fold in 25μl volume across a 96-well V 
bottom plate. The 1% RBC solution was then added to each well using a multichannel 
pipette and left for 2 hours. Viral titre was determined by taking the reciprocal of the 
last virus dilution that exhibited hemagglutination activity (e.g. for a dilution of 512-
fold, the titre would be 512HA/25μl, which is equivalent to 20.48HA/μl). 
 
Hemagglutination Inhibition Assay 
1. Mouse serum was treated with receptor destroying enzyme (RDE) II (Denka 
Seiken, Japan) to remove non-specific hemagglutination inhibiting activity by 
adding 4 parts of RDE to 1 part of serum and incubating at 37oC overnight.  
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2. After digestion, the RDE was destroyed by addition of an equal volume (5 
parts) of 1.6% sodium citrate to the RDE-treated serum and incubating at 
56oC for half hour. This results in a final 10-fold dilution of serum.  
3. One part of neat guinea pig RBC pellet was added to 10 parts of RDE treated 
serum and incubated for a further half hour at room temperature to remove 
any non-specific binding of RBCs to the serum. The RBCs were pelleted and 
the supernatant containing the serum was removed. As neat RBC pellet was 
added, this does not cause further dilution as the RBCs do not add to the 
volume of the serum.  
4. Serial 2-fold dilutions of the serum were made in 96-well U-bottom plates 
with 25μl per well following which 25μl of influenza virus containing 4 HAU 
were added. The plate was incubated for half an hour to allow the antibodies 
to bind to the virus.  
5. Finally, 50μl of 1% guinea pig RBC were added and the HAI titre was 
determined 2 hours later, defined as the reciprocal of the maximum dilution of 
serum that resulted in inhibition of virus hemagglutining activity. 
 
Plaque Forming Assay 
1. MDCK cells were seeded at 2.5  105 cells/well in a 24-well plate and 
cultured in complete DMEM until fully confluent and the spaces between 
cells barely distinguishable. This typically takes 2-3 days.  
2. Immediately before infection, the media was withdrawn and the cells were 
washed once with PBS to remove any traces of serum which may affect the 
ability of the virus to bind to the cells.  
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3. The influenza virus was serially diluted 10-fold in plain DMEM and 
introduced to the MDCK cells and incubated for 1 hour at 37oC to allow the 
virus to adsorb onto the cells. The volume of the inoculum was kept small, 
typically 250μl per well so as to ensure maximal adsorption of the virus onto 
the cells.  
4. During the incubation period, a 2% agarose solution in sterile water was 
prepared by microwaving the agarose solution until it completely molten. The 
agarose solution was cooled and kept in the molten state by incubating in a 
water bath at 47oC.  
5. At the same time, 2 DMEM was warmed to 37oC and TPCK Trypsin was 
added to a final concentration of 4μg/ml.  
6. When the 1 hour incubation was up, the molten 2% agarose was mixed with 
an equal volume of 2  DMEM to obtain a 1 DMEM agarose solution. This 
solution was kept in the molten state inside the BSC by placing it in a beaker 
of water taken from the 47oC water bath.  
7. The virus inoculums were quickly removed starting from the highest dilution 
to minimise any carry-over effect and overlaid with the DMEM-agarose. The 
agarose overlay was left to cool inside the BSC until it hardened before 
incubating for 3 days at 37oC to allow plaques to form.  
8. To visualise plaques on the third day, 0.5 to 1ml of PBS was added on top of 
the agarose layer to facilitate removal of the agarose overlay and a bent needle 
was used to gently dig out the agarose layer above the cells. Care must be 
taken to avoid scratching the bottom of the plate.  
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9. The plaques were visuliased by adding 0.2ml of 0.5% aqueous crystal violet 
and incubating for at least 5 minutes. Excess stain was removed by washing 
the plate under running tap water. 
 
Concentration of Influenza Virus 
The supernatants containing the virus were first passed through a 0.22μm filter 
(Nalgene, USA) using a vacuum pump to remove small cell debris. The filtered virus 
was then placed in the upper chamber of a Vivaspin 20 centrifugal concentrator with 
a membrane pore size of 100’000 molecular weight cut-off (Sartorius AG, Germany). 
The concentrator was centrifuged at 3000g at 4oC, stopping at intervals of 30 mins to 
resuspend the top fractions to permit a better flow rate and to discard the flowthrough 
in the bottom fraction. Once the top fractions have been adequately concentrated, they 
were pooled for labelling with lipophillic DiD dye.  
 
Buffers for labelling influenza 
Sterile 50% (w/v) sucrose and 20% (w/v) sucrose solutions were prepared by 
dissolving sucrose in 1  PBS followed by sterile filtration through a vacuum driven 
0.22μm filter. 
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Labelling of Influenza Virus with the lipophillic DiD dye 
1. Solid DiD was dissolved in DMSO to obtain a 20mg/ml concentration, and 
stored in the dark at -30oC until ready for use. Influenza virus was labelled 
with the lipophillic dye 1,1’-dioctadecyl-
3,3,3’,3’,tetramethylindodicarbocyanine (DiD) (Molecular Probes, Invitrogen. 
USA) as previously described (Lakadamyali et al. 2003) with a few 
modifications.  
2. To label the virus, 20μl of the the DiD stock solution was added to 1ml of the 
virus. The solution will turn deep blue and a substantial amount of precipitate 
will form due to the poor solubility of DiD in aqueous media. Incubate for one 
hour at room temperature with frequent mixing.  
3. After incubation, DiD precipitate was pelleted by centrifugation at 5000  g 
for 5 mins and the supernatant harvested. 
4. Ultracentrifugation was then used to purify the virus using a sucrose step 
gradient.  This was prepared by first loading 50% sucrose solution at the 
bottom of the ultracentrifuge tube followed by a layer of 20% sucrose solution 
and finally layering the labelled virus solution on the top.  
5. The step gradient was ultracentrifuged at 112,000  g (Hitachi-Koki, Japan) 
for 90 mins to separate the virus which forms a blue interface between the 
20% and 50% sucrose layers.  
6. The layer containing the virus was harvested and buffer exchange was 
performed using NAP-5 columns (GE Healthcare, USA) or Zeba desalting 
columns (7000MW cut-off, Pierce, USA) according to the manufacturer’s 
protocol.  
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UV Irradiation of Influenza Virus 
 
Influenza virus was irradiated with 240 mJ/cm2 UV light using a UV crosslinker 
(Spectroline, NY, USA). This corresponds to two cycles of the optimal cross-linking 
setting on the machine. 
 
2.5    Flow Cytometry and Cell Sorting 
 
Staining of Cell Surface Markers for Flow Cytometry 
1. Cells for FACS staining were transferred into FACS tube and pelleted by 
centrifugation at 400  g for 5mins. Tubes were inverted to discard the 
supernatant and were further blotted on tissue paper to remove the excess 
supernatant that collected near the edge of the tube after inversion.  
2. The cell pellet was then disrupted by raking on tube racks. Fc Block (2.4G2) 
was added at 0.2g per million cells and incubated for 5 mins at 4oC to 
prevent non-specific binding of antibodies to Fc receptors.  
3. Antibodies directly conjugated to fluorophores were added to the cells at 
0.02g per million cells and incubated in the dark at 4oC for 30mins. After 
incubation, cells were washed twice with at least 1ml of FACS buffer to 
remove unbound antibodies.  
4. Cells were resuspended in 350l of FACS buffer if analysis was performed 
within several hours or fixed with 1% PFA if analysed on a separate occasion. 
5. To fix with 1% PFA, the cells were pelleted and the FACS buffer supernatant 
discarded. To prevent the formation of cell clumps during fixation, the cell 
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pellet was well disrupted by raking several times on tube racks and vortexed 
at 3000rpm while simultaneously adding 1% PFA. 
 
Intracellular Staining for Flow Cytometry 
1. Intracellular staining of antigens was performed after staining of cell surface 
markers. Stained cells were fixed following the protocol above and kept at 
4oC for 15 mins to allow fixation to be complete.  
2. Fixed cells were pelleted by spinning at 500  g for 5 mins and the 1% PFA 
supernatant was discarded.  
3. The cell pellet was disrupted by raking and permeablised by adding 1ml of 
permeablization buffer. Cells were then incubated in the dark for 10 mins at 
room temperature to allow permeablisation to be complete. Permeablised cells 
were then pelleted at 600  g and the supernatant discarded before raking the 
tube to resuspend the cell pellet.  
4. Antibodies directly conjugated to fluorophores were added to the cells at 
0.02g per million cells and incubated in the dark at 4oC for 30mins.  
5. After incubation, cells were washed twice with at least 1ml of Permeablisation 
buffer to remove unbound antibodies. Cells were finally resuspended in 350l 
of FACS buffer for analysis. 
 
Intracellular Cytokine Staining 
For intracellular staining of cytokines in cells, synthesis of cytokines was stimulated 
by addition of the appropriate stimulus. Cytokine secretion from the cell was blocked 
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by the addition of Brefeldin A (BD Pharmingen, USA) and Golgi stop (BD 
Pharmingen, USA) containing monensin into the culture medium. Both Brefeldin A 
and Golgi stop was added at 1l per 1ml of culture medium. After 6 hours, cells were 
harvested, transferred into FACS tubes before proceeding for surface staining of 
markers, followed by intracellular staining for cytokines. 
 
Sorting of Dendritic Cells from the Lung 
1. Lung cells were enriched for DCs using OPTIPREP as described earlier. The 
cells accumulating at the OPTIPREP and FCS interface were collected, 
counted and pelleted in sterile FACs tubes.  
2. The concentration of the cells was adjusted to approximately 50 million 
cells/ml using MACS buffer. Where single stains were required for 
multicoloured cell sorting, small amount of cells were taken for single stains 
at this point.  
3. Fc Block (2.4G2) was added at 0.2g per million cells and incubated for 5 
mins at 4oC to prevent non-specific binding of antibodies to Fc receptors. 
Antibodies directly conjugated to fluorophores were added to the cells at 
0.02g per million cells and incubated in the dark at 4oC for 30mins.  
4. After incubation, cells were washed once with 2 to 3ml of MACS buffer. 
Cells were then resuspended in 2 ml of MACS buffer and passed through a 
61m strainer to filter out cell clumps or any tissue pieces which may clog the 
cell sorter.  
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5. The filtered cells were then pelleted once more. Cells were finally 
resuspended to a concentration of between 20-50 million cells/ml and DCs 
were sorted using the MOFLO (Beckman Coulter, USA).  
6. DCs were collected in sterile FACS tubes containing complete RPMI or neat 
FCS. 
 
Sorting of Dendritic Cells from the Lymph Node 
The protocol for sorting DCs from the lymph node is identical to that for sorting DCs 
from the lung, with the exception that OPTIPREP density centrifugation is not 
performed. The cells obtained after digestion of the lymph node are directly stained 
for DC markers and are sent for cell sorting. 
As DCs constitute a small minority within the lymph node of approximately 1 to 2 
percent of the total cells, typically 5 to 6 lymph nodes are pooled together to obtain 
sufficient DC numbers for sorting. An estimated yield is about 40,000 DCs can be 
isolated from 5 lymph nodes at 3 days post-infection.  
 
Tetramer Staining of Influenza-Specific CD8 T-cells 
Influenza-specific CD8 T-cells were detected using the tetramer ASNENMETM H-
2Db PE (Proimmune, UK). Tetramer staining was done simultaneously with the 
surface staining antibodies anti-CD8 and anti-CD3 at 4oC for half an hour. The cells 
were washed twice in cold FACS buffer and fixed with 1% PFA before FACS 
analysis to prevent internalisation of tetramers by the T-cells. 
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2.6    Culture of Dendritic cells and T-cells 
 
DC and CD8 T-cell Co-Cultures 
Sorted DCs subsets (1  104) were cultured with with freshly isolated CFSE-labelled 
CD8 T-cells (1  105) in a 96-well U-bottom well plate to achieve a 1:10 (DC to T-
cell) ratio. For experiments where a 1:3 (DC to T-cell ratio) was used, the number of 
T-cells remained constant and 3.3  104 sorted DCs were cultured with 1  105 CD8 
T-cells. 
 
In experiments where SIINFEKL peptide-pulsed DCs were cultured with CD8 T-
cells, the sorted DCs were first incubated with the indicated peptide concentration at 
37oC for 30 mins, washed twice with warm medium before culturing with CD8 T-
cells. 
In vitro assay for DC uptake of DiD influenza virus 
 
CD11c+ lung cells were isolated by positive selection using anti-CD11c MACS beads 
(Miltenyi Biotec, Germany) and cultured in a 96-well flat botton plate at either 37oC 
or 4oC. DiD-influenza virus was added at an MOI of 1 and the cells were cultured at 
their respective temperatures for 40 mins. Cells were washed twice before staining for 
FACS analysis. 
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2.7    Reverse transcription of mRNA, RT-PCR and primers 
 
Reverse transcription of lung DC mRNA 
Total RNA was obtained from sorted lung DCs using the RNeasy kit (Qiagen, 
Singapore). Cells were pelleted and lysed with 350l RLT buffer and passed through 
a QIAshredder column (Qiagen, Singapore) to homogenise lysate. 1 volumne of 70% 
isopropanol was added to precipitate RNA and the column centrifuged. The column-
bound RNA was washed once with 700l RW1 buffer, followed by two washes with 
500l RPE buffer. Column was centrifuged once more to ensure complete removal of 
residual ethanol from RPE buffer. RNA was eluted by addition of 15l of RNase-free 
water and the liquid collected after centrifugation was put through the column one 
more time to enhance yield. cDNA was then obtained using QuantiTect Reverse 
Transcription Kit (Qiagen, Singapore) according to manufacturer’s instructions. All 
primers were synthesised by AIT Biotech Singapore and the sequences of primer 
pairs are provided in the table below: 
 
thods 
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REF FORWARD REVERSE Size 
01303 AGGCCGGTGCTGAGTATGTCG GCAGAAGGGGCGGAGATGAT 112 
83 GGAGGCCTTGGCTTACGTCGC GGAGCCCACAGCCTTCTGCA 214 
30 CCGGACCTGCCTTTCCTCATAGC CCGCAGGTTGATCCTGGACATGG 233 
52.2 GATTGAATTTTACGCCCCTTGGTG TGGCTGGTGAGAAGTAGATGGTAGGAA 182 
18.2 CCAGCACTCTCTTCAGCCTCTCC CCACTGTTGCCATGGTGATGAC 86 
24 CTCGGACCCGGGACACTACAGTT ACTTGAAGGCGAGTGTGGTTGTG 158 
85 CATGAACCGAGATGGCTCTAGTGG GTCACTCATCGTAGAATTTTGGCAGC 116 
40 CACGGTCACCCGTATCCTGC CGTAGAGCTGAGGTCCGTTCAAAT 104 
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Real Time PCR 
Real time PCR was performed on an ABI7500 Real-time PCR system using SYBR 
Green (Applied Biosystems, USA). For all experiments, the primer concentration and 
the volume of the reaction mix were fixed at 300nM and 25l respectively. The 
relative quantities of target gene expression were quantified by comparative CT 
method and normalised to GAPDH. 
2.8    Fluorescent Microscopy 
 
Fluorescent Microscopy 
All slides were mounted in Prolong Gold Antifade Reagent (Molecular Probes, 
Invitrogen, USA) and viewed using Carl Zeiss Axio imager.Z1 fluorescent 
microscope (Axiocam HRM camera; Carl Zeiss Micro Imaging, Germany). Images 
were processed using Axiovision Rel 4.8 software (Carl Zeiss Micro Imaging, 
Germany). 
 
Tyramide Signal Amplification for detection of SIINFEKL-Kb complexes 
 
DCs were stained for surface antigens without using PE conjugated antibodies and 
sorted using MoFlo. DCs were cultured on polylysine-coated slides for 45 mins to 
adhere and fixed with acetone. Blocking was performed using Fc blocking antibody 
(2.4G2) and 1% BSA for 10 mins. Tyramide signal amplification was performed 
using TSA Biotin System kit according to manufacturer’s recommendation (Perkin-
Elmer, MA, USA). Briefly, primary staining with biotinylated 25-D1.16 antibody was 
performed for 30 mins followed by strepavidin-HRP for 30 mins. Biotinylated 
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tyramide amplification was then performed for 8 mins followed by detection using 
strepavidin Dylight 546 (Jackson ImmunoResearch Laboratories, PA, USA). Slides 
were viewed under a fluorescent microscope as described below. 
 
2.9    Haematoxylin and Eosin Staining 
 
1. Mouse lungs were perfused with 15ml of PBS through the right cardiac 
ventricle and the right lobe of the mouse lung was excised and fixed in 4% 
PFA for at least 48 hours.  
2. Lungs were then put through an automated tissue processor (Shandon, UK) to 
embed in paraffin.  
3. Transverse sections 5m thick were made near the point of bronchus 
bifurcation to visualise the large conducting airways.  
4. Sections were deparaffinised in two changes of 100% xylene for 1 minute 
each and gradually hydrated by placing in 100% ethanol for 1 minute, 95% 
for 1 minute, followed by 70% ethanol for 1 minute.  
5. Sections were overstained with gill’s haematoxylin II (Sigma, Singapore) for 
3 minutes and washed in distilled water.  
6. Excess haematoxylin stain was removed by placing in acid alcohol solution 
(1% v/v HCl in 70% ethanol) until the haematoxylin stain has been adequately 
differentiated. This typically takes between 30 seconds to 1 minute.  
7. Slides were washed again in distilled water and placed into Scott’s tap water 
substitute, a ‘blueing’ agent, for 1 minute.  
Chapter 2: Materials and Methods 
60 
 
8. Thereafter, slides were washed in distilled water and dehydrated briefly in 
95% ethanol, followed by 30 seconds staining in alcohol eosin. Care must be 
taken not to overstain in alcohol eosin.  
9. Excess eosin is washed off in 95% ethanol and slides are dehydrated in 2 
changes of 100% ethanol for 1 minute each.  
10. Slides are prepared for mounting by placing in a 50% xylene, 50% ethanol 
solution for 1 minute, followed by 2 changes of 100% xylene for 1 minute 
each. Sections are mounted using histomount (Sigma, Singapore). 
 
Scott’s Tap Water Substitute 
Sodium Bicarbonate  3.5g 
Magnesium sulphate  20g 
Distilled water   1 litre 
 
2.10  Mice 
 
C57BL6 were obtained from Harlan Laboratories (UK) and OT-I mice were obtained 
from Charles River Laboratories (France). BALBc mice were obtained from the 
university Laboratory Animals Centre (Singapore) and Clone 4 mice were purchased 
from The Jackson Laboratory (Bar Harbour, USA). All mice were maintained under 
specific pathogen-free conditions within National University of Singapore’s animal 
holding unit. C57BL6 and BALBc mice used were 6-8 weeks old. OT-I and Clone 4 
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mice used were 7-10 weeks old. Intranasal challenge of mice with influenza was 
performed by injecting mice with ketamine (100mg/kg) and medotomidine (15mg/kg, 
both from Sigma-Aldrich, Singapore) i.p and administering 20 haemagglutinating 
units (HAU) of influenza in 20μl volume. Atipamezole (5mg/kg, Orion Pharma, 
Finland) was administered i.p as reversal.  
 
The experiments were carried out in accordance with the guidelines of the National 
Advisory Committee for Laboratory Animal Research (NACLAR), Singapore. The 
protocols (Protocol numbers are 094/06 and 137/08) were approved by the 
Institutional Animal Care and Use Committee (IACUC) of the National University of 
Singapore. Unless indicated otherwise, all of the experiments in this study were 
performed with C57BL6 mice. 
 
2.11  Genotyping of Clone 4 Mice 
 
Clone 4 mice obtained from The Jackson Laboratory were hemizygous for the TCR 
transgene and hence offspring had to genotyped to determine whether they carried the 
transgenic TCR in their genome. Instead of the traditional approach of using PCR to 
detect the presence of the transgene, we adopted a more rapid FACS-based approach 
for screening mice using anti-TCR V-beta chain antibodies (the clone 4 TCR is 
characterised by Valpha10 and Vbeta8.2). Peripheral blood from the mice was 
obtained by submandibular puncture and the red blood cells lysed. The remaining 
cells were passed through a 61μm filter mesh to remove tissue pieces from the 
submandibular puncture and the cells were stained for CD8, CD3 and the TCR chain 
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V-beta 8.2. Typical profiles of transgenic and non-transgenic littermates are shown 
below.   
 
 
Figure 2.11.1 Screening of CD8 T cells from offspring from hemizygous clone 4 
transgenic mice using anti-Vbeta 8.2 TCR antibody  
 
Peripheral blood from Clone 4 mice were stained for CD3, CD8 and Vbeta8.2 
antibody. Mice carrying the clone 4 transgenic TCR were identified as having >95% 
Vbeta 8.2+  CD8 T-cells. 
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Chapter 3: Mouse Model of Influenza Infection and Characterisation of Lung 
Antigen Presenting Cells  
 
3.1    Introduction 
 
Animal models of influenza infection have been widely used to study the properties 
of the influenza virus and its modes of transmissions. The ferret model of influenza 
infection is widely held as the ideal small animal model for influenza research as the 
pathogenesis and many of the clinical symptoms observed closely resemble those in 
humans such as sneezing, nasal discharge and pyrexia (Matsuoka et al. 2009). 
Moreover, ferrets are naturally infected with both the influenza A and B viruses and 
the infection is transmissible, hence their extensive use in studying various aspects of 
influenza disease. In contrast, mouse models of influenza infection poorly 
recapitulate the clinical symptoms of human disease. Infection with influenza induces 
a drop in body temperatures of mice instead of inducing fever (Bender et al. 1996). 
The virus cannot be efficiently transmitted between litter-mates, even the highly 
pathogenic H5N1 and the 1918 H1N1 virus (Lowen et al. 2006). Many strains of 
influenza also require several rounds of serial passage in mice to adapt to their non-
natural host and although viral replication can be detected with infection of a non-
adapted strain, the high titre of virus is not accompanied by visible pathogenic effects 
and lung lesions (Hirst 1947; Ward 1997).  
 
Despite these drawbacks, mouse models of influenza infection remain the primary 
means for the investigation of influenza pathogenesis, immune responses and 
evaluation of anti-viral therapies. This is due to the low cost of maintenance, well 
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characterised and uniform genetic background which allows economic use of animals 
to obtain statistically robust data. Mouse models of influenza are also popular due to 
the availability of gene-modified transgenic mice, a diverse assortment of reagents for 
research and also detailed characterisation of the innate and adaptive immune system 
and its strong parallels to human immunology. For these reasons, in vivo safety and 
efficacy studies for anti-influenza biologics are often performed in mice, such as the 
M2 ion channel inhibitor amantadine (Davies et al. 1964) and the NA inhibitor 
zanamivir (von Itzstein et al. 1993). Moreover, murine influenza models have also 
allowed the successful evaluation of antiviral therapeutics against pandemic strains 
which are unable to be clinically tested (Tumpey et al. 2002) and hence are a valuable 
preclinical tool for researchers to assess the efficacy of novel antiviral strategies. 
 
The use of different influenza strains can result in differing infection kinetics due to 
variable host tropism. In BALBc mice, the LD50 for the X-31 H3N2 virus is more 
than a 1000-fold higher than the PR8 H1N1 virus even though the core proteins in 
both virus strains are identical (Bouvier and Lowen 2011). The genetic background of 
the host is also a significant determining factor on the outcome of infection. An 
analysis of seven inbred laboratory strains of mice showed that the DBA/2J and A/J 
strains were highly susceptible to infection compared to other strains and the LD50 for 
DBA/2J mice was more than 1000-fold lower than C57BL6 mice (Srivastava et al. 
2009). Differences in infectivity and lethal doses can also be observed even when the 
same strain is used owing to variation in the number of passages in mice, 
embroynated chicken eggs or tissue culture resulting in differing extents of adaptation 
to the host as shown by the studies cited here (Song et al. 2007; Hamada et al. 2009).  
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In this chapter, we set out to establish a mouse model of infection using the influenza 
A/PR8/34 strain and characterise the ensuing immune response by parameters such as 
weight loss, proinflammatory cytokines in the bronchoalveolar space, virus-specific 
CD8 T-cells as well as the humoral response. Subsequently, we investigated how 
lung dendritic cells and marcophages could be efficiently isolated from the lung 
tissue, the phenotype of these cells, and finally how these populations and their 
phenotype changes following infection with influenza. 
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3.2    Weight Loss and Bronchoalveolar Lavage 
 
The loss of body weight in mice provides a rough indication of the severity of 
infection and is a convenient, non-invasive means to assess infection induced 
morbidity. Influenza A PR/8/34 virus was grown in 9-day old embroynated chicken 
eggs and the virus titre determined by a plaque forming assay with monolayers of 
MDCK cells.  Mice infected with a sublethal dose of 5-10 plaque forming units 
(PFU) began to show gradual weight loss from day 3 onwards. Rapid weight loss was 
consistently observed between days 6 to 8 with maximal weight loss typically 
occurring at days 8-9 and rapid regain of weight thereafter (Figure 3.2.1). The effects 
of infection could be observed by the behavior and general appearance of mice. At 
about days 5 to 6 p.i., the mice began to exhibit signs of lethargy and poor grooming. 
By days 7 and 8, the mice were visibly emaciated and very lethargic. Response of the 
mice to external stimuli such as tapping of the cage was also reduced and their fur 
appeared ruffled and unkempt. From day 10 onwards, the activity level of the mice 
had returned to normal and apart from a thin appearance, the mice did not exhibit any 
others visible signs of illness. 
 
To determine the extent of airway inflammation, we performed bronchoalveolar 
lavage (BAL) to analyse the levels of proinflammatory cytokines into the airspaces at 
various time points following infection by ELISA. We could not detect IFN- in the 
BAL fluid during the early phase of infection from day 1 to 4. At day 7 p.i. however, 
high concentrations of IFN- were detected and levels rapidly declined back to base-
line levels by day 10 p.i (Figure 3.2.2A). Unlike IFN-, TNF- levels in the BAL 
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fluid could be detected during the early phase of infection, albeit at low levels, and at 
day 7-8 p.i. TNF- levels had reach maximal levels and thereafter declined (Figure 
3.2.2B). From the data, high levels of proinflammatory cytokines within the airspaces 
were associated with the period of maximal weight loss which occurs late in 
infection, suggesting that the adaptive immune response makes a significant 
contribution to immunopathology. 
 
 
  
Figure 3.2.1 Percentage weight change of mice over the course of infection with 5 
PFU influenza virus.  
Graph shows mean ± S.E of C57BL6 mice body weight measured daily over the 
course of influenza infection. Data representative of 3 experiments. n = 6 for the set 
of data shown.  
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Figure 3.2.2 Levels of proinflammatory cytokines in the bronchoalveolar lavage 
fluid 
 
C57BL6 mice were sacrificed at the following time points and BAL fluid was 
obtained by lavaging lungs with a total volume of 2ml of PBS. (A) Levels of IFN- 
and (B) levels of TNF- determined by ELISA. Graph shows mean + S.E. n = at least 
6 for all time points except for days 3 and 10 p.i where n=4.  
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3.3    Histopathology of the lung 
 
Histological sections of the lung were taken to have a clearer understanding of the 
extent of inflammation and also to visualise gross structural changes to the lung tissue 
at various stages following infection with 5 PFU of influenza. We chose to focus on 
the large conducting airways close to the site of bronchus bifurcation as this is the site 
of viral replication during early infection and provides clear visualisation of the 
bronchial epithelial lining and cellular infiltration into the peribronchial and alveolar 
spaces. 
 
In the uninfected lung, the characteristic ‘honeycomb’ appearance and fine structure 
of the alveolar sacs could be easily discerned. The peribronchial spaces were free 
from surrounding inflammatory infiltrate and the conducting airways were also 
completely clear (Figure 3.3.1). At day 3 p.i., epithelial cell desquamation can be 
observed in approximately half of the bronchial lining indicating that the virus was 
spreading through the epithelium. A small degree of peribronchial cellular infiltrate 
could be seen at one end of the bronchus, proximal to the region of epithelial cell 
destruction whereas the other end remained free from any signs of inflammation 
(Figure 3.3.2). By day 5 p.i., a large number of cells were seen in the conducting 
airways together with cellular debris. Traces of red blood cells were also detected in 
the conducting airways as well as the alveolar air spaces, indicative of pulmonary 
haemorrhage.  Hypertrophy of the bronchial smooth muscle layer was also observed 
as evidenced by thickening of the bronchial wall (Figure 3.3.3). At day 7 p.i., cellular 
infiltrate into the alveolar spaces had significantly increased. The bronchial wall had 
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also continued to thicken and was now approximately 3 times the original thickness 
compared to the uninfected lung. Hypertrophy of the bronchial epithelial cells was 
also observed and the cellular morphology had changed to become more elongated 
and less uniformly cuboidal (Figure 3.3.4). At day 10 p.i., pathology of the lung was 
severe and highly dense cellular infiltrate into the alveolar spaces could be seen 
(Figure 3.3.5). Notably, at this point the mice had already begun to recover weight 
and did not display outward signs of illness 
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Figure 3.3.1 H&E staining of transverse section of large conducting airways in 
uninfected mice.  
Red box indicates field of view of 300  magnification. Images representative of 
sections taken from 2 C57BL6 mice. Section thickness 5m.  
Uninfected 150 
Uninfected 300 
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Figure 3.3.2 H&E staining of transverse section of large conducting airways in 
day 3 p.i. mice.  
Red box indicates field of view of 300  magnification. Images representative of 
sections taken from 3 C57BL6 mice. Section thickness 5m. Arrows indicates 
desquamated epithelium.  
Day 3 p.i.150
Day 3 p.i.300
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Figure 3.3.3 H&E staining of transverse section of large conducting airways in 
day 5 p.i. mice.  
Red box indicates field of view of 300  magnification. Images representative of 
sections taken from 3 C57BL6 mice. Section thickness 5m. Arrows indicates RBCs 
in the airway.  
Day 5 p.i. 150 
Day 5 p.i. 300 
Chapter 3: Mouse Model of Influenza Infection and Characterisation of Lung 
Antigen Presenting Cells 
74 
 
 
Figure 3.3.4 H&E staining of transverse section of large conducting airways in 
day 7 p.i. mice.  
Red box indicates field of view of 300  magnification. Images representative of 
sections taken from 3 C57BL6 mice. Section thickness 5m.  
Day 7 p.i.150
Day 7 p.i.300
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Figure 3.3.5 H&E staining of transverse section of large conducting airways in 
day 10 p.i. mice.  
Red box indicates field of view of 300  magnification. Images representative of 
sections taken from 3 C57BL6 mice. Section thickness 5m.  
Day 10 p.i. 150 
Day 10 p.i. 300 
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3.4    Virus specific CD8 T-cell response 
 
CD8 T-cells constitute a significant proportion of the cellular infiltrate into the lung at 
the late stage of inflammation (Lawrence et al. 2005) and have an essential role in 
mediating viral clearance (Bender et al. 1992). To estimate the magnitude of the virus 
specific CD8 T-cell response induced by infection, we used the MHC I tetramer 
NP366-374 ‘ASNENMETM-H-2Kb’, an immunodominant epitope, to detect for 
influenza-specific CD8 T-cells (Figure 3.4.1). NP366-374 specific CD8 T-cells were 
readily detectable in the BAL and the lung from day 8 p.i. with the peak response 
seen at day 11 p.i. (Figure 3.4.2A). The data here supports the histological analysis in 
the previous section which showed a high cellular infiltrate into the lung late in 
infection at day 10 compared to the day 7.  
 
We also examined for the presence of virus specific cells in the lung draining lymph 
node in a smaller number of mice. In comparison with the lung, the total number of 
CD8 T-cells in the lymph node are comparable (Figure 3.4.2A and B), but the number 
of virus-specific cells was approximately 10-fold lower. This suggests that although 
there is a high rate of recruitment of CD8 T-cells to the lymph node, the majority of 
the virus-specific CD8 T-cells have already egressed from the lymph node and 
infiltrated the lung by day 8. Another possible factor for this large difference is that 
virus-specific CD8 T-cells continue to proliferate after arriving in the lung (McGill 
and Legge 2009), especially upon interaction with DCs presenting antigen in the lung 
parenchyma (McGill et al. 2008). The survival of the virus-specific cells in the lung is 
also enhanced as they receive pro-survival signals in the form of trans-presented IL-
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15 via DC-expressed IL-15R (McGill et al. 2010) and also autocrine IL-2 signalling 
induced by costimulation via CD70-CD27 interaction (Peperzak et al. 2010). 
 
 
Figure 3.4.1 Detection of virus specific CD8 T-cells using ASNENMETM 
tetramer after influenza infection 
 
Representative FACS plots of tetramer staining to detect influenza-specific CD8 T-
cells at various time points. C57BL6 mice were sacrificed at the indicated time points 
after infection with 5 PFU of influenza virus. BAL cells were obtained by lavage with 
2ml of cold buffer. Lungs cells were obtained by digestion with liberase followed by 
density centrifugation using Ficoll-paque. Autofluorescent cells which may interfere 
with tetramer signal were gated out using CD11c following which cells were gated on 
CD8+ and CD3+ events. n = 13 for each time point. 
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Figure 3.4.2 Total CD8 T-cells and virus-specific CD8 T-cells in the lung and 
BAL after influenza infection 
 
(A) Enumeration of total CD8 T-cells and virus-specific T-cells using 
ASNENMETM tetramer after infection with 5 PFU of influenza virus. Graph shows 
mean ± S.E. Data pooled from 3 experiments, n = 13 for each time point. 
 
(B)  Similar analysis as (A) performed on lymph node cells. Graph shows mean ± 
S.E. n = 5. 
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3.5    Antibody Response 
 
The humoral response is an important component for mediating viral clearance and 
clearance of the virus from the respiratory tract during primary challenge was 
compromised in mice deficient in antibodies (Kris et al. 1985; Topham and Doherty 
1998). To ascertain the kinetics of the antibody response to infection, serum 
neutralising antibody titres were determined using a hemagglutination inhibition 
(HAI) assay. We observed that neutralising antibody titres could be detected at day 8, 
continued to rise and peaked at day 11 p.i and declined slightly at day 14 p.i. This 
closely mirrored the pattern of virus-specific CD8 T-cell response described in the 
previous section (Figure 3.4.2). It is noteworthy that serum HAI levels at day 8 p.i. 
had already exceeded 40, which is widely regarded as the minimum titre for 
seroprotection, demonstrating that neutralising titres against the influenza virus were 
rapidly engendered (Figure 3.5).  
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
Figure 3.5 Serum neutralising antibody titre  
 
Serum was obtained from C57BL6 mice sacrificed at the indicated time points after 
infection with 5 PFU of influenza virus. Neutralising antibody titre was determined 
by hemagglutination inhibition assay. Graph shows reciprocal of the maximum serum 
dilution that could inhibit HA. Graph shows mean ± S.E. Data pooled from 3 
experiments n = at least 7 mice for each time point. 
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3.6    Surface Markers of Cells Isolated from the Alveolar Compartment 
 
Having established a working mouse model of infection, we investigated the various 
populations of antigen presenting cells within the lung and characterised their 
phenotype. Similar to organs such as the gut and skin, the lung is constantly exposed 
to the environment and hence is well-equipped with an extensive network of APCs 
that function as sentinels to detect pathogenic insults and initiate immune responses 
to maintain sterility. The mouse lung can be broadly divided into large conducting 
airways comprising the trachea and bronchi, and the lung interstitium containing the 
alveolar septae which is the site of gas exchange. APCs can be found in both the 
conducting airways and lung interstitium, although the majority are found in the lung 
tissue owing to its larger surface area. 
 
We started by examining the alveolar compartment and obtained cells by lavaging the 
lungs of uninfected mice. The cells were stained for typical APC markers, CD11c, 
CD11b and MHC Class II and their morphology examined by differential staining on 
cytospins. Consistent with reports in the literature, the majority of the cells isolated 
by lavage of the alveolar compartment were alveolar macrophages which have a 
large, vacuolated cytoplasm (Fig 3.6A). These cells were positive for CD11c, but 
negative for CD11b and MHC Class II I-A/I-E (Fig 3.6B). This was surprising as 
macrophages classically express high levels of CD11b. Alveolar macrophages also 
expressed F4/80 albeit at low levels (Figure 3.6C), in contrast to peritoneal 
macrophages which highly express CD11b and F4/80 (Zhang et al. 2008). We also 
Chapter 3: Mouse Model of Influenza Infection and Characterisation of Lung 
Antigen Presenting Cells 
82 
 
observed CD11c+ MHC Class II+ cells which may likely represent alveolar DCs, 
however, the number of these cells are extremely low (Figure 3.6B) 
 
 
 
Figure 3.6 Surface markers and morphology of alveolar macrophages 
 
(A) Lungs of uninfected C57BL6 mice were lavaged with PBS. Alveolar 
macrophages which comprised the majority of cells were spun onto slides by cytospin 
and cellular morphology was visualiased by differential cell staining.  
 
(B) Surface markers of BAL cells were analysed by flow cytometry. The vast 
majority of cells were alveolar macrophages which were CD11c+CD11bnegMHC IIneg 
(i). The BAL also contained a small population of alveolar DCs which were 
CD11c+MHC II+ (ii).  
 
(C) F4/80 expression on alveolar macrophages, gated on CD11c+MHC IIneg events. 
Empty histogram represents isotype control staining and shaded histogram shows 
staining intensity of F4/80. 
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3.7    Surface markers of cells isolated from the Lung Parenchyma 
 
Next, we investigated the APC populations within the lung parenchyma. To isolate 
cells from the lung tissue, the lungs were finely cut into small pieces and subjected to 
enzymatic digestion using collagenase to release the cells. However, as the lung 
parenchyma has an extremely fibrous structure, collagenase digestion was insufficient 
to completely disrupt the tissue into single cell suspension and necessitated 
mechanical disruption by repeated forceful pipetting and physically pushing the tissue 
pieces against the surface of a cell strainer to break it up. As the frequency of DCs in 
the lung parenchyma is significantly lower compared to lymphoid organs such as the 
spleen, the use of a technique to enrich for DCs would greatly facilitate analysis and 
further downstream purification. To do this, we adapted a procedure previously 
employed by our laboratory for isolating splenic DCs (Wong et al. 2008; Wong et al. 
2009) which utilises OPTIPREP density centrifugation. Using OPTIPREP at a 
density of g=1.064g/ml, CD11c+ APCs from lung tissue were enriched approximately 
4-fold from 6% to 23% (Figure 3.7.1). This also had an added advantage of removing 
large cellular debris as well as dead cells that resulted from enzymatic digestion and 
physical disruption of the lung tissue which typically formed about 30-40% of all 
cells obtained.  
 
After enrichment with OPTIPREP, we were also able to further purify CD11c+ cells 
to ~90% by using MACS beads. Using the same combination of CD11c, CD11b and 
MHC II, we could identify three major groups of APCs in lung tissue. They were (i) 
CD11c+ CD11b+ MHCII+ dendritic cells, (ii) CD11c+ CD11b-ve MHCIIhi dendritic 
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cells and (iii) CD11c+ CD11b-ve MHCII-ve/low interstitial macrophages (Fig 3.7.2). 
Alveolar macrophages surface markers were identical to that of interstitial 
macrophages and therefore we could not distinguish between these two macrophages 
aside from their anatomical location (Fig 3.6). However, it is needful to bear in mind 
that lavage may not be able to wash out all airspaces and hence lung interstitial 
macrophages may also comprise alveolar macrophages that were washed out. 
Consistent with observations by other groups (del Rio et al. 2007), lung parenchymal 
DCs did not express such markers such as CD8 and CD4 which are commonly used 
to differentiate splenic DCs (Figure 3.7.3). Lung DCs could also be distinguished 
from macrophages by their side scatter (SS) and autofluorescence on the FL1 channel 
(Figure 3.7.4). Hence, for all subsequent analysis of lung DC populations, we gated 
on SSlow events or low autofluorescent cells on FL1 (when the channel was not in 
use) so as minimize spillover of macrophages into the DC populations during 
analysis. 
 
Figure 3.7.1 Enrichment of lung APCs from whole lung digest using OPTIPREP 
 
Representative FACS plot showing the percentage of CD11c+ lung APCs from whole 
lung digest from C57BL6 mice with or without enrichment using OPTIPREP density 
centrifugation.  FACS plots are gated on live cells. n = 6 mice. 
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Figure 3.7.2 Surface markers of lung antigen presenting cells from the lung 
parenchyma  
   
Typical FACS profile of lung APCs after isolation with CD11c magnetic beads. BAL 
was performed on C57BL6 mice before lungs were excised and digested in 
colleganase. Cells were enriched for APCs by density centrifugation using 
OPTIPREP following which CD11c+ cells were purified by positive selection using 
MACS beads. Using CD11c, CD11b and MHC II markers, 3 populations can be 
identified: (i) CD11c+MHCII+CD11bhi DCs, (ii) CD11chiMHCII+CD11blo/neg DCs and 
(iii) CD11chiCD11bnegMHCIIlo/neg interstitial macrophages.  
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Figure 3.7.3 Lung DCs do not express CD8 and CD4 
 
Lung DCs of C57BL6 mice were enriched from the lung parenchyma using anti-
CD11c MACS beads. Cells were split into 3 groups and stained for CD11c, MHC II 
and either CD8, CD4 or isotype antibody conjugated to the same fluorochrome. 
Data representative of 2 experiments.  
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Figure 3.7.4 Lung DCs and macrophages can be additionally distinguished by 
side scatter and autofluorescence  
 
Representative FACS plot of lung cells after enrichment for APCs using OPTIPREP. 
DCs were defined as CD11c+MHCIIhi cells whereas macophages were defined as 
CD11c+MHCIIlo/neg cells. FACS plot shows a backgating analysis of the side scatter 
and FL1 autofluorescence profile of DCs and macrophages. Data representative of 3 
experiments.   
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3.8    Maturation status of lung dendritic cells 
 
The maturation status of DCs can be determined by several ways. Mature DCs 
display higher surface expression of MHC Class I and Class II, upregulated co-
stimulatory molecules and downregulated ability to endocytose and phagocytose 
antigenic material. We used three parameters to assay the maturation status of 
dendritic cells in the lung and the lung draining lymph node – surface expression of 
MHC Class I, MHC Class II and endocytotic ability of dendritic cells using FITC-
labelled dextran (Figures 3.8.1 and 3.8.2). Dextran is a complex, branched 
polysaccharide derived from bacterial synthesis and is bound by mannose receptors 
which are expressed at high levels on macrophages and dendritic cells (Wileman et al. 
1986; Sallusto et al. 1995). 
 
Consistent with reports by others (Vermaelen et al. 2001), we observed that DCs 
within the lung parenchyma possessed a more immature phenotype compared to DCs 
that had migrated to the draining lymph node. DCs in the lung expressed lower levels 
of surface MHC Class I and Class II (Figures 3.8.1) and had enhanced capacity for 
receptor-mediated endocytosis of FITC-Dextran, as demonstrated by a higher MFI 
ratio compared to DCs from the lymph node (Figures 3.8.2). We also observed that 
lung SShiCD11c+MHCIIlo/neg macrophages were better at endocytosis of FITC-
Dextran compared to DCs. This suggests that DCs in the lung parenchyma are kept in 
an immature state and are specialised for surveillance of the lung tissue for foreign 
insults. Lung DCs then mature and migrate to the draining lymph node where they 
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downregulate antigen uptake and upregulate molecules involved in antigen 
presentation, such as MHC I, MHC II and co-stimulatory molecules. 
 
  
 
Figure 3.8.1 MHC Class I and Class II expression on lymph node and lung DCs 
 
CD11c+MHC II+ dendritic cells from the lung and lung draining lymph nodes were 
obtained from uninfected C57BL6 mice and stained for surface expression of MHC 
Class I and Class II molecules. Data representative of 2 experiments. 
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Figure 3.8.2 Lung and Lymph Node DC endocytosis of FITC Dextran  
 
Bulk lymph node cells and MACS purified lung CD11c+ cells from uninfected 
C57BL6 mice were incubated with 0.5mg/ml of 40,000MW FITC Dextran in 
complete RPMI at either 37oC or 4oC for 45 mins in a 96-well plate. Cells were then 
analysed by FACS for FITC Dextran uptake. Mean Fluorescence Intensity (MFI) 
ratio of FITC Dextran uptake was calculated by dividing MFI at 37oC by MFI at 4oC. 
Data representative of 2 experiments. 
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3.9    Change in antigen presenting cell populations after influenza infection 
 
Having identified the characteristics of the various lung dendritic cells populations at 
resting state in the previous sections, we next examined the changes in lung APC 
population over the course of influenza infection. Mice were infected with 10 PFU of 
PR8 and culled at various time points to determine the number as well as phenotype 
of APCs in the lung and lymph node. With the onset of infection, we observed a 
gradual increase in the number of DCs and macrophages in the lung which reached a 
peak at day 7 before contracting back to basal levels in tandem with resolution of 
infection (Figure 3.9.1). CD11bhi DCs consistently formed the majority of DCs in the 
lung, and could be found in large numbers within the lung at the peak of response. 
 
We also stained for co-stimulatory molecule expression on DCs from the lung 
parenchyma and lymph node. DC expression of CD80 and 86 in the lymph node was 
consistently higher than the lung, in line with earlier observations that DCs in the 
lung have a more immature status compared to those that have already migrated to 
the lymph node. We observed that infection induced a modest upregulation of CD80 
and CD86 in lung DCs with a peak response in the early stages of infection (day 2 to 
3), and that by the later stages of infection, co-stimulatory molecule expression had 
either declined slightly or returned close to basal levels (Figure 3.9.2). This patern of 
transient upregulation of co-stimulatory molecules was also observed for DCs in the 
mediastinal lymph node (Figure 3.9.3), suggesting that the peak antigen presentation 
by DCs occurs during the early phase of infection. 
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Figure 3.9.1 Change in DC and macrophage cell numbers in the lung after 
infection with influenza virus. 
 
Groups of 4 C57BL6 mice were infected with 5 PFU PR8 and the culled at the 
indicated points. The 4 lungs were pooled and CD11c+ cells were obtained by 
positive selection using MACS beads and analysed by FACS to determine the relative 
proportions of macrophage and CD11bhi and CD11blo/neg DC subsets. Total numbers 
of each cell type were calculated and divided by 4 to obtain the average number per 
mouse lung.  
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Figure 3.9.2 Analysis of co-stimulatory molecules expression on lung 
parenchyma CD11bhi and CD11blo/neg DCs by FACS at various time points of 
influenza infection.   
 
Shaded histograms indicate isotype antibody staining and open histograms indicate 
co-stimulatory molecule staining staining. Numbers in each panel indicate the mean 
fluorescence intensity (MFI) of the co-stimulatory molecule staining after subtracting 
MFI of isotype staining. Data representative of 2 experiments. 
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Figure 3.9.3 Analysis of co-stimulatory molecules on CD11c+ MHCIIhi DCs in the 
mediastinal lymph nodes at various time points of influenza infection.  
 
Shaded histograms indicate isotype antibody staining and open histograms indicate 
co-stimulatory molecule staining staining. Numbers in each panel indicate the mean 
fluorescence intensity (MFI) of the co-stimulatory molecule staining after subtracting 
MFI of isotype staining. Data representative of 2 experiments. 
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3.10   Discussion 
 
In this chapter, we have established a mouse model of influenza infection and broadly 
characterised the immune response to a sublethal infection with the PR/8/34 strain. 
One of the interesting features we noted was that there is a disparity between the peak 
of virus specific CD8 T-cell numbers in the BAL and lung tissue, and the levels of 
IFN- in the BAL fluid (Figure 3.2.2 and 3.4.2). Levels of IFN- in the BAL were 
observed to peak earlier at around day 7. p.i. whereas virus-specific CD8 T-cell 
responses only reached a maximum much later at day 11 p.i. Furthermore, IFN- 
levels in the BAL had already declined back to base-line levels by day 11 p.i., 
indicating that the large numbers of virus-specific cells were not actively secreting 
effector cytokines such as IFN-, which is surprising given that effector CD8 T-cells 
typically secrete large amounts of cytokines during division. Data from the 
histological sections of the lung showing an increase in the amount pulmonary 
infiltrate into the lung from day 7 to day 10 further supports the observation of large 
numbers of CD8 T-cells within the lung (Figure 3.3.5). Also, the inability to detect 
CD8 effector cytokines within the BAL late in infection cannot be attributed to the 
localisation of cytokine secreting CD8 T-cells within the tissue and not the 
brochoalveolar spaces  because a large number of antigen-specific CD8 T-cells could 
be detected in the BAL at day 11 (Figure 3.4.2A).  
 
As the clonal burst size of virus specific CD8 T-cells determines the magnitude of the 
memory response (Hou et al. 1994), the continued expansion of CD8 T-cells within 
the lung may represent the means of generating a robust memory response. The lack 
of detection of high levels of IFN- at day 10-11 period suggests that this expansion 
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of the virus-specific CD8 T-cells does not result in the release of a large amount of 
cytokines and may represent a mechanism to prevent cytokine-induced 
immunopathology while retaining T-cell proliferation to ensure adequate memory 
formation. Another possible mechanism for this observation is provided by a very 
recent publication which showed that interaction of influenza specific T-cells with 
lung DCs is required for T-cell secretion of proinflammatory cytokines (Hufford et al. 
2011). Thus, the decline of DC numbers at the late time points may thus be one 
means of limiting cytokine secretion when CD8 T-cell numbers peak.  
 
Unlike their splenic counterparts, lung DCs have not been extensively studied due to 
the complexity of isolating these cells and also the difficulty of obtaining a sufficient 
quantity to perform biological assays. Lung DCs are rare and form approximately 
0.2% of total cells in the lung. Isolation of these DCs requires enzymatic digestion of 
the lung to efficiently liberate the cells and the use of enrichment steps downstream 
will facilitate analysis. The techniques employed by early studies to isolate lung DCs 
exploited the properties of DCs to initially adhere to plastic but detach later to 
eliminate T cells and B cells from the lung preparation (Masten and Lipscomb 1999). 
However it was later shown that the adherence of DCs and overnight culture 
necessary for the cells to detach not only resulted in maturation of the DCs but also 
effected changes in the expression of chemokine receptors and the acquisition of the 
surface marker CD8 which is not found in freshly isolated cells (Swanson et al. 
2004). This suggests that the isolation technique used to obtain lung DCs can have a 
profound effect on the phenotype and function of the cells and warrants caution when 
drawing conclusions from lung DCs which have been manipulated by culturing on 
plastic as the findings may not be readily extrapolated to steady-state lung DCs.  
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At the time when these experiments were conducted, there has been some confusion 
on the surface markers defining lung APCs, in particular lung DCs. Several groups 
have defined lung DCs to be CD11c+CD11bnegMHCII+/neg, attributing low MHC II 
expression on CD11c+ cells to a population of immature DCs (Bosio and Dow 2005), 
or as a uniform myeloid linage of CD11c+CD11b+MHCIIhigh cells (von Garnier et al. 
2005). Another study suggests that CD11chighMHCIIhigh lung DCs can be further 
subdivided into two subsets on the basis of expression of CD11b, CD103 and 
Langerin (Sung et al. 2006). Although the integrin CD11c is widely used as a marker 
for dendritic cells in mice, it is important to note that macrophages in the lung also 
express CD11c as shown here (Figure 3.7 and 3.8.1). Data from a recent study 
suggests that the unique expression of CD11c on alveolar macrophages is due to the 
influence of the lung microenviroment of which lung-derived GM-CSF is one of the 
dominant contributing factors (Guth et al. 2009). The expression of CD11c on 
macrophages is not unique to the lung. Several recent studies have described that 
activated M1-polarized macrophages in inflamed adipose tissues also express CD11c 
in addition to F4/80 and CD11b, highlighting the need to be careful in delineating DC 
and macrophage populations (Lumeng et al. 2007; Li et al. 2010).  
 
In light of this, the conclusions of lung DC function in the studies that mistakenly 
classify all CD11c+ lung cells as DCs may potentially be eroded by high levels of 
lung macrophage contamination. Macrophage contamination of DC cultures is 
particularly problematic owing to the fact that macrophages are poor stimulators of T-
cell responses and are inherently immunosuppressive due to their production of 
inhibitory molecules such as NO and TGF- (Vignola et al. 1996; Miles et al. 1998), 
hence the release of such soluble mediators may have a profound influence on the 
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function and proliferation of the other cells in culture. Lung macrophages can be 
phenotypically distinguished from lung DCs by several means, and those employed in 
this study include high scatter, high autofluorescence on FL1 (Figure 3.7.4) and low 
expression of MHC II (Figure 3.6 and 3.7.2). Lung macrophages are also functionally 
distinct from lung DCs and exhibit high endocytic uptake of FITC dextran (Figure 
3.8.2). It is also known that macrophages can increase expression of MHC II during 
infection or conditions of inflammation, hence the additional use of FL1 
autofluorescence (where possible) and side scatter to further distinguish macrophages 
and DCs is useful to avoid cross contamination during analysis. We also observed 
that DCs freshly isolated from the lung are largely in an immature state, evidenced by 
low expression of MHC I and II and also high endocytic capacity. Upon migration to 
the lymph node, lung DCs acquire a mature status and upregulate MHC I and II, co-
stimulatory molecules, and downregulate antigen uptake by endocytosis, suggesting 
that the lung microenvironment may be a factor regulating the maturity status of lung 
DCs. This is likely to be the case as Li and colleagues observed that culture of bone 
marrow-derived DCs with pulmonary stromal cells could result in proliferation and 
differentiation into a distinct regulatory phenotype, with low levels of MHC II 
expression but high secretion of IL-10, NO and prostaglandin E2, which closely 
resembles the characteristics of lung DCs (Li et al. 2008). 
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Chapter 4: Lipophillic Dye-Labelling of Influenza virus 
 
4.1    Introduction  
 
Although the host inflammatory response mounted against the influenza virus is well-
studied, little is known about the uptake of the virus by different inflammatory cells 
owing to difficulties in visualising the virus inside cells. Moreover, despite the fact 
that antibodies against virtually all the 11 influenza glycoproteins have been 
generated, intracellular staining for the virus is only able to detect cells in which the 
virus is actively replicating and cells that have taken up non-replicating viruses are 
poorly detected due to low amounts of viral protein. This necessitates the 
development of tracking tools to visualise the influenza virus such as a fluorescently 
labelled virus. 
 
Attempts at creating a fluorescent influenza virus have met with limited success due 
to the difficulty of inserting a fluorescent tag such as GFP (which is approximately 
714 bp in length) into the small influenza genome size of 14kb. This is further 
complicated by the fact that the influenza genome exists as 8 separate viral RNA 
segments, of which the largest is only approximately 2300 bases long. The insertion 
of a large fluorescent tag such as GFP will undoubtedly interfere with viral assembly 
and may well disrupt the function of the viral protein which it is tagged to. As a 
result, prior attempts to incorporate GFP into the virus has only been achieved in 
mutant strains which carried deletions in NA and NS1 viral segments in order to 
accommodate the fluorescent reporter tag (Kittel et al. 2004; Shinya et al. 2004). 
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Recently, a GFP influenza virus was successfully generated by recombinant insertion 
of GFP into the NS1 RNA segment without any deletion, however the virus is 100-
fold less infectious than the wild-type virus and up to 30% of virus isolated from lung 
homogenate became GFP-negative by 36 hours p.i., reflecting the inherent instability 
of the GFP insert within the viral RNA segment (Manicassamy et al. 2010).  
 
To circumvent these problems, we adopted an approach used by Zhuang and 
colleagues to label the lipid coat of the influenza virus using a fluorescent lipophilic 
dye, 1,1’-dioctadecyl-3,3,3’,3’,tetramethylindodicarbocyanine (DiD) (Lakadamyali et 
al. 2003; Rust et al. 2004; Chen and Zhuang 2008). This leaves the protein structure 
of the virus untouched and consequently avoids any perturbations to viral proteins. 
DiD is a long-chain dialkylcarbocyanine that has a maximal excitation at 647nm and 
has an emission wavelength at 669nm (Figure 4.1.1), which is similar to the 
excitation and emission spectrum of APC, thus permitting detection by flow 
cytometry using conventional filter sets. The dye is transmitted to the host cells upon 
viral entry, specifically during fusion of the viral lipid coat with the endosome 
membrane during endosomal maturation. Thus far, the studies undertaken by Zhuang 
and colleagues with DiD-labelled influenza have been limited to in vitro experiments 
examining virus interaction with host proteins regulating endocytosis and fusion. We 
were therefore interested to see if DiD-labelled influenza could be effectively used in
vivo to characterise the uptake of the virus by DCs and track the migration of DCs 
carrying viral antigen to the draining lymph node. 
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Figure 4.1.1 Fluorescence spectra and chemical structure of DiD  
 
(A) Absorption (left) an emission (right) spectra of DiD, 1,1’-dioctadecyl-
3,3,3’,3’,tetramethylindodicarbocyanine when bound to phospholipid bilayer 
membranes. The dye has a maximal excitation at 647nm and maximal emission 
wavelength at 669nm.  
 
(B) DiD is a long-chain dialkylcarbocyanine and is insoluble in water due to its 
overall hydrophobic properties. Source: Molecule Probes, Invitrogen    
C67H103ClN2O3S
MW 1052.08
A
B
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4.2    DiD labelling does not compromise influenza virus infectivity 
 
To determine if DiD labelling of the influenza virus resulted in any adverse effect on 
viral function, we compared labelled and unlabelled viruses to hemagglutinate RBCs 
as well as to form plaques on monolayers of MDCK cells. The ability of the influenza 
virus to mediate the agglutination of RBCs is dependent on its surface hemagglutinin 
molecules, therefore the hemagglutination assay will be a simple but effective method 
to determine if the virus surface antigens were negatively affected by the presence of 
DiD label within the lipid envelope. In contrast, the plaque assay will help to 
determine if DiD labelling had any effect on internal core proteins and viral RNA 
which are involved in replication. To ensure a fair comparison between the DiD 
labelled and unlabelled influenza virus, the virus was prepared as described earlier in 
section 2.4, split into two equal parts and incubated with either the DiD solution or 
DMSO, which was the solvent used to dissolve solid DiD. Both sets of viruses were 
then subjected to the same downstream purification procedure. As shown in figure 
4.2.1, DiD labelling of influenza (DiD-influenza) did not compromise viral function 
as both DiD-labelled and unlabelled virus induced similar levels of guinea pig RBC 
hemagglutination (Figure 4.2.1A) and plaque formation in monolayers of MDCK 
cells (Figure 4.2.1B). We went on to determine whether DiD-influenza was also 
infectious in vivo. Mice were infected with 20 HAU DiD-influenza and their weight 
was monitored daily. The mice exhibited pronounced weight loss by day 5 p.i. 
(Figure 4.2.2) and lung histological sections obtained from these animals stained 
positive for viral antigen (Figure 4.2.3), demonstrating that the virus was able to 
replicate in vivo.   
Chapter 4: Lipophillic Dye-Labelling of Influenza Virus 
103 
 
 
 
Figure 4.2.1 DiD labelling does not compromise influenza virus infectivity  
 
(A) Comparison of serially diluted unlabelled and DiD-influenza to induce 
hemagglutination guinea pig RBCs. Data representative of 2 experiments. 
 
(B) Comparison of serially diluted unlabelled and DiD-influenza to form plaques on 
monolayers of MDCK cells. Data representative of 2 experiments. 
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Figure 4.2.2 DiD influenza is infectious in vivo 
 
Morbidity of C57BL6 mice presented as a mean of percentage original body weight ± 
S.E after intranasal infection with 20 HAU of DiD-influenza (n=10 for infected mice, 
n=6 for uninfected mice). Data representative of 2 experiments.  
 
  
80
85
90
95
100
105
110
0 1 2 3 4 5
%
 In
iti
al
 B
od
y 
W
ei
gh
t
Day p.i.
Uninfected DiD-influenza
Chapter 4: Lipophillic Dye-Labelling of Influenza Virus 
105 
 
 
 
Figure 4.2.3 Visualisation of influenza infection in mouse lungs using DiD 
 
Immunofluorescence staining of C57BL6 mouse lung cryosections at 7hrs p.i with 20 
HAU of DiD-influenza. Magnification 400 . White bar represents 20μm.  
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4.3    Comparative analysis of DiD-influenza acquisition in the lung parenchyma 
 
We next investigated the distribution of DiD label within pulmonary immune cells in 
response to infection with DiD-influenza. Mouse lungs were harvested at various 
timepoints following infection and the various cells types, T-cells, B-cells, 
neutrophils, macrophages and dendritic cells were examined for the presence of DiD 
using flow cytometry. Across all timepoints, DiD label was only localized within the 
phagocytic leukocyte population comprised of neutrophils, macrophages and DCs 
(Figures 4.3.1A). Macrophages were by far the most efficient at acquiring DiD label, 
with as much as 60% being DiD+ by day 2 p.i. The initial kinetics of DiD 
accumulation by neutrophils and DCs were similar for the first 48 hours following 
inoculation, after which the proportion of DiD+ DCs continued to increase whereas 
DiD+ neutrophils started to decline, a likely result of continued uptake by DCs of the 
debris from necrotic and apoptitic cells infected by the initial wave of labelled virus 
(Figure 4.3.1B). We were unable to detect significant amounts of DiD label within T 
and B cells, with less than 1% of either lymphocyte subset being DiD+. 
 
Next, lung DCs were further analyzed for expression of co-stimulatory molecules. 
Both CD11blo/neg and CD11bhi DCs collected from the lungs of DiD-influenza 
infected mice at day 2 p.i had upregulated expression of co-stimulatory molecules 
CD80 and CD86 compared to uninfected mice (Figure 4.3.2A). In addition, when 
each DC population was further segregated on the basis of DiD staining, DCs positive 
for DiD exhibited higher expression of both CD80 and CD86 compared to the DiD 
negative population in both subsets, indicative of a more mature or activated state 
(Figure 4.3.2B).   
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Figure 4.3.1 Kinetics of DiD uptake by leukocyte populations in the lung after 
infection   
 
(A) Acquisition of DiD by phagocytic cells in the lungs of C57BL6 mice over time. 
Error bars show mean ± S.E. Neu – Neutrophils, Macs – Macrophages, DCs – 
Dendritic cells. Data pooled from 3 experiments. n = at least 6 mice for each time 
point. 
(B) Representative FACS profile of various immune cell populations in the lung 
showing relative acquisition of DiD label at day 2 p.i.  
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Figure 4.3.2 Co-stimulatory molecule expression on lung DCs   
 
(A) Analysis of co-stimulatory molecules CD80 and CD86 expression on lung DCs 
before and after infection with DiD Virus in C57BL6 mice. For infected mice, lung 
DCs were analysed at day 2 p.i. 
(B) Enhanced expression of CD80 and CD86 when gating on DiD+  DCs compared to 
DiDneg DCs from the same sample in (A). FACS data representative of 3 experiments. 
CD86
CD80
CD11bhi DC CD11blo/neg DC
Isotype
Uninfected
DiD Influenza
A
CD80
CD11bhi DC CD11blo/neg DC
Isotype
CD86
Isotype
DiDneg DC
DiD+ve DC
B
Chapter 4: Lipophillic Dye-Labelling of Influenza Virus 
109 
 
4.4    Comparative analysis of DiD virus acquisition by lung dendritic cells
 
Next, we examined the relative ability of lung DC populations to acquire DiD over 
the time course of influenza infection. At all time points examined, CD11blo/neg DC 
exhibited stable uptake of DiD while CD11bhi DCs initially demonstrated a similarly 
low level of DiD uptake on day 1 that increased 6-fold by day 2 p.i and remained 
elevated thereafter (Figure 4.4.1). This suggests that CD11bhi DCs rapidly acquired 
the capacity to take up the virus as the infection progressed, in contrast to the static 
behavior of CD11blo/neg DCs. To exclude the possibility that this was due to differing 
abilities of the DCs to take up cellular material from DiD-influenza infected cells, we 
compared the capacity of CD11bhi and CD11blo/neg DCs to directly take up virus ex
vivo as well as in vivo by exploiting the ability to visualize viral uptake using DiD-
influenza. Ex vivo uptake of DiD-influenza by CD11bhi DC was enhanced compared 
to CD11blo/neg DCs from influenza infected mice (Figure 4.4.2), indicating that 
CD11bhi DCs indeed have augmented capacity for virus uptake under conditions of 
infection. To validate this in vivo, we infected mice with unlabelled flu to establish an 
infection and create an inflammatory environment and subsequently inoculated the 
same mice with DiD-influenza at day 3 p.i. and removed the lungs 4 hours later to 
compare uptake of the virus between the two DC subsets. As a control, uninfected 
mice were administered DiD-influenza and the lungs were also removed 4 hours after 
inoculation to examine DC acquisition of the virus. Consistent with the ex vivo data, 
CD11bhi DC from the infected mice exhibited an enhanced capacity under conditions 
of infection and took up 5-fold more virus than CD11blo/neg DCs in vivo (Figure 
4.4.3). 
Chapter 4: Lipophillic Dye-Labelling of Influenza Virus 
110 
 
 
 
Figure 4.4.1 CD11bhi DCs have enhanced accumulation of DiD in vivo 
 
(A) Accumulation of  DiD in lung DCs over time after initial infection with 20 HAU 
of DiD-influenza in C57BL6 mice. Graphs show pooled data from 3 experiments as 
mean ± S.E. of at least 6 mice for each time point. * p < 0.05. 
 
(B) Representative FACS plots from (A) showing DiD accumulation in lung DCs at 
various time points after infection. 
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Figure 4.4.2 Lung DC ex vivo DiD-influenza uptake assay 
 
CD11c+ lung cells were isolated using MACS beads from uninfected and C57BL6 
mice infected with unlabelled influenza virus at day 3 p.i. and cultured at 37oC for 40 
mins with DiD-influenza at an MOI of 1 to allow the cells to take up the virus. Cells 
were then harvested, washed and stained for FACS analysis. Data pooled from 4 
experiments. *** p<0.001, NS = not significant. 
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Figure 4.4.3 Lung DC in vivo DiD-influenza uptake assay 
 
C57BL6 mice were first infected with 20 HAU unlabelled influenza virus to establish 
lung inflammation and at day 3 p.i. the same mice were intranasally inoculated with 
20 HAU of DiD-influenza and culled 4 hours after to analyse relative uptake by DCs. 
Data pooled from 3 experiments and shows mean + S.E. n = 9 for uninfected mice 
and n = 7 for infected mice. * p<0.05, NS = not significant.  
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4.5    Comparative analysis of lung dendritic cells to endocytose the influenza 
virus
 
The influenza virus binds to cell surface glycoproteins and glycolipids containing 
terminal sialyl-galactosyl residues through the hemagglutinin molecule. The binding 
specificity of hemagglutinin differs between virus strains; human strains (H1 to H3) 
preferentially bind to linkages terminating with 2,6-linked sialic acid whereas avian 
strains (H4 to H16) bind preferentially to 2,3-linked sialic acid residues. The 
expression of surface 2,6-linked sialyl-galactosyl residues on both DC subsets (since 
the PR8 virus is a human strain) was therefore determined to see if it could account 
for the difference in the capacity of lung DCs to bind and therefore take up whole 
viruses. This was performed using the Sambucus nigra lectin which binds 
preferentially to sialic acid attached to terminal galactose in (2,6), and to a lesser 
degree, (2,3), linkage (Figure 4.5.1). 
As no large differences were observed in the surface expression of 2,6-linked sialic 
acid residues between the DC subsets, a remaining possibility to explain the large 
difference observed in viral uptake was that the DCs had varied capacity for 
endocytosis of bound virus. To examine this, we assayed the ex vivo endocytic 
abilities of CD11bhi and CD11blo/neg DCs collected from both influenza infected and 
control mice for their ability to take up FITC-labeled dextran. We found no change in 
FITC-dextran uptake between DC populations collected from uninfected animals, 
however when DCs were collected from influenza infected mice, CD11bhi DCs 
demonstrated potentiated endocytosis compared to their CD11blo/neg counterparts 
(Figure 4.5.2). 
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Figure 4.5.1 Surface levels of 2-6 sialic acid receptors on the surface of lung 
DCs  
 
(Upper panel) 2-6 sialic acid glycosation of surface receptors on lung DCs from 
uninfected and C57BL6 mice infected with 20HAU at day 3 p.i. were examined using 
biotinlyated Sambucus niagra lectin which binds preferentially to 2-6 sialic acid. 
Numbers indicate MFI of lectin staining after subtracting background signal (no 
lectin added). Data representative of 3 experiments. (Lower panel) Percentage of each 
DC subset positive for 2-6 sialic acid calculated from the 3 experiments, shown as 
mean + S.E. 
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Figure 4.5.2 Relative capacities of lung DCs to endocytose of FITC Dextran  
 
CD11c+ lung cells were isolated using MACs beads from uninfected and day 3 p.i. 
C57BL6 mice and cultured for 40mins in 0.5mg/ml of 40,000 MW FITC-conjugated 
dextran in complete media at either 37 or 4oC. Cells were washed twice and stained 
for surface markers. Gating on DCs, the rate of endocytosis was assessed using the 
ratio of Mean Fluorescence Intensity (MFI) at 37o C to MFI at 4oC. Graph showing 
mean + S.E. of 4 experiments. * p < 0.05, NS = not significant. 
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4.6    Comparative analysis of proinflammatory cytokine production by lung 
dendritic cells
 
Having demonstrated that CD11bhi DCs possessed an enhanced capacity for viral 
uptake within the lung, we wanted to investigate whether this would translate to a 
potentiated ability to release proinflammatory cytokines. To do this, CD11c+ lung 
APCs were stimulated with the TLR3 ligand Poly I:C to mimic stimulation of DCs by 
double stranded RNA generated during influenza virus replication and intracellularly 
stained for TNF-, which is an important anti-viral cytokine (Seo and Webster 2002).  
In uninfected mice, we observed that CD11bhi DCs were marginally but significantly 
higher producers of TNF- compared to CD11blo/neg DCs. Upon infection however, 
this difference became more dramatic and more than half of the CD11bhi DCs 
produced TNF- in response to TLR3 stimulation compared to only 9% in 
CD11blo/neg DCs (Figure 4.6.1). Taken together with the results in the previous 
sections, this suggests that the contribution of CD11bhi DCs towards host defense 
during early influenza infection is to take up virus and produce proinflammatory 
cytokines such as TNF- within the lung. 
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Figure 4.6.1 CD11bhi DCs are potent producers of TNF-alpha 
 
CD11c+ cells were isolated from the lung tissue of uninfected and day 2 p.i C57BL6 
mice by positive selection using MACS beads. Cells were restimulated with 10μg/ml 
of Poly(I:C)  in the presence of brefeldin A and monensin for 6 hours and stained for 
intracellular TNF-. Representative staining profile is shown in the FACS plot above. 
Graph below is a summary of data pooled from 4 experiments.  
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4.7     Lung DCs have different capacities to migrate to the draining lymph nodes 
 
CCR7 is a key chemokine receptor that controls the migration of peripheral tissue-
resident DCs to the draining lymph nodes (Forster et al. 1999).  Upon maturation, 
dendritic cells express CCR7 (Yanagihara et al. 1998) and become sensitive to 
chemokine gradients of its ligands CCL19 and CCL21 secreted by high endothelial 
venules and lymphatic endothelium (Kellermann et al. 1999). The migration of DCs 
from the lung parenchyma to the draining lymph nodes is also critically dependent on 
CCR7 (del Rio et al. 2007; Kim and Braciale 2009). We therefore examined lung DC 
expression of CCR7 both in uninfected and infected mice to determine if there were 
differences in expression between the subsets. Although infection resulted in 
upregulation of CCR7 on both subsets, CCR7 expression on CD11blo/negDCs always 
remained substantially higher than on CD11bhiDCs (Figure 4.7.1).  
 
We next examined the mediastinal lymph nodes for DiD+ DCs to ascertain the relative 
capacities of lung DCs to migrate to the lymph nodes carrying antigen. CD11blo/neg 
DC consistently formed the majority of DiD+ DCs across all time points examined, 
indicating an efficient uptake of antigen from the lung and migration to the draining 
lymph node (Figure 4.7.2). These data suggest that CD11blo/neg DCs are a highly 
migratory lung DC population that efficiently transports viral antigen obtained from 
the lung to the lymph node.  
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Figure 4.7.1 Surface expression of CCR7 on DCs subsets in the lung parenchyma 
 
(A) Representative FACS plots for CCR7 staining each time point shown above.   
 
(B) Percentages of lung DC subsets from C57BL6 mice expressing CCR7 at various 
time points after infection with influenza. n = at least 6 mice for each time point. 
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Figure 4.7.2 Proportion of DC subsets that comprise total DiD+ DCs in the 
lymph node  
 
At the indicated time points, mediastinal lymph nodes from C57BL6 mice were 
removed and analysed by FACS. Gating on DCs that have acquired antigen which are 
represented by DiD+CD11c+MHCIIhi events, cells were separated into CD11bhi and 
CD11blo/neg DCs and the relative frequencies recorded. Graph shows pooled data from 
at least 3 experiments, n=at least 6 for each timepoint. * p<0.05, ** p<0.01, *** 
p<0.001  
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4.8    Antigen presentation by Lung DCs occurs in the Posterior Mediastinal 
Lymph Node 
 
The trafficking of DCs carrying viral antigen from the lung to the lymph node is a 
key step in the initiation of adaptive immunity in response to the viral infection. To 
determine the site where antigen presentation occurred, lung DC migration to two 
prominent lymph nodes in close proximity to the lung, the anterior and posterior 
mediastinal lymph nodes (aMLN and pMLN)  was tracked using DiD. (Figure 4.8.1). 
DiD label was only detected in the DCs in the pMLN and not in the aMLN across a 
series of time-points, indicating that lung DCs were migrating to this lymph node 
exclusively (Figure 4.8.2). To verify whether the pMLN was the site of antigen 
presentation, we adoptively transferred antigen-specific CFSE labelled Clone 4 CD8 
T-cells which recognise the epitope HA512-520 into BALBc mice and infected them 
with unlabelled influenza. Proliferation of CD8 T-cells was observed in the pMLN at 
days 3 and 4 p.i and not in the aMLN (Figure 4.8.3), confirming that this was the site 
of antigen presentation. Although labelled T-cells with diluted CFSE staining could 
be seen in the aMLN at day 5 p.i, it is likely that these were not primed at that site as 
T-cell proliferation was absent in the preceding days, but instead were labelled T-
cells that had moved into circulation. We repeated the experiment in C57BL6 mice 
using a recombinant PR8 strain containing the ovalbumin epitope SIINFEKL (PR8 
OT-I) (Jenkins et al. 2006) together with OT-I CD8 T-cells specific for SIINFEKL 
and similarly observed T-cell priming in the pMLN (Figure 4.8.4).   
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These results, however, do not differentiate between active migration of lung DCs 
from the site of infection or the possible leakage of labelled virus or cellular debris 
into the lymphatics. To confirm that DiD in the lymph node was specifically due to 
DC migration, mice were intranasally administered pertussis toxin (PTX), an 
inhibitor of G-protein coupled receptor (GPCR) signaling which has been 
demonstrated to be effective in inhibiting DC migration (Aoshi et al. 2008; Jakubzick 
et al. 2008). As most chemokine receptors including CCR7 (Birkenbach et al. 1993) 
signal via GPCRs, PTX acts to inhibit DC migration via inhibition of chemokine 
signaling. Intranasal administration of PTX in conjunction with DiD-influenza 
potently inhibited DC migration and was associated with the abrogation of DiD+DCs 
within the lymph node, demonstrating that DiD does not passively diffuse into lymph 
node where it is picked up by resident DCs, but that lung DCs take up the label in the 
lung and undergo activate migration (Figure 4.8.5).  
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Figure 4.8.1 Photographs showing anatomical location of the anterior 
mediastinal (aMLN) and posterior (pMLN) lymph nodes within the thoracic 
cavity 
 
Pictures and schematic diagrams showing the location of the aMLN and pMLN in 
uninfected C57BL6 mice. The aMLNs are paired lymph nodes, located lateral to the 
thymus (arrows in black). The pMLN is a single lymph node diagonally below the 
anterior MLNs, beside the oesophagus (arrow in black). Only one aMLN is visible in 
the photo on the left as it is partially obstucted by the thymus. The letters H and T 
indicate the position of the heart and thymus respectively. 
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Figure 4.8.2 Kinetics of DiD+ DC accumulation in the pMLN and aMLN over 
time 
 
Lymph nodes were removed from C57BL6 mice at the indicated time points after 
infection with 20 HAU DiD-influenza and examined for the presence of DiD+ DCs.  
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Figure 4.8.3 CD8 T-cell priming occurs in the pMLN and not the aMLN in 
BALBc mice 
 
2  106 CFSE labelled clone 4 CD8 T-cells were intravenously transferred into 
BALBc mice infected with unlabelled PR8 influenza virus on the same day. Mice 
were sacrificed at the indicated time points. aMLN and pMLN were removed and 
stained for FACS analysis. Histograms are gated on CFSE+ CD8 T-cells to exclude 
host CD8 T-cells. n = at least 3 mice for each time point. 
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Figure 4.8.4 CD8 T-cell priming occurs in the pMLN and not the aMLN in 
C57BL6 mice  
 
2 x 106 CFSE labelled OT-I CD8 T-cells were intravenously transferred into 
C57BL/6 mice infected with OT-I PR8 influenza virus on the same day. Mice were 
sacrificed at the indicated time points. aMLN and pMLN were removed and stained 
for FACS analysis. Histograms are gated on CFSE+ CD8 T-cells to exclude host CD8 
T-cells. n = at least 3 mice for each time point. 
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Figure 4.8.5 DiD label in lymph node DCs is due to migration of DCs and not 
leakage of the virus into lymphatics  
 
1μg of Bordetella pertussis toxin (PTX) was simultaenously administered to C57BL6 
mice with DiD influenza virus and pMLNs were harvested 24 hours later and 
analysed for the presence of DiD+ DCs. Data shown as mean + S.E of 3 experiments. 
** p<0.01. 
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4.9     Detection of non-replicating virus uptake using DiD-influenza 
 
In the experiments thus far, live, replication-competent DiD-influenza was used to 
detect the uptake of the virus and viral antigens by cells in the lung. As viral 
replication within the lung triggers a strong host inflammatory response, the uptake of 
the virus by cells could be strongly influenced by the inflammatory milieu within the 
lung. We were therefore curious if DiD-influenza could detect the entry of non-
replicating UV-irradiated virus into cells which would in turn allow us to determine 
the uptake of influenza viruses in the lungs of mice in the absence of a highly 
inflammatory environment. We began by firstly evaluating if UV-irradiated DiD-
influenza could efficiently detect viral entry in vitro using MDCK cells. MDCK cells 
were infected overnight with either UV-irradiated or unirradiated virus at an MOI of 
approximately 2 and analysed for intracellular HA to ascertain the rate of infection of 
cells. Interestingly, DiD-influenza could detect the entry of non-replicating UV-
irradiated virus into cells whereas intracellular staining of hemagglutinin – a major 
flu antigen, in the same cells failed to give any signal (Figure 4.9.1).  
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Figure 4.9.1 DiD-influenza is able to detect the uptake of non-replicating virus  
 
(A) Plaque assay performed on monolayer of MDCK cells using either 140 PFU of 
UV irradiated (240 mJ/cm2 UV) or unirradiated virus. Cells were stained with crystal 
violet to visualise plaques. Complete inhibition of plaque forming activity of the virus 
was seen after UV-irradiation. 
 
(B) DiD is superior in detecting uptake of UV irradiated virus by MDCK cells 
compared to intracellular HA antibody staining.  MDCK cells were infected 
overnight at an MOI of 2 with either DiD-influenza or UV-irradiated DiD-influenza 
(240 mJ/cm2 UV) followed by intracellular staining for HA. Numbers in the 
quadrants reflect the percentage of HA+DiD+ cells. Data representative of 2 
experiments. 
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4.10  Poor acquisition of UV-irradiated virus by dendritic cells in the lung and 
subsequent poor CD8 T-cell priming 
 
As DiD labelling provided the sensitivity to observe uptake of UV-irradiated virus in
vitro, we were interested to determine if there was any difference in the uptake of the 
influenza virus in vivo by phagocytic cells in the absence of viral replication. Mice 
were inoculated with UV-inactivated DiD-influenza and the lungs were examined 3 
days later to compare the rate of virus uptake by neutrophils, macrophages and DCs. 
These results were then juxtaposed with the data obtained previously from mice 
inoculated with non-irradiated DiD-influenza at day 3 p.i in Figure 4.3.1A. The 
comparison of DiD uptake in the presence or absence of replicating virus showed a 
significantly reduced uptake of DiD by DCs and neutrophils but not macrophages. 
This suggests that in the absence of tissue damage, clearance of influenza is primarily 
mediated by lung macrophages (Figure 4.10.1). To confirm this, UV inactivated DiD 
virus was mixed with ‘live’ infectious PR8 and intranasally administered to mice. We 
observed that the uptake of DiD by neturophils and DCs was similar to the non-
irradiated DiD-influenza, demonstrating that acquisition of viral antigen by 
neutrophils and DCs requires tissue damage resulting from viral replication.  
 
As lung DC uptake of non-replicating DiD-influenza was significantly lower 
compared to replicating virus, we hypothesized that the low efficiency of antigen 
capture would have a detrimental downstream effect on CD8 T-cell priming in the 
lymph node. To investigate this, CFSE-labelled clone 4 CD8 T-cells were adoptively 
transferred into BALB/c mice and these mice were subsequently inoculated with 
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either 20HAU of unlabelled PR8 or 20HAU of non-replicating, UV-irradiated PR8. 
The mice were sacrificed 4 days later and the pMLN removed and examined for the 
presence of the transferred CD8 T-cells. 
As shown in Fig 4.10.2, although CD8 T-cells proliferation was observed when mice 
were inoculated with UV-irradiated influenza, the degree of proliferation was 
significantly attenuated compared to the infectious, non-irradiated virus. We also 
utilised the congenic marker CD90.1 (Thy1.1) which enables the tracking of 
transferred cells even after CFSE has been diluted out, to determine the relative 
frequency of the transferred CD8 T-cell population. In the mice that had received 
UV-irradiated virus, donor CD90.1+ CD8 T-cells only comprised 0.5% of the total 
CD8 T-cells in the pMLN compared to 8% in mice that had been received the 
infectious virus, confirming that poor lung DC acquisition of the virus was associated 
with limited expansion of virus-specific CD8 T-cells. 
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Figure 4.10.1 Comparison of the relative uptake of DiD by phagocytic cells after 
inoculation with either UV irradiated or non-irradiated DiD-influenza 
 
Acquisition of DiD by phagocytic cells in the lung of C57BL6 mice 3 days after i.n. 
inoculation with 20 HAU of UV-irradiated or non-irradiated DiD-influenza or 20 
HAU of UV-irradiated DiD-influenza in combination with 20 HAU of PR8. Error 
bars show mean + S.E. Neu – Neutrophils, Macs – Macrophages, DCs – Dendritic 
cells. Data pooled from 2 to 3 experiments for each group of mice and juxtaposed in 
this figure. n = at least 6 mice for each time point. ** p<0.01, *** p<0.001, NS = not 
significant. 
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Figure 4.10.2 Poor proliferation of CD8 T-cells in pMLN of mice inoculated with 
UV-irradiated influenza virus 
 
(A) CFSE dilution of adoptively transferred Clone 4 CD8 T-cells in the pMLN of 
BALBc mice 4 days after inoculation with either 20HAU of unlabelled PR8 or UV-
irradiated unlabelled PR8. Numbers indicate the percentage of cells that have 
undergone at least one division. Histograms were gated on CD3+CD8+CFSE+ cells to 
exclude host CD8 T-cells. 
 
(B) Representative FACS plot of adoptively transferred CD90.1+ Clone 4 CD8 T-
cells, gated on all CD3+CD8+ T-cells in the pMLN. Numbers indicate the percentage 
of CD90.1+ CD8 T-cells. Graph on the right shows pooled data from at least 7 mice 
per group. **p<0.01  
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4.11  Discussion 
 
In this chapter, we demonstrate that DiD labelling is a viable method to fluorescently 
label and track influenza virus entry into cells as well as to follow the uptake of viral 
antigen by various immune cells including DCs in vivo. As DiD incorporation into 
the virus lipid envelope did not perturb the function of the virus in any way (Figures 
4.2.1 and 4.2.2), this method of labelling the influenza virus can potentially be 
extended to other enveloped viruses for tracking studies similar to these we have 
performed. A further advantage of using DiD is its high sensitivity which enables 
tracking of non-replicating UV-irradiated virus entry into cells whereas antibody 
staining for the virus fails to provide a signal (Figure 4.9.1). This ability to detect 
viral entry is a useful feature for the evaluation and optimisation of rational vaccine 
designs aiming to enhance virus delivery to DCs at the site of inoculation, especially 
if the virus used are inactivated forms. Coincidentally, along the course of this study, 
a study employing a similar approach of labelling influenza virus with DiD was 
published, examining follicular DC acquisition of inactivated virus in the lymph node 
and its importance for antibody response (Gonzalez et al. 2010). This further 
underscores the potential of labelling virus particles to visualise uptake by various 
immune cells to elucidate their function during vaccination or primary infection.  
 
Our observation that both CD11bhi and CD11blo/neg DCs migrate to the lymph node 
carrying antigen from the lung is consistent with previous studies that employed 
fluorescent tracers to track pulmonary DC migration (Belz et al. 2004; Jakubzick et 
al. 2008). Our results went a step further to demonstrate that CD11blo/neg DCs were 
superior at transporting influenza antigen to the lymph node (Figure 4.7.2) and a 
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possible explanation for this is differential expression of CCR7 (Figure 4.7.1). It is 
intriguing to note that CD11bhi DCs poorly migrated to the lymph node with antigen 
despite the fact that they were the dominant DC population in the lung taking up the 
virus (Figure 4.4.1). This provides further evidence to support the current paradigm of 
lung dendritic cell function (GeurtsvanKessel and Lambrecht 2008) that there is a 
dichotomy of DC specialization for the uptake of antigen and migration to the lymph 
node during early infection, i.e. CD11blo/neg DCs are functionally specialised for 
efficient transportation of antigen to the draining lymph node by virtue of CCR7 
expression whereas CD11bhi DCs remain in the lung and contribute to viral clearance 
by active uptake of the virus and cytokine production.  
It is intriguing to note that although both the anterior and posterior mediastinal lymph 
nodes in the thoracic cavity are within close physical proximity to the lung, only the 
posterior mediastinal lymph node directly drains the lung. To our knowledge, there 
have been no reports describing lymphatic drainage in the mouse lung, possibly due 
to the difficulty of administering lymph tracking dyes into the lung without 
interfering with gas exchange. Furthermore, no effort has been made in studies 
describing lung DC migration or T-cell proliferation in response to antigen challenge 
in the lung to identify or describe which lymph nodes were examined. In these 
reports, it is only mentioned that the posterior mediastinal lymph node was examined. 
By combinatorial use of a labelled antigen and antigen-specific T-cell proliferation, 
we have determined that the pMLN is the immediate site where lung DCs migrate to 
and present antigen. It remains to be discovered which tissue site drains into the 
aMLN or whether there is a sequential lymphatic flow from the pMLN to the aMLN. 
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Dendritic cell acquisition of viral antigen is the very first step in antigen presentation 
and is often one of the limiting factors to the potency of vaccination-induced T-cell 
responses. Our experiments involving the inoculation mice with UV-irradiated 
influenza also suggest that poor CD8 T-cell proliferation is associated with low levels 
of lung DC acquisition of the virus in the absence of extensive lung tissue damage 
that results from viral replication (Figures 4.10.1 and 4.10.2). The limited access by 
DCs to antigen in the lung air space in the absence of disruption to the lung epithelial 
lining is hence one of the major obstacles for mucosal vaccines that aim to engender a 
robust CD8 T-cell response. Although CD103+ DCs have been shown to be able to 
extend their dendrites between the tight junctions of epithelial cells into the lumen of 
the lung air spaces to sample antigen (Sung et al. 2006; Hammad and Lambrecht 
2008), the vast surface area of the lung broncho-alveolar network presents a 
significant challenge for the efficient acquisition of antigen by DCs. Furthermore, as 
the virus is incapable of replication, the amount of antigen within the lung is limited. 
Even if DCs are able to internalise the virus, the amount of antigen acquired and 
density of viral peptides presented on surface MHC I may be insufficient for efficient 
priming of CD8 T-cells. Moreover, the lung is populated by a large number of 
macrophages which clear free-floating antigen by phagocytosis (Figure 4.10.1), 
which further reduces the chances of lung DCs to acquire the antigen.  
 
Targeting of antigens to DCs in situ via monoclonal antibodies to augment DC access 
to antigen has gained considerable interest in the recent years. Notably, phase II 
clinical trials are currently underway to target tumor antigens to DCs using a fusion 
protein of the tumor antigen (NY-ESO-1) and an antibody against DEC205 which is a 
lectin uniquely expressed on certain DC subsets. The targeted delivery of whole 
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influenza virus to lung DCs may thus represent a viable strategy to overcome poor 
DC acquisition of the virus and enhance the development of cross-protective CD8 T-
cell responses, especially in light of the fact that current influenza vaccination 
strategies however, are unable to elicit a potent CD8 T-cell response (Brown and 
Kelso 2009).  The potential for this rational vaccine design is particularly attractive as 
cross-reactive CD8 T-cells recognising epitopes from H5N1 and pandemic H1N1 
2009 strains could be isolated from healthy individuals with no prior exposure to the 
virus (Lee et al. 2008; Teijaro et al. 2010), which thus suggests that a vaccine strategy 
that is able to boost already existing CD8 T-cell memory will be a useful tool to 
provide immunity to a pandemic strain. The use of fluorescent lipophillic dye-
labelled influenza virus in this approach will enable tracking of virus delivery to DCs 
and hence will be a useful tool for the rapid evaluation and optimisation of such 
rational vaccine designs. 
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Chapter 5: Antigen Presentation Capacities of Lung DC Populations 
5.1    Introduction 
 
DCs can be distinguished from other professional APCs by their unique ability to 
potently prime naive T-cells. However, when divided into subsets, DCs display 
varying capacity for activation of CD8 and CD4 T-cells (Heath and Carbone 2009), 
and this is true of DCs from various tissue origins such as the skin, spleen and the 
lung. In the context on an influenza infection, there is some controversy over the 
capacity of different lung DC subsets to mediate CD8 T-cell priming. Early studies 
by Belz et al. identified that airway derived CD11blo/neg DCs and not CD11b+ DCs 
were responsible for presenting influenza antigens to CD8 T-cells (Belz et al. 2004; 
Belz et al. 2007). Similar experiments performed by Lambrecht and colleagues 
confirmed this finding and further demonstrated that depletion of CD11blo/neg DCs 
resulted in a dramatic attenuation of the virus-specific influenza CD8 T-cell response 
(GeurtsvanKessel et al. 2008). In contrast, a recent report by Inguilli et al. described 
that CD11b+ DCs in the draining lymph node were the only DCs presenting influenza 
antigen on MHC-I by using a recombinant influenza virus expressing the ovalbumin 
epitope SIINFEKL in combination with a TCR-like monoclonal antibody against 
SIINFEKL-Kb (Ingulli et al. 2009). Further adding to the ambiguity of the capacity of 
lung DCs to prime CD8 T-cells was a study by Kim and Braciale which showed that 
both CD11blo/neg as well as CD11bhi DCs could potently prime CD8 T-cells, although 
CD11bhi DCs were six-fold less efficient than CD11blo/neg DCs (Kim and Braciale 
2009).  
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To provide clarity to this controversy, we carried out a series of experiments to 
ascertain the veracity of these conclusions as well as to examine the underlying 
mechanisms of DC-mediated antigen presentation to T-cells. In this chapter we 
provide evidence that only CD11blo/neg DCs and not CD11bhi DCs can efficiently 
prime naïve CD8 T-cells; CD11bhi DCs on the other hand could only mediate the 
expansion of CD4 T-cells. We also show that this unique capacity of CD11blo/neg DCs 
to prime CD8 T-cells is due to efficient loading of viral peptide onto MHC-I. 
CD11blo/neg DCs also constitutively express higher levels of the peptide transporter 
TAP as a well as components of the immunoproteasome, which provides preliminary 
evidence that these cells have a unique regulation of the antigen processing pathway. 
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5.2    Only CD103+CD11blo/neg DCs have the capacity to potently prime naive 
CD8 T-cells ex vivo 
 
As shown earlier in figure 4.7.2, both lung CD11bhi and CD11blo/neg DCs are capable 
of transporting DiD to the pMLN. We tested the ability of these two DC populations 
to induce proliferation of naïve CD8 T-cells ex vivo by isolating DCs from both the 
lungs and pMLN of infected mice and culturing them with freshly isolated virus-
specific transgenic CD8 T-cells. This assay was performed with both C57BL6 and 
BALBc mice. The C57BL6 mice were infected with OT-I PR8 and sorted DCs were 
cultured with OT-I CD8 T-cells, whereas BALBc mice were infected with PR8 and 
the sorted DCs cultured with Clone 4 CD8 T-cells. Consistent with previous reports 
(Belz et al. 2004; Belz et al. 2007; GeurtsvanKessel et al. 2008), a strong induction of 
CD8 T-cell proliferation was only observed when the CD8 T-cells were cultured with 
CD11blo/neg DCs but not with CD11bhi DCs (Figure 5.2.1). We also increased the ratio 
of lung CD11bhi DCs to CD8 T-cells in culture but did not observe a large increase in 
the number of proliferating T-cells (Figure 5.2.2). 
 
We took care to exclude LN-resident DCs by gating on CD4/CD8neg DCs as shown in 
Figure 5.2.1A as LN-resident CD8+ DCs have been demonstrated to contribute to 
CD8 T-cell priming as well (Belz et al. 2004). In fact, when we deliberately omitted 
CD8 and CD4 markers when performing LN DC sorting experiments, we could 
observe significant proliferation of CD8 T-cells with the sorted CD11bhi DCs (Figure 
5.2.3). This may explain why Kim and Braciale observed that CD11bhi DCs could 
also prime CD8 T-cells as they did not exclude LN-resident DCs when sorting DCs 
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from the MLN (Kim and Braciale 2009). An analysis on the CD11bhi DCs from the 
pMLN revealed that contaminating CD8+ DCs consist of approximately 5% of the 
CD11bhi DCs (Figure 5.2.3). As a result, CD8+ LN DCs capable of cross-priming 
CD8 T-cells were inevitably included into the sorted CD11bhi lung DCs, resulting in 
the observation of naive CD8 T-cells priming by these DCs. This was surprising as 
CD8+ DCs in the spleen do not express CD11b. However, our observations were 
consistent with a report by Randolph and colleagues (Jakubzick et al. 2008) which 
showed that a small population of CD8+ DCs positive for both CD11b and CD11c 
could be detected in the draining lymph nodes. 
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Figure 5.2.1 Only CD11blo/neg DCs from have the ability to potently stimulate 
naïve CD8 T-cell proliferation 
 
(A) CD11bhiCD103neg and CD11blo/negCD103+ DCs were sorted from the pMLNs of 
influenza infected BALBc at day 3 p.i. gated on CD4/8 negative events to avoid 
contamination with lymph node resident DCs. DCs were cultured with naïve CFSE 
labelled Clone 4 CD8 T-cells for 3 days at DC:CD8 T-cell ratio of 1:10. CFSE 
dilution was used to assess extent of proliferation of Clone 4 CD8 T-cells and 7-AAD 
was used to exclude dead cells from analysis. 
 
(B) CD11bhiCD103neg and CD11blo/negCD103+ DCs were sorted from the lungs of 
influenza infected BALBc at day 2 p.i. and cultured with naïve CFSE labelled Clone 
4 CD8 T-cells for 3 days at DC:CD8 T-cell ratio of 1:10. CFSE dilution was used to 
assess extent of proliferation of Clone 4 CD8 T-cells and 7-AAD was used to exclude 
dead cells from analysis. Data representative of 3 experiments.  
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Figure 5.2.2 Poor antigen presenting capacity of lung CD11bhi DCs 
 
BALBc and C57BL6 mice were infected with 20 HAU PR8 and OT-I PR8 influenza 
respectively. CD11bhi and CD11blo/neg DCs were sorted from the lungs of the mice 
day 2 p.i. and cultured with naïve CFSE labelled Clone 4 (BALBc) and OT-I 
(C57BL6) CD8 T-cells at the indicated ratios for 3 days. Proliferation was assessed 
by CFSE dilution. Data representative of 3 experiments. N.D indicates not done due 
to limited cell numbers.  
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Figure 5.2.3 CD11bhi DCs from pMLN of infected mice contain a small amount 
of CD8+ DCs which can induce proliferation of naïve CD8 T-cells 
 
CD11bhiCD103neg and CD11blo/negCD103+ DCs were sorted from the pMLN and lung 
of influenza infected BALBc mice without gating out CD8+ DCs and cultured with 
naïve CFSE labelled Clone 4 CD8 T-cells for 3 days. Data representative of 3 
experiments.  
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5.3    Both CD11blo/neg and CD11bhi DCs have the capacity to prime naïve CD4 T-
cells 
 
To investigate the ability of DC subsets to prime CD4 T-cells, we used a recombinant 
strain of the influenza virus which incorporated the ovalbumin CD4 T-cell epitope 
OVA323-339 (PR8-OT-II) that is recognized by the OT-II transgenic T-cells. Mice were 
infected with the PR8-OT-II virus and CD11blo/neg and CD11bhi DCs were sorted from 
the pMLN. In contrast to the previous experiment where only CD11blo/neg DCs could 
prime naïve CD8 T-cells, both CD11blo/neg and CD11bhi DCs demonstrated 
comparable capacity to stimulate naïve CD4 T-cells to proliferate (Figure 5.3.1). In 
context of the results in the previous section, this data suggests that the role of 
CD11bhi DCs is not to mediate CD8 T-cell priming but to mediate the expansion of 
virus-specific CD4 T-cells within the lymph node. 
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Figure 5.3.1 Both CD11blo/neg and CD11bhi DCs have the capacity to prime naïve 
CD4 T-cells  
 
CD11bhiCD103neg and CD11blo/negCD103+ DCs were sorted from the pMLNs of 
influenza infected C57BL6 mice at day 3 p.i. and cultured with CD4 T-cells isolated 
from OT-II mice labelled with CFSE. OT-II cells were cultured with DCs at a 10:1 
ratio for 4 days. Proliferation was assessed by CFSE dilution. Data representative of 2 
experiments. 
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5.4    Infection of DCs by the influenza virus 
 
A possible explanation for the differential ability of lung DCs to mediate the priming 
of CD8 T-cells could be the capacity of the DCs to be infected by the virus. This is a 
compelling hypothesis as CD11blo/negCD103+ DCs have been demonstrated to be 
more susceptible to infection by the influenza virus (Hao et al. 2008; Kim and 
Braciale 2009). To investigate this, we obtained an anti-HA monoclonal antibody 
generated by Hanson and colleagues that efficiently detects HA in influenza infected 
cells (Lim et al. 2008). We examined DCs from both the lung and pMLN for 
intracellular HA staining which is indicative of viral replication at day 2 p.i (Figure 
5.4.1). Interestingly, although the percentage of HA+ CD11blo/neg DCs in the pMLN 
was significantly higher than CD11bhi DCs, we observed a similar rate of infection of 
the DC subsets in the lung parenchyma. When taken with the results from section 5.2, 
the ability of CD11blo/neg DCs to potently mediate CD8 T-cell priming could not be 
explained by the differential capacity of the DCs to be infected with the virus. This is 
because lung derived CD11bhi DCs manifested poor CD8 T-cell priming potential 
compared to CD11blo/neg DCs even though both DCs were infected at similar rates. 
Moreover, even when the ratio of DC to T-cell culture was increased by 
approximately 3-fold, CD11bhi DCs still failed to demonstrate strong priming of CD8 
T-cells. Therefore, even though a significant difference in infection rates of DCs was 
observed in the pMLN, it is likely that the ability of DCs to be infected is not the 
main contributing factor to the differential ability of DCs to stimulate CD8 T-cell 
proliferation.  
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Figure 5.4.1 Rate of infection of CD11blo/neg and CD11bhi DCs in the lung and 
pMLN  
 
DCs from the lungs of C57BL6 mice were obtained at day 2 p.i. and from the pMLN 
at day 3 p.i. and intracellularly stained for influenza HA. Data pooled from 
experiments, n = 6 for the lung and n = 7 for the pMLN. *** p<0.001, NS = not 
significant. 
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5.5    Analysis of MHC-I and co-stimulatory molecule expression on lung DCs 
 
The next possibility that we considered to explain the differential ability of lung DC 
subsets to mediate CD8 T-cell priming was surface expression of MHC-I molecules. 
We took uninfected and day 2 p.i mice and examined MHC-I levels on DCs isolated 
from both the lung and pMLN. In uninfected mice, both CD11blo/neg and CD11bhi DCs 
exhibited similar expression of surface MHC-I in the lung as well as the pMLN 
(Figure 5.5.1). In the infected mice, the expression of surface MHC-I on CD11blo/neg 
and CD11bhi DCs within the pMLN was upregulated to a similar extent, however in 
the lung we observed a marked upregulation of MHC I expression in CD11bhi DCs 
that was not seen in the CD11blo/neg DCs. This was a surprising result as it was 
paradoxical that CD11bhi DCs displayed enhanced MHC I expression and yet lacked 
the ability to initiate CD8 proliferation. In addition to MHC-I, we also considered the 
expression levels of co-stimulatory molecules on DCs. As shown earlier in Figure 
4.3.2, both CD11bhi and CD11blo/neg DCs isolated from the lung upregulated 
expression of co-stimulatory molecules CD80 and CD86 to similar extents upon 
infection. Therefore, we concluded that the differential ability of lung DCs to prime 
CD8 T-cells could not be attributed to differences in the expression of MHC-I or co-
stimulatory molecules. 
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Figure 5.5.1 Expression of MHC I molecules on CD11bhi and CD11blo/neg DCs in 
the lung and pMLN  
 
Lungs and pMLN were obtained from uninfected and day 2 p.i. C57BL6 mice and 
analysed for surface expression of total surface MHC I molecules, H-2Kb and H-2Db. 
Data shown representative of 3 experiments. 
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5.6    Equivalent capacity of peptide pulsed lung DC populations to prime CD8 
T-cells 
 
Having ruled out the possibilities of infection rates, MHC-I and co-stimulatory 
molecule expression, we hypothesised therefore that the inability of CD11bhi DCs to 
stimulate CD8 T-cells was due to insufficient presentation of viral peptide on MHC I. 
To investigate if this was the case, lung DCs were sorted from uninfected C57BL6 
mice and briefly pulsed with 1M SIINFEKL peptide and cultured with CFSE-
labelled OT-I CD8 T-cells for 3 days. We observed that both CD11blo/neg and CD11bhi 
DCs demonstrated a comparable ability to stimulate CD8 T-cell proliferation and 
acquisition of effector function (Granzyme B) (Figure 5.6.1A).  
 
To exclude the possibility that pulsing with a high peptide concentration may result in 
unphysiological concentrations of peptide-MHC complexes on the surface of DCs, 
we repeated the experiment using low levels of peptide concentrations (	10-9 M) to 
examine if there was any difference in the ability of the DCs to initiate CD8 T-cell 
proliferation. Consistent with the previous observation, CD11bhi DCs demonstrated 
equal potential to stimulate CD8 T-cell to proliferate as CD11blo/neg DCs across 
various peptide concentrations (Figure 5.6.1B).  
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Figure 5.6.1 Peptide pulsed CD11bhi DCs and CD11blo/neg DCs induce similar 
activation of CD8 T-cells  
 
(A) Proliferation and intracellular granzyme B expression of OT-I CD8 T-cells when 
cultured with lung CD11bhi and CD11blo/neg DCs pulsed with 1μM SIINFEKL 
peptide and cultured at a DC to CD8 T-cell ratio of 1:10. Data representative of 2 
experiments. 
 
(B) Proliferation of OT-I CD8 T-cells when cultured with lung CD11bhi and 
CD11blo/neg DCs pulsed with various concentrations of SIINFEKL peptide.  
The DC to CD8 T-cell culture was 1:10 for experiments in (A) and (B). Data 
representative of 2 experiments.  
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5.7    CD11blo/neg lung DCs efficiently load viral peptide onto MHC-I complexes 
 
Having demonstrated that CD11bhi DCs could acquire similar ability as CD11blo/neg 
DCs to stimulate CD8 T-cell proliferation when pulsed with exogenous peptide, we 
wanted to determine if peptide-MHC concentrations were different in the DC subsets 
during infection. To detect viral peptide-MHC complexes ex vivo, we isolated DCs 
from the pMLN of mice infected with OT-I PR8 at day 2 p.i and used a monoclonal 
TCR-like antibody (25.D1-16) that specifically detects the SIINFEKL peptide in the 
context of H-2Kb (SIINFEKL-Kb). Unfortunately, the number of SIINFEKL-Kb 
complexes on the DCs was below the limit of detection using standard flow 
cytometry techniques (Figure 5.7.1). In order to enhance the sensitivity of detection, 
we employed tyramide signal amplification to amplify the signal as this has been 
demonstrated to be effective for detection of SIINFEKL-Kb complexes on tissue 
sections (Castiglioni et al. 2008). To do this, DCs were sorted and briefly cultured 
onto slides, fixed and stained using SIINFEKL-Kb primary antibody followed by 
tyramide amplification. DCs positive for SIINFEKL-Kb were then enumerated under 
fluorescent microscopy. Using this method, we detected SIINFEKL-Kb complexes on 
37% of CD11blo/negDCs whereas only 3% of CD11bhiDCs were positive (Figure 
5.7.2), confirming that CD11blo/negDCs were indeed superior at loading viral antigen 
onto MHC-I. 
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Figure 5.7.1 SIINFEKL-Kb complexes on the surface of lung DCs in the pMLN 
are below the limit of detection by flow cytometry 
 
pMLNs were obtained from C57BL6 mice that were either infected with OT-I PR8 or 
PR8 as a control at day 2 p.i. Cells were stained for surface SIINFEKL-Kb complexes 
using 25-D1.16 antibody. Data shown is representative of 2 experiments.  
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Figure 5.7.2 Immunofluorescence staining of SIINFEKL-Kb complexes on 
pMLN CD11bhi and CD11blo/neg DCs after tyramide signal amplification 
 
pMLNs were obtained from uninfected and infected C57BL6 mice inoculated with 
20HAU of PR8-OT-I influenza at day 2 p.i. DCs were sorted and spun onto slides 
after which tyramide signal amplification was performed to enhance signal intensity 
of SIINFEKL-Kb complex detection using the TCR-like monoclonal antibody 25.D1-
16. Representative immunofluorescence staining of SIINFEKL-Kb (in red) together 
with cell nuclei stained using DAPI (in blue). Relative percentages of SIINFEKL-Kb 
positive DCs obtained by counting cells from high powered fields over 3 
experiments, n=252 for CD11bhi DCs, n=575 for CD11blo/neg DCs. Magnification 
400. White bar represents 20μm.  
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5.8    CD11blo/neg DCs have higher mRNA transcript levels of TAP1 and TAP2  
 
Having determined that CD11bhi DCs had higher amounts of viral peptide loaded 
onto MHC-I, the mRNA transcript levels of proteins involved in the MHC Class I 
loading pathway were then examined for differences between the two DCs subsets. 
Using a dataset of microarray profiles of CD11bhi and CD11blo/neg lung DC deposited 
at the Gene Expression Omnibus (GEO) database (Edelson et al. 2010), we found that 
TAP1 and TAP2 transcripts as well as components of the immunoproteasome, 
PSMB8 and PSMB9, commonly known as LMP2 and LMP7, were significantly 
upregulated on CD11blo/neg DCs compared to CD11bhi DCs (Table 2). TAP1 and 
TAP2 belong to the ATP-binding cassette family of transporters and the two subunits 
form a heterodimer responsible for the ATP-dependent transport of peptides 
generated from proteasomal degradation of cytosolic proteins into the endoplasmic 
reticulum for loading onto MHC Class I molecules. PSMB8/LMP7 and 
PSMB9/LMP2 are catalytically active proteasome  subunits that are incorporated 
into nascent proteasome complexes upon interferon-mediated induction. Together 
with PSMB10/MECL1, these transform the regular proteasome to an alternative form 
called the immunoproteasome, which generates a different repertoire of peptides for 
presentation on MHC I molecules (Yewdell 2005). We also looked at the transcript 
levels for several proteins which are key components of the MHC Class I processing 
machinery such as Calnexin, Calreticulin and Tapasin (also known as Tap binding 
protein) but did not observe any significant upregulation of those genes (Table 2). 
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In order to validate the microarray data on the differential expression of TAP1, TAP2, 
PSMB8 and PSMB9 proteins, cDNA was obtained by reverse transcription of mRNA 
from CD11blo/neg and CD11bhi DCs sorted from the lungs of naïve C57BL6 and 
BALBc mice. The relative transcript levels of TAP1, TAP2, TAPASIN, PSMB8, 
PSMB9, and PSMB10 were quantified using RT-PCR with GAPDH as the 
endogenous control. The results indicate that CD11blo/neg DCs had significantly higher 
expression of TAP1, TAP2, TAPASIN as well as PSMB8 and 9 mRNA transcripts 
(Figure 5.8.1).  We note in contrast to the RT-PCR results, the microarray data did 
not indicate that TAPASIN levels were significantly different in CD11blo/neg DCs. 
This is likely due to the inherent inaccuracy of the microarray as TAPASIN transcript 
levels were consistently higher in two strains of mice when quantitated by RT-PCR. 
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Gene symbol Title Unigene ID  Fold 
Difference 
p-value 
Tap1 Transporter 1, ATP-binding 
cassette, sub-family B 
(MDR/TAP) 
Mm.207996 2.53 0.000756 
Tap2 Transporter 2, ATP-binding 
cassette, sub-family B 
(MDR/TAP) 
Mm.14814 1.83 0.0232 
Tapbp TAP binding protein
(TAPASIN) 
Mm.154457 1.04 0.791 
PSMB8 Proteasome Subunit, 
(prosome, macropain) beta 
type 8 (LMP 7) 
Mm.180191 1.71 0.00724 
PSMB9 Proteasome Subunit, 
(prosome, macropain) beta 
type 8 (LMP 2) 
Mm.390983 3.39 0.000866 
PSMB10 Proteasome Subunit, 
(prosome, macropain) beta 
type 10 (MECL1) 
Mm.787 1.06 0.221 
Canx Calnexin Mm.248827 -1.18 0.1033 
Calr Calreticulin Mm.1971 -1.11 0.295 
2m Beta-2 microglobulin Mm.163 -1.07 0.136 
PDIA3 Protein Disulfide Isomerase 
Associated 3 (Erp57) 
Mm.263177 1.18 0.364 
 
Table 2: Summary of MHC Class I-related genes from lung DC microarray 
analysis  
 
Raw data from microarray was obtained from GEO dataset GSE17322 and analysed. 
using Genespring software. Values for fold-difference refer to the fold difference of 
transcript levels in CD11blo/negCD103+ DCs compared to CD11bhiCD103neg DCs. p-
values < 0.05 are highlighted in bold. 
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Figure 5.8.1 CD11blo/neg DC have higher expression of TAP1, TAP2, TAPASIN, 
PSMB 8 and 9  
 
Real time PCR analysis of relative mRNA transcript abundance of TAP1, TAP2, 
TAPASIN, PSMB 8, 9 and 10 in lung DCs. DCs were sorted from the lungs of 
uninfected C57BL6 mice and BALBc mice. Each set of data representative of 2 
experiments. * p <0.05, ** p <0.01, *** p <0.001, NS not significant. 
   
0
1
2
3
4
5
6
TAP1 TAP2 TAPASIN PSMB8 PSMB9 PSMB10
R
Q
C57BL6
CD11bhi DC CD11blo/neg DC
***
**
*
** **
NS
0
1
2
3
4
TAP 1 TAP 2 TAPASIN PMSB8 PMSB9 PMSB10
R
Q
BALBc
CD11bhi DC CD11b lo/neg DC
NS
**
***
*** *** ***
Chapter 5: Antigen Presentation Capacities Of Lung DC Populations 
160 
 
5.9    CD11blo/neg DCs have higher protein expression of TAP1 and TAP2  
 
To determine whether the increased TAP1 and TAP2 mRNA transcripts in the 
CD11blo/neg DCs corresponded to higher protein expression of TAP1 and TAP2, 
intracellular staining of lung DCs using anti-TAP1 and anti-TAP2 polyclonal 
antibodies was performed on DCs isolated from both the lung and lymph node from 
uninfected and infected mice (Figure 5.9.1). We also further subdivided the CD11bhi 
DCs from the lung parenchyma of infected mice into Ly6Clo/neg and Ly6Chi subsets 
(Aldridge et al. 2009). Consistent with the mRNA transcript levels, CD11blo/neg DCs 
had higher TAP1 and TAP2 expression compared to CD11bhi DCs regardless of 
whether the mice were infected or not. Notably, DC expression of TAP1 and TAP2 
was further enhanced in the pMLN compared to the lung suggesting an enhanced 
antigen processing capacity as DC mature and migrate to the draining lymph node. 
Interestingly, although infection resulted in increased DC expression of TAP1 and 
TAP2 in the pMLN, DCs in the lung displayed reduced TAP expression. This is 
likely the result of mature DCs migrating from the lung to the draining lymph node, 
giving rise to a predominantly immature DC population remaining in the lung. To 
verify the specificity of this polyclonal antibody, intracellular staining for TAP1 and 
TAP2 was also performed on splenic DC subsets as CD8+ DCs have been identified 
to have higher TAP1 and TAP2 protein levels by western blotting compared to all 
other subsets within the spleen (Dudziak et al. 2007). The results indicate that the 
polyclonal antibodies were indeed specific for TAP1 and TAP2 and were suitable for 
use to detect TAP1 and TAP2 using flow cytometry (Figure 5.9.2).  
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Figure 5.9.1 Intracellular staining of TAP1 and TAP2 in DCs from lung and 
pMLN  
 
Lungs and pMLN were obtained from uninfected and day 2 p.i C57BL6 mice and DC 
subsets were intracellularly stained for TAP1 and TAP2. Numbers in the quadrant 
indicate mean fluorescent intensity of signal (1o + 2o Ab) after subtracting 
background (2o Ab only). Data representative of 4 experiments.  
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Figure 5.9.1 Intracellular staining of TAP1 and TAP2 in DCs from lung and 
pMLN (continued) 
 
Graph shows summary of data pooled from 4 experiments. * p < 0.05, ** p < 0.01, 
*** p < 0.001   
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Figure 5.9.2 Validation of TAP1 and TAP2 polyclonal antibodies for flow 
cytometric use  
 
Splenic DCs from C57BL6 mice were divided into three subsets, CD8+, CD4+ and 
CD8negCD4neg (Double negative DCs, DNDCs) and intracellularly stained for TAP1 
and TAP2. Numbers in the quadrant indicate mean fluorescent intensity of signal (1o 
+ 2o Ab) after subtracting background (2o Ab only). Data representative of 2 
experiments.  
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5.10   Discussion 
 
There is a growing body of evidence suggesting that CD103+CD11blo/neg DCs are a 
highly specialised subset of non-lymphoid tissue DCs which form a vital link 
between the innate immune system and the adaptive cytotoxic T-cell response. The 
data reported here is consistent with previous observations by other groups that 
CD11blo/neg DCs are highly efficient in priming CD8 T-cells during influenza 
infection (Belz et al. 2004; Belz et al. 2007; GeurtsvanKessel et al. 2008; Kim and 
Braciale 2009). Although these studies show the dominance of CD11blo/neg DCs in 
mediating CD8 T-cell priming during early infection, they fail to identify any 
mechanism for this observation. We demonstrate here that CD11blo/neg DCs are 
capable of inducing naive CD8 T-cell expansion by virtue of efficient loading of viral 
peptide onto MHC-I complexes. Our data also suggests that one of the underlying 
mechanisms that may be responsible for the efficient presentation of viral antigen is a 
higher constitutive expression of the peptide transporter TAP and possibly also 
TAPASIN and components of the immunoproteasome in CD11blo/neg DCs. We 
postulate that CD11blo/neg DCs have a unique regulation of the MHC I antigen 
processing pathway by virtue of the observation that the mRNA transcripts of several 
key proteins are constitutively expressed at higher levels compared to CD11bhi DCs. 
As the differentiation of CD103+CD11blo/neg DCs from precursors cells in vivo is 
absolutely reliant on the expression of transcription factors IRF-8, Id2 and BATF3 
(Edelson et al. 2010), we postulate that these transcription factors also play a role in 
mediating the constitutive expression of the TAP peptide transporter and 
immunoproteasome components. However, it is currently impossible to investigate 
this hypothesis as mice deficient for any of these transcription factors exhibit near 
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complete ablation of CD103+CD11blo/neg DCs in the lung. Until transgenic mouse 
models which permit the inducible knockdown of these transcription factors become 
available, it will be remain difficult to determine whether these transcription factors 
have a key role in conferring CD103+CD11blo/neg DCs a unique regulation of the 
MHC I antigen processing pathway and enhanced presentation to CD8 T-cells. 
 
The role of CD11bhiCD103neg DCs in mediating CD8 T-cell priming is not as 
unanimous however. We and others observed that CD11bhi DCs are unable to initiate 
CD8 T-cells priming during influenza infection (Belz et al. 2004; Belz et al. 2007; 
GeurtsvanKessel et al. 2008) in contrast to studies by Kim and Braciale (Kim and 
Braciale 2009) as well as Ballesteros and colleagues who show data that CD11bhi 
DCs can stimulate CD8 T-cell expansion to a reasonable degree (Ballesteros-Tato et 
al. 2010). As we have shown in section 5.2.2, care must be exercised to exclude 
lymph node resident DCs when sorting CD11bhi DCs from the lymph node as these 
cells possess the ability to prime naïve CD8 T-cells and a certain percentage of these 
cells express CD11b. We note that the study reported by Kim and Braciale did not 
include means to exclude lymph node resident DCs in their cell sorting strategy 
which may explain why they observed a substantial degree of naïve CD8 T-cell 
priming with CD11bhi DCs. In the study by Ballesteros and colleagues, unlike all the 
previous studies which used naïve CD8 T-cells isolated from transgenic mice, the 
source of virus specific CD8 T-cells was the spleens of day 7 p.i mice. This presents a 
significant confounding factor as the virus-specific CD8 T-cells would be effector 
cells and not naïve during this point of infection. It is essential to note that the 
requirements for stimulation of naïve T-cells to proliferate are far more stringent 
compared to effector cells, requiring at least 10 to 100-fold higher MHC-peptide 
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concentrations to achieve comparable proliferation (Sagerstrom et al. 1993; Dubey et 
al. 1996). As we have shown in sections 5.6 and 5.7, CD11bhi DCs are less efficient at 
loading peptide onto MHC-I and can only potently stimulate naïve CD8 T-cell 
proliferation when the density of surface peptide-MHC complexes are artificially 
enhanced. In light of this, the proliferation of CD8 T-cells mediated by CD11bhi DCs 
reported in their study very likely represents the capacity of the DCs to restimulate 
effector CD8 T-cells rather than priming of naïve CD8 T-cells. In other words, the 
density of cognate peptide presented on MHC-I by CD11bhi DC may be inadequate to 
stimulate naïve T-cell expansion, but sufficient for restimulation of effector T-cells. 
 
Although CD11bhi DCs do not make a significant contribution to the initiation of 
CD8 responses during early infection, they play an essential role in orchestrating CD8 
responses during the late phase of infection by mediating the expansion of effector 
CD8 T-cells (Aldridge et al. 2009), restimulating them for optimal cytotoxicity 
(McGill et al. 2008) and promoting their survival through CD70-CD27 interactions 
(Ballesteros-Tato et al. 2010). CD11bhi DCs also have a role in priming CD4 T-cells 
in the early phase of influenza infection although there is an overlap of DC function 
here as CD11blo/neg DCs are also capable of performing this role (Figure 5.3.1) 
(GeurtsvanKessel and Lambrecht 2008; Kim and Braciale 2009). 
 
Antigen processing and presentation via the MHC Class I pathway is an essential 
mechanism that is necessary both for the initiation of CD8 T-cell responses by DCs 
and the CD8 T-cell recognition and killing of cells infected with intracellular 
pathogens such as the influenza virus. The heterodimer TAP1/TAP2 peptide 
transporter is a critical component to the MHC Class I machinery located in the ER 
Chapter 5: Antigen Presentation Capacities Of Lung DC Populations 
167 
 
and cis-Golgi (Kleijmeer et al. 1992) that mediates the transport of peptides produced 
in the proteasome and a defect in either component abrogates peptide loading of 
MHC-I resulting in the destabilisation of MHC-I complexes and consequently low 
surface MHC-I expression (Van Kaer et al. 1992; Yang et al. 1992). Furthermore, 
TAP1 and TAP2 deficient mice exhibit severely reduced CD8 T-cell numbers, 
comparable to that observed in 2-microglobulin knockout mice, which are also 
deficient in MHC-I expression (Van Kaer et al. 1992; Theodoratos et al. 2009). TAP1 
and TAP2 expression has been associated with the ability of DCs as well as 
macrophages to cross-present exogenous antigens (Chefalo et al. 2003; Vitalis et al. 
2005). Within DC subsets, there is also a correlation of TAP expression with the 
ability of DCs to cross-present antigens; splenic CD8+ and lung CD103+ DCs are by 
far the most efficient at mediating cross-presentation and these DCs subsets also 
exhibit high expression of TAP molecules. 
 
The cross-presentation of antigens by DCs during viral infections is a well established 
feature (Heath and Carbone 2001) and this has also been documented for the 
influenza virus (Belz et al. 2004). However, it is currently not known to what extent 
cross-presentation of viral antigens by DCs contribute to the overall CD8 T-cell 
response in vivo. This is due to the fact that DCs can also be directly infected by the 
virus and present cytosolic antigens derived from viral replication to CD8 T-cells. 
Lung CD11blo/neg DCs are potent mediators of cross-presentation (del Rio et al. 2007) 
and by ex vivo analysis, our data suggests that cross-presentation by CD11blo/neg DCs 
may have a significant contribution to the priming of naïve CD8 T-cell during the 
early phase of infection as only 10% of the CD11blo/neg DCs are infected with the 
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virus in the pMLN. Further supporting this hypothesis is the data in figure 5.2.1 
where only CD11blo/neg DCs were able to potently stimulate proliferation of CD8 T-
cells, whereas CD11bhi DCs poorly did so despite a similar low rate of viral infection 
(5 to 6%) of both DCs in the lung parenchyma (Figure 5.4.1). A small degree of 
proliferation was observed with CD11bhi DCs when the ratio of DCs to T-cells was 
increased, suggesting that infected DCs also contribute to priming of CD8 T-cells but 
with much lower efficiency (Figure 5.2.2), most likely due to the low percentage of 
DCs infected by the virus. Taking into account that CD11bhi DCs exhibited a higher 
capacity to take up the virus compared to CD11blo/neg DCs (Section 4.4), it is thus 
likely that the superior antigen presentation by CD11blo/neg DCs is due to cross-
presentation. Cross presentation of viral antigens by CD11blo/neg DCs may thus be a 
strategy of the host immune response to increase the number of DCs presenting 
influenza antigens to CD8 T-cells. 
 
Our results also demonstrate for the first time that the commercially available anti-
TAP1 and anti-TAP2 antibodies supplied by Santa Cruz Biotechnologies are suitable 
for use in flow cytometry. The use of the antibodies, in particular anti-TAP1 has been 
widely reported in the literature, although its application has been restricted to 
western blots for the large majority of studies. The ability to use anti-TAP antibodies 
for flow cytometry is especially useful in determining the levels of TAP expression 
within cells present at low frequency such as CD103+ DCs within the lung. This is in 
contrast to western blot assays which require a large number of cells (typically 
0.3x106 cells per lane) in order to obtain sufficient protein for detection, which may 
prove difficult if rare populations of cells are being analyzed such as DCs from the 
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lymph node. Furthermore, quantifying TAP expression by western blots requires that 
cells of interest be isolated in high purity, which in the case of DC subsets requires 
cell sorting due to their heterogenous nature. Moreover, the quantification of relative 
protein levels in western blots is difficult and even when done by densitometry is 
semi-quantitative at best.  These problems are easily overcome in flow cytometry 
where the use of multi-colour analysis can accommodate the acquisition of multiple 
parameters at a single cell level and simultaneously quantify TAP expression. In the 
course of experiments, we also tested the anti-human TAP2 polyclonal antibody 
(clone H-210) from Santa Cruz however it did not give satisfactory staining although 
the datasheet specifies that it is cross-reactive for mouse, rat and human. Instead, only 
the clone (M-20) gave satisfactory staining. A possible explanation for this is that the 
immunogen used to generate the H-210 antibody was taken from the human TAP2 
protein sequence whereas the immunogen for the M-20 antibody was taken from the 
mouse TAP2 C-terminal sequence. It is thus likely that the H-210 antibody is only 
able to detect linear epitopes on mouse TAP2 when the protein is linearised on an 
SDS-PAGE and therefore not able to bind to native folded TAP2 protein. 
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6.1    Brief Summary of Main Findings 
 
In this study, we established a mouse model of influenza infection and characterised 
DC subsets within the lung. Using a fluorescent lipophillic dye-labelled influenza 
virus we demonstrated that CD11blo/negCD103+ lung DCs were the dominant DC 
population that efficiently mediated the transport of influenza antigens from the lung 
to the draining lymph node. By contrast, CD11bhiCD103neg DCs although more 
efficient for taking up the virus in the lung, migrated poorly to the lymph node and 
remained in the lung to produce pro-inflammatory cytokines such as TNF- instead. 
One possible reason for the observed difference in migratory capacity is that 
CD11blo/neg lung DCs readily expressed CCR7. CD11blo/neg DCs were also far superior 
in priming virus-specific CD8 T-cells compared to CD11bhi DCs and efficiently 
loaded viral peptide onto MHC-I complexes. CD11blo/neg DCs also had higher 
constitutive expression of the peptide transporter TAP, as well as components of the 
immunoproteasome LMP2 and LMP7, indicating that the antigen processing pathway 
in these cells is highly efficient at delivering viral peptides to MHC I. Collectively, 
our findings indicate that CD11blo/neg lung DCs have a critical role for the 
development of antiviral CD8 T-cell responses and hence represent a target-of-choice 
for vaccines aiming to engender protective CD8 T-cell responses. 
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6.2    Limitations of Study 
 
The main weakness of this study is that the fluorescent lipid dye is only able to label 
the initial wave of influenza virions and subsequent progeny virus will be unlabelled. 
This limits the time period of tracking uptake of the virus to the early phase after 
inoculation and will inadvertently underestimate the actual number of DCs carrying 
viral antigen to the lymph node. This however does not affect the conclusions of the 
study as the relative ability of DCs to take up the virus and transporting it to the 
lymph node are reflected in the proportion that are positive for DiD. Another result of 
the limitation of the labelling technique is that inoculation with a high dose of virus 
particles is required in order to introduce sufficient dye to allow tracking studies to be 
performed. This precludes the use of non-lethal doses and prevents the analysis of 
events late in infection as the mice may not survive long enough given the high dose 
administered. Also, the dye used to label the virus is lipophilic and is thus associated 
with the lipid envelope of the virus and not the protein. Hence, the use of DiD 
positivity of host immune cells as a readout for acquisition of the virus or its antigens 
assumes that protein antigens of the virus are acquired together with the labelled lipid 
membranes. In the case of uptake of the whole influenza virion, this assumption is 
most likely to be true. However, in the case of uptake of labelled membranes from 
cells rendered necrotic after infection, the extent to which the labelled membrane 
correlates with viral protein is uncertain although it is arguable that HA NA and M2 
proteins are membrane associated and hence should be present to some degree on the 
labelled membranes. 
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6.3    The need to identify lung DC subsets in humans 
 
While the identification and functional characterization of mouse DC subsets has seen 
tremendous progress, identification of the equivalent subsets in humans has not 
advanced equally. Work on human DC subsets has largely been restricted to the 
blood and hence only DCs found within the peripheral circulation have been well-
characterised, such as the plasmacytoid, myeloid and monocyte-derived inflammatory 
DCs. Recently, several studies have emerged suggesting that CD141+ (BDCA-3+) 
DCs may be the equivalent of murine CD8+ DCs as these cells share many of the 
unique characteristics seen in CD8+ DCs such as high expression of TLR3, 
production of IL-12p70 and efficient cross-presentation of exogenous antigen 
(Bachem et al. 2010; Jongbloed et al. 2010). Interestingly, HLA-DR+BDCA-3+ DCs, 
also termed as myeloid DC type 2, have been reported to be present in human lung 
parenchyma (Demedts et al. 2005) and BAL fluid as well (Tsoumakidou et al. 2006). 
Further characterisation of these cells is required to determine whether they are the 
homologues of murine lung CD11blo/negCD103+ DCs. From our data, it would be 
interesting to see if BDCA-3+ DCs also exhibit high constitutive TAP1/2 expression 
and express high levels of CCR7.  
 
Getting access to healthy human lung tissue may prove to be the biggest hurdle to 
better define the function and phenotype of human lung DC subsets. Furthermore, as 
the virus can only be introduced in vitro, it will be extremely difficult to assess the 
capacity of human lung DCs to prime T-cells during infection. One method of 
gaining access to human lung DCs is by the use of humanized mice. Humanized mice 
are typically made using nonobese diabetic severe combined immunodeficiency 
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(NOD/SCID) mice lacking the IL-2R chain and hence are deficient for T-cells, B-
cells and NK cells. Human hematopoietic stem cells isolated from peripheral blood, 
fetal liver or thymus are then adoptively transferred into the mice to reconstitute the 
immune system. Notably, NOD/SCID 2 microglobulin deficient mice have been 
successfully engrafted with human CD34+ hematopoietic progenitors that develop 
into functional myeloid and plasmacytoid DCs that populate various tissue sites 
including the lung (Palucka et al. 2003). The same humanized mice have also been 
demonstrated to mount broad influenza-specific CD8 T-cell immune responses when 
vaccinated with live attenuate influenza virus vaccines (Yu et al. 2008), 
demonstrating the utility of this model as a surrogate means to investigate the role of 
human lung DCs in priming T-cells. Humanized mice therefore represent a 
convenient but powerful means to study the function of human lung DC subsets in the 
setting of a pulmonary viral infection. Furthermore, as these mice can be generated on 
large scale, access to large numbers of human lung DCs is possible and will be a 
useful preclinical resource for testing hypotheses before validating these observations 
on actual human lung samples.  
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6.4    CD8 T-cell influenza vaccination strategy 
 
Current influenza vaccines are available as either injectable killed virus or as a nasal 
spray of live attenuated virus and mainly exploit humoral immunity for protection 
against the virus. Although extremely effective, these vaccination strategies have 
several shortcomings. Firstly, the high variability of HA and NA surface antigens 
prevents the development of a broad spectrum vaccine against the virus. Neutralising 
antibodies developed against the virus are primarily targeted against conformational 
epitopes clustered in 4 to 5 non-overlapping antigenic sites surrounding the receptor 
binding site on the HA and the enzyme active site of the NA, and the epitopes in 
these sites are readily lost by mutations (Brown and Kelso 2009). Secondly, as the 
strains incorporated into the vaccine are forecasted based on seasonal surveillance 
information, the predicted strains are prone to mismatch with the actual circulating 
strains due to the uncertain nature of antigenic shift and drift. These inadequacies 
have been dramatically highlighted by the recent emergence of the 2009 H1N1 
pandemic and clearly demonstrate that alternative vaccination approaches must be 
adopted to improve the efficacy of influenza vaccines.  
 
CD8 T-cells hold tremendous potential for such vaccine strategies as they are able to 
recognize core epitopes conserved across a wide range of influenza strains (Kees and 
Krammer 1984). This is highlighted by the fact that cross-reactive CD8 T-cells 
recognising epitopes from H5N1 and pandemic H1N1 2009 strains could be isolated 
from healthy individuals that had no prior exposure to these viruses (Lee et al. 2008; 
Teijaro et al. 2010). This raises hope that protective CD8 T-cell responses can be 
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readily engendered by vaccinating the population to boost numbers of existing cross-
reactive memory CD8 T-cells in the face of an emerging pandemic threat. Although 
the presence of influenza-specific memory CD8 T-cells will not be able to prevent 
infection, they are able to reduce viral loads by mediating cytolysis of infected cells, 
reduce the severity of illness (McMichael et al. 1983), and in the case of highly 
pathogenic viruses, confer protection against lethality (Christensen et al. 2000). 
 
So far, the vast majority of the data demonstrating a direct role of CD8 T-cells in viral 
clearance has come from studies in rodents and there has been a paucity of similar 
studies in humans. Nonetheless there are two key studies in humans that provide 
convincing evidence that the observations reported in mice are also consistent in 
humans. In the first study, it was observed in an experimental infection of volunteers 
with live unattenuated influenza A/Munich/1/79 virus that individuals with a 
demonstratable recall CD8 T-cell response were able to clear the virus effectively 
even though they lacked specific antibody against the challenge strain (McMichael et 
al. 1983). The second study involved a retrospective analysis of archived health data 
collected from the members of 60 families over a period of 10 years from the 1947 to 
1957 in the Cleveland Family Study (Epstein 2006). Data from this study showed that 
only 5.6% of the adults who exhibited symptomatic influenza A in the early years 
developed influenza during the 1957 Asian flu pandemic whereas 55.2% of children 
who also had influenza before contracted it again. This difference in the rate of 
infection in adults and children could not be attributed to humoral immunity as the 
sera from these individuals did not react with the 1957 H2N2 virus strain. It was 
therefore concluded that the basis of protection is likely a result of accumulated 
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heterosubtypic immunity which was present only in adults and not in children, which 
strongly suggests the involvement of cross-protective CD8 T-cells. 
 
In comparison with the induction of CD4 T-cell and B-cell antibody responses, 
vaccination to engender a strong CD8 T-cell response is more challenging as the 
exogenously administered antigen must gain access to the MHC Class I processing 
pathway in DCs. Although the virus per se is an obligate intracellular pathogen and 
would be expected to naturally presented on MHC Class I, it is unclear if DCs at the 
site of vaccination are able to access sufficient quantities of virus and whether they 
are able to efficiently migrate to the lymph node to mediate efficient priming of CD8 
T-cells. What is certain however is that current vaccination strategies are unable to 
elicit a potent CD8 T-cell response (Brown and Kelso 2009) and there is an urgent 
need to develop novel vaccination approaches to either replace or complement 
existing methods to ensure that that robust CD8 T-cell memory responses can be 
engendered in tandem with humoral immunity. One such experimental approach 
which has seen phase I trial in humans is a transcutaneous application of an 
inactivated influenza vaccine (Combadiere et al. 2010). This could significantly 
amplify CD8 T-cell responses compared to intramuscular injection of the same 
vaccine formulation. Even more recently, another vaccine approach tested at a phase I 
trial reported that flu-specific CD8 T-cell immunity could be induced utilising a 
modified Vaccinia virus carrying influenza NP and M1 protein as a vector (Berthoud 
et al. 2011). These studies represent a step forward in the development of CD8 T-cell 
vaccines for influenza, however it remains to be demonstrated whether the CD8 T-
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cell responses engendered by these vaccination approaches are sufficient to control 
viral replication and confer protection during infection.  
 
Another vaccine strategy that shows promising results although still in the preclinical 
stage of development is the use of cationic liposome nanoparticles in conjunction 
with viral proteins or peptides to augment intracellular loading of MHC Class I. The 
use of cationic liposomes also has an added benefit of acting as a adjuvant and can 
enhance CD4 and CD8 T-cell as well as antibody responses when administered in 
conjunction with soluble proteins (Zaks et al. 2006). The combined use of a cationic 
liposome with a commercial split trivalent influenza vaccine could elicit increased 
antibody and T-cell responses in mice and non-human primates compared to 
vaccination with the split vaccine alone. Moreover, the combinatorial use of the 
liposome with the split vaccine could engender protective T-cell responses and confer 
protection against lethal heterosubtypic infection, whereas inoculation with the 
vaccine failed to confer little or no protection (Lay et al. 2009). Memory CD8 T-cell 
responses achieved by such methods are long-lived and in one study, cross protection 
lasted at least 6 months after immunization (Matsui et al. 2010).  
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6.5    Targeting antigen to DC in situ as an efficient method to stimulate host 
CD8 T-cell responses 
 
DC-based vaccines are a promising method of generating T-cell responses in vivo and 
have largely been exploited by tumor immunologists to expand and stimulate the 
host’s anti-tumour response in a bid to destroy cancerous tissues that are not easily 
eradicated by chemotherapy. Current DC-based tumour vaccines typically comprises 
autologous DCs pulsed with tumor lysates or RNA extracted from tumour cells, 
matured by addition of various TLR ligands or recombinant cytokines and injected 
back into the patient. These autologous DCs are generated in vitro from peripheral 
blood monocytes using a combination of GM-CSF and IL-4 or from CD34+ 
hematopoetic progenitor cells using Flt3L.  
 
As pulsing DCs ex vivo with antigen is not only time-consuming but also laborious, 
there has been a shift towards direct delivery of antigen to DCs in situ by constructing 
a fusion antibody comprising the protein of interest and a mAb against DC-specific 
lectins. DCs express many lectins such as the mannose receptor, Langerin, Dectin-1, 
DC-SIGN, Clec9A and DEC205. Clec9A and DEC205 are particularly attractive 
targets as they are expressed at high levels on cross-presenting DCs murine and 
human DCs. Apart from efficiently directing antigen to DCs, targeting proteins to 
DCs via surface lectins has an added benefit of increasing the immunogenicity of the 
protein as binding of the antibody to the lectins can trigger an immune response 
which serves as a self-adjuvant effect (Caminschi et al. 2008). There is strong 
preclinical evidence for the safety and efficacy of this method in inducing robust CD8 
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T-cell responses to eradicate tumours (Idoyaga et al. 2008; Idoyaga et al. 2011) and is 
now seeing phase II clinical trials. With the exception of therapeutic treatment of 
HIV, this technique has not yet been adopted for vaccination against infectious 
diseases.   In light of the fact that lung CD11blo/negCD103+ DCs are potent mediators 
of CD8 T-cell priming, we propose that influenza core antigens can be target to these 
DCs by a similar approach to generate a pool of cross-protective CD8 T-cells. Also, 
only CD11blo/neg and not CD11bhi lung DCs express high levels of Clec9A (Helft et 
al. 2010), hence existing humanized anti-Clec9A antibodies can be readily adapted to 
incorporate influenza core protein antigens for preclinical as well as  clinical trials. 
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6.6    Future Direction 
 
Strategies to enhance CD11blo/neg uptake of virus for intranasal vaccine  
Intranasal influenza vaccines provide a higher degree of cross-protection compared to 
other routes of vaccination such as subcutaneous, intravenous and intraperitoneal 
(Alsharifi et al. 2009). However in our experiments, we observed that lung DCs 
poorly acquired intranasally administered UV inactivated virus and that this was 
associated with poor CD8 T-cell priming in the draining lymph node. Several 
methods can be employed to overcome this problem of poor virus acquisition. Lung 
CD11blo/neg DC numbers can be artificially increased by intranasal pretreatment with 
Flt3. Alternatively, lung CD11blo/neg DCs can be pulsed with the virus ex vivo and 
adoptively transferred back into the mice intratracheally. Another approach would be 
to chemically couple antibodies (anti-CD103 or anti-langerin) to the whole virus to 
directly deliver viral antigen to the DCs. If successful, this idea although being more 
radical, holds more potential for translation into clinical testing as the antibodies used 
can be easily switched to target human lung DC subsets. 
 
Exploring the unique antigen presentation capacity of CD11blo/neg DCs 
CD11blo/negCD103+ DC are currently thought to be the non-lymphoid counterparts of 
splenic CD8+ DCs as both DC subsets share many features. Apart from both DCs 
being efficient mediators of cross-presentation, they both are derived from the same 
pre-DC precursor cells, are dependent on the same transcription factors IRF-8, Id2 
and BATF3 for differentiation in vivo (Edelson et al. 2010) and have high expression 
of TLR3 as well as TAP1/2. It was recently shown that a subset of splenic CD8+ 
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DCs possess the capacity to divert endocytosed antigens into the cytosol, conferring it 
with the ability to cross-present exogenously acquired antigen (Lin et al. 2008). It 
would be interesting to perform similar experiments with lung CD11blo/negCD103+ 
DCs to see if the same mechanism exists in these cells. In this study, we also report 
that components of the immunoproteasome LMP2 and LMP7 are constitutively 
expressed at high levels in CD11blo/neg DCs, leading us to hypothesise that these cells 
have a unique regulation of the MHC Class I antigen processing pathway. A 
biochemical assay to demonstrate enhanced functional immunoproteasome activity in 
CD11blo/neg DCs would lend strength to this hypothesis. Similarly, it would be ideal to 
set up an assay to show that the higher levels of TAP1/2 in CD11blo/neg DCs indeed 
translate to augmented capacity for cytosolic peptide import into the ER.  
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